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A brachial plexus injury (BPI) is caused by traction on the brachial plexus during 
delivery or due to a high-energy road traffic accident in young adults 1, 2. Multiple 
synonyms are used for an obstetric brachial plexus injury (OBPI), including neonatal, 
congenital and perinatal brachial plexus palsy. However OBPI is the most preferred 
terminology in Europe and is therefore used in this thesis 3. The incidence of an 
OBPI during delivery varies between 0.4 and 2.9 per 1000 live births 4-6. The upper 
part of the brachial plexus (C5,C6) is most often affected, resulting in variable 
weakness of active  shoulder and elbow flexion movements 7. Elbow extension, 
wrist and hand function are additionally impaired when the C7, C8, T1, medial 
trunk and inferior trunk are involved. An isolated injury of the lower brachial plexus 
(C8-T1) is rare. 
The first focus for therapy is on the type of injury of the peripheral nerve, 
for that matter, to the severity of the traction injury which may extend from 
minimal (axonotmesis) to severe (neurotmesis and avulsion) traction, as addressed 
in previous theses 8, 9. However, little attention has been paid to the effects on 
the end organ of the nerve: the muscle and its sequelae on functionality for the 
patient. A large variety of outcome measures have been used to evaluate the 
natural history and the effect of treatment, however there is no consensus on which 
outcome measures are the most ap propriate 10, 11. The International Classification of 
Functioning, Disability and Health (ICF) is a worldwide accepted model providing 
a universal language for the description of functioning and includes the domains 
Body Structures, Body Functions, Activities and Participation as well as Personal and 
Environmental Factors 12. ICF Core Sets are generally used to describe the typical 
spectrum of problems of functioning and health patients with a specific condition 
(e.g. brachial plexus injury). An important base for the optimal management of OBPI 
is an in-depth understanding, systematic consideration and sound measurement 
of the impact of OBPI on health and health-related domains of these patients. To 
date however, no universally accepted overall framework is available to assess the 
outcome of patients with (obstetric) BPI. 
Muscle degeneration
Long-term denervation results in muscle degeneration including muscle atrophy, 
fatty degeneration and interstitial fibrosis in the muscle. Current literature 
on muscle degeneration in the upper extremity of BPI only focuses on total 
muscle cross sectional area (CSA) and on a qualitative assessment of muscle 
fatty degeneration including the Goutallier score as a surrogate for contractile 




reliability of the Goutallier score is moderate even in experienced hands 21, 22. 
Furthermore, qualitative assessment of fatty degeneration is less sensitive in 
detecting small differences 23 24, 25. Quantitative measurements which assess the 
decrease in contractile CSA compared to the sound extremity could improve 
insight in the extent of muscle degeneration and would thus facilitate a better 
treatment strategy. 
Muscle denervation and subsequent muscle degeneration results in functional 
limitations, contractures and osseous deformities. With respect to the elbow, 
the main complication occurring during follow-up is a flexion contracture, with 
a prevalence of 50 to 90% 26, 27. Flexion contractures limited to 10° to 30° can 
be treated by range of motion exercises and nighttime splinting. In a minority 
of cases, however, if the contracture exceeds 30°, additional treatment is 
needed such as serial casting 26, 27. Although serial casting is frequently applied 
and globally considered to be the preferred therapy, literature is limited on 
the effect of stretching by serial casting for elbow contractures. Other clinical 
consequences of muscle degeneration around the elbow include supination 
contractures and limited active elbow flexion for which surgical procedures are 
being performed including forearm osteotomies, biceps rerouting and Steindler 
elbow flexorplasty 28-33.
Around the shoulder, muscle degeneration often results in internal rotation 
contractures, with a subsequent posterior humeral subluxation in the growing 
child, glenoid retroversion and glenoid and humeral head malformation 16, 17, 34. The 
prevalence of internal rotation contractures can be as high as 39% depending on 
the extent and severity of the BPI 35, 36. Muscle degeneration is most prominent in 
the subscapular muscle 16, 17. Treatments of internal rotation contractures include 
surgical subscapular release combined with transfer of the latissimus dorsi and/
or teres major tendon to the rotator cuff to create active external rotation 37-39. 
Disadvantages of subscapular release and/or tendon transfer include weaker 
adduction and potential partial power loss of internal rotation with a subsequent 
risk for an external rotation contracture of the shoulder. Therefore, coracohumeral 
ligament releases have been advocated by our group. An even less invasive method 
to address this internal rotation contracture of the shoulder is the injection of 
botulinum toxin A (BTX-A) 40, 41. There have been some reports on BTX-A injections 
but no clear conclusions could be drawn from these studies since heterogeneity of 
included patients as well as technique were large (i.e. number and units of BTX-A 
injections, variety of muscles, combination with tendon transfer surgery etc.) 42-47. 
Other surgical procedures to improve shoulder functionality of BPI patients include 






The regenerative potential of skeletal muscle is determined by muscle stem cells, 
which are called satellite cells. These are quiescent mononucleated cells that are 
sequestered between the basal lamina and the plasma membrane of the myofibers 
and can be identified by the expression of the paired box transcription factor Pax7 
52, 53. The number of satellite cells in adult human has been shown to range from 7% in 
young age (20 years old) to 1% of all skeletal muscle nuclei in old age (73 years old) 54. 
In response to injury, they become activated, proliferate, differentiate and fuse to 
existing muscle fibers or fuse together to form new myofibers during regeneration of 
damaged skeletal muscle 55. This regenerative potential is influenced by replicative 
and stress-induced premature senescence and apoptosis of these cells. 
Replicative senescence is indicated by exhaustion of the pool of available 
satellite cells and their proliferative capacity which is limited by the mitotic clock 56-58. 
Progressive erosion of telomeres after each cell division leads to critically short 
telomere length and the activation of replicative senescence through a p53 and p21 
dependent pathway 59. The erosion of telomeres can be prevented by the catalytic 
subunit of the human telomerase reversed transcriptase (hTERT) leading to extension 
of replicative life 60.  Furthermore, lack of differentiation may contribute to poor 
functional recovery of long-term denervated muscle 61, 62. Up-regulation of the 
p16 dependent pathway results in proliferative arrest before telomeres reach their 
critical length known as stress induced premature senescence 63, 64. The regenerative 
potential of satellite cells is also limited by the extent of apoptosis. Upon denervation, 
the susceptibility of satellite cells to apoptosis has been shown to increase 65, 66. 
Satellite cell activity can be modulated by a microenvironment inducing inflammatory 
cytokines, however  underlying factors influencing the regenerative potential of 
satellite cells have not yet been identified 58, 67. 
Cell therapy has the goal to repair damaged cells and to replenish the exhausted 
satellite cell pool by (systemic or local) injection of cells with myoregenerative properties. 
Transplantation of primairy satellite cells has been shown to improve the properties 
of reinnervated skeletal muscles 68. However, poor cellular survival and limited cell 
dissemination hampers successful satellite cell transplantation. Furthermore, only few 
transplanted cells fuse with host muscle cell fibers. This suggests that a subpopulation 
of myogenic cells (i.e. stem cells) may be optimally suited for transplantation 69, 70. 
Bone marrow (BM)-derived cells migrate to the site of muscle injury and contribute to 
the satellite cell pool 71-73. The injection of autologous BM-derived mononuclear cells 
(MNCs) has been applied in clinical studies focusing on the muscles of the heart and 
leg 74-77. Cell therapy could potentially regenerate partially denervated muscle in BPI 
by replenishment of the satellite cell pool and re-establishment of vascular and neural 




aIM of tHIS tHeSIS
The aim of this thesis is to evaluate determinants of outcome, which will have 
an effect on overall functionality of the patient with a BPI.  Deterioration of 
functionality will either occur immediate after the injury, but will also occur years 
after the initial peripheral nerve injury. They are generally, but not exclusively, 
related to the primary target organ of the nerve: the muscle. Secondary to these 
impaired muscles with subsequent impaired movement of the extremities, joint 
development in the growing child will be affected. This will have effect at the 
functionality level of the patient. To this end, outcome measures of functionality 
using the ICF model are developed (chapter 2). At the clinical level, muscle and 
joint deformities and their treatment options are addressed (chapter 3, 4, 5). At 
the cellular level, a deteriorated muscle is characterized in both inflammatory as 
well as nerve injury patients (chapter 6, 7). Finally, a possible treatment option with 
cell therapy for this muscle in nerve injury patients is used (chapter 8). The results 
of this thesis are summarized and future perspectives of muscle degeneration and 
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Background: Symptoms of obstetric brachial plexus injury (OBPI) vary widely 
over the course of time and from individual to individual and can include various 
degrees of denervation, muscle weakness, contractures, bone deformities and 
functional limitations. To date, no universally accepted overall framework is 
available to assess the outcome of patients with OBPI. The objective of this paper is 
to outline the proposed process for the development of International Classification 
of Functioning, Disability and Health (ICF) Core Sets for patients with an OBPI. 
Methods: The first step is to conduct four preparatory studies to identify ICF 
categories important for OBPI: a) a systematic literature review to identify outcome 
measures, b) a qualitative study using focus groups, c) an expert survey and d) a 
cross-sectional, multicentre study. A first version of ICF Core Sets will be defined 
at a consensus conference, which will integrate the evidence from the preparatory 
studies. In a second step, field-testing among patients will validate this first version 
of Core Sets for OBPI. 
Discussion: The proposed method to develop ICF Core Sets for OBPI yields a 
practical tool for multiple purposes: for clinicians to systematically assess and 
evaluate the individual’s functioning, for researchers to design and compare 




Core sets for oBPI
IntRoDuctIon
An obstetric brachial plexus injury (OBPI) is caused by traction on the brachial plexus 
during delivery and can result in severe disabilities in arm function. The incidence 
varies between 0.4 and 2.9 per 1000 live births 1-3. The severity of the injury of the 
brachial plexus may vary from neuropraxia and axonotmesis to neurotmesis and 
avulsion of rootlets from the spinal cord. The upper part of the brachial plexus 
is most often affected, resulting in variable weakness of the shoulder and elbow 
flexion 4. Elbow extension, wrist and hand function are additionally impaired when 
the C7, C8, T1, medial trunk and inferior trunk are involved. An isolated injury of the 
lower brachial plexus (C8-T1) is rare. Depending on the severity and extent of the 
OBPI, the overall quality of life of patients is very much affected due to impaired 
upper-limb function. Symptoms of OBPI can vary widely between individuals 
and clinical studies have been performed to identify the natural history and to 
improve treatment 5-13. A large variety of outcome measures is used to evaluate 
the natural history and the effect of treatment, however there is no consensus on 
which outcome measures are the most ap propriate 14, 15. 
An important base for the optimal management of OBPI is an in-depth 
understanding, systematic consideration and sound measurement of the impact 
of OBPI on health and health-related domains. The International Classification of 
Functioning, Disability and Health (ICF) is a worldwide accepted model providing 
a universal language for the description of functioning and includes the domains 
Body Structures, Body Functions, Activities and Participation as well as Personal 
and Environmental Factors (figure 1) 16. These ICF domains, which contain together 
more than 1400 categories, can serve as a reference for purposes in the clinical 
practice 17, 18. ICF Core Sets are generally agreed on lists of ICF categories and 
contain as few as possible but as much as necessary ICF categories to describe the 
typical spectrum of problems of functioning and health of patients with a specific 
condition. To date, ICF Core Sets have already been or are being developed 
for more than 20 health conditions, including neurological, musculoskeletal and 
cardiovascular diseases 19-25. However, ICF Core Sets for OBPI are not available so 
far. The objective of this paper is to outline the proposed developmental process 






The development of the ICF Core Sets for OBPI is a collaborative project of the 
Leiden University Medical Center (LUMC) and the ICF Research Branch of the 
Collaboration Centre of the Family of International Classifications (DIMDI) at the 
Ludwig-Maximilian University (Munich, Germany). Figure 2 shows the three phases 
in the development of the ICF Core Sets for OBPI: the preparatory phase with the 
international consensus conference (phase I) and the testing and implementation 
phase (phase II). A summary of the methods is shown in Table I. The project will 
be conducted in conformity with the ethical principles of Declaration of Helsinki. 
All appropriate study-related documents will be presented to the Medical Ethics 
Committees for review and approval.
Figure 1: The International Classification of Functioning, Disability and Health of the World 
Health Organization
Diagram showing the International Classification of Functioning, Disability and Health (ICF) 
model domains. ‘Health condition’ is an umbrella term for disease, disorder, injury or trauma 
and may also include other circumstances, such as aging, stress, congenital anomaly, or genetic 
predisposition. It may also include information about pathogeneses and/or aetiology. ‘Body 
function’ is defined as the physiological functions of body systems, including psychological 
functions. ‘Body structure’ refers to the anatomical parts of the body, such as organs, limbs and 
their components. ‘Activity’ is the execution of a task or action by an individual and represents 
the individual perspective of functioning. ‘Participation’ refers to the involvement of an individual 
in an everyday situation and represents the societal perspective of functioning. ‘Environmental 
factors’ make up the physical, social and attitudinal environment in which people live their lives. 
‘Personal factors’ are the particular background of an individual’s life and living situation, and 
comprise features that are not part of a health condition, such as gender, age, race, fitness, 
lifestyle, habits, and social background. They can be referred to as those factors that define the 
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Preparatory phase
The preparatory phase aims at identifying concepts relevant to patients with 
OBPI from 4 different points of view. Therefore, this phase consists of 4 different 
preparatory studies: a systematic review, a qualitative study, an expert survey and 
a cross-sectional study.
Systematic review: The objective of this study is to capture the researchers’ 
perspective (a) by identifying outcome measures cited in published studies with the 
focus on individuals with OBPI and (b) by identifying and quantifying the concepts 
contained in these measures using the ICF as a reference. Electronic databases 
regarding the measures used in clinical trials and in observational studies identifying 
concepts from the researchers’ point of view. The data collection process consists 
of three subsequently steps: Firstly, the parameters used in published studies are 
identified; secondly the items of all retrieved parameters and their underlying 
concepts are specified. Finally, these concepts will be linked to the categories of 
the ICF using standardized linking rules 26, 27. Absolute and relative frequencies of 
the parameters and the linked ICF categories will be reported.
Qualitative study: The objective of this study is (a) to explore and understand the 
perspective of patients with OBPI on functioning and health and (b) to identify and 
quantify the concepts of functioning and health important to patients with OBPI 
using the ICF as a reference. It is important to include the patients’ perspective 
because personal values for outcomes vary between and within patients. To identify 
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Table I: Summary of the methods for the development of International Classification of 












world literature on 
OBPI
(a) To identify outcome 
measures cited in published 
studies with the focus on 
patients with OBPI
(b) To identify and quantify the 
concepts contained in these 
measures using the ICF as a 
reference
To obtain the researchers 
perspective, electronic 
databases will be 
search using keywords 
including  “Brachial Plexus 
Neuropathies”, ”Brachial 
Plexus injuries”, ”Erb 
Paralysis”, ”Klumpke 





technique is a 
qualitative method 
valid to explore 
the perspective 
of those who 
experience 
OBPI, i.e. the 
so-called patient 
perspective
(a) To explore and understand 
the perspective of patients with 
OBPI on functioning and health 
(b) To identify and quantify the 
concepts of functioning and 
health important to patients 
with OBPI using the ICF as a 
reference
To obtain an international 
perspective, focus groups are 
conducted with people with 
OBPI in different countries
Expert survey A survey 
involving experts 
experienced in 
the treatment of 
individuals with 
OBPI
(a) To identify the most relevant 
problems of patients with OBPI 
from the perspective of clinical 
experts
(b) To identify and quantify the 
concepts contained in these 
problems using the ICF as a 
reference
To obtain a worldwide 
perspective, experts from 
all over the world and from 






study that involves 
data collection at 
one time point
(a) To describe the prevalence 
of problems in functioning of 
patients with OBPI 
(b) To identify the categories 
that explain most of the 
variance of external standards
To obtain an international 
perspective, centers in 








that helps to 
prioritize issues 
during an expert’s 
conference
To develop ICF Core Sets 
for OBPI in a formal decision 
making and consensus process, 
integrating evidence gathered 
from preliminary studies and 
expert opinion
The number of groups is 
set at 4, always including 7 
experts to address the main 
interests and to involve the 
different professions and 
WHO regions. Each group 
will consist of different 
health professionals who 
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the prototypical spectrum of problems of patients with OBPI small groups with up 
to eight individuals, between the age of eight and eighteen years, are interviewed. 
These focus groups are likely to generate more concepts then individual interviews 
because the interaction and group process can enrich the information generated 
within a group of patients 28, 29. A topic guide based on the components Body 
Structures, Body Functions, Activities and Participation, Environmental Factors 
and Personal Factors of the bio-psycho-social model will be applied. All interviews 
will be digitally recorded, transcribed verbatim and evaluated again by two 
independent persons. Participants will be included in the study until saturation 
is reached which is defined as the point during data collection when the linking 
of the retrieved concepts to the 2nd level of the ICF classification is less than 5% 
of the number of 2nd level ICF category nominated so far. The frequencies of the 
parameters and the linked ICF categories from the focus groups will be reported.
Expert survey: An Internet based expert survey will be conducted (a) to collect 
the health professionals’ perspective on relevant problems of patients with OBPI 
and (b) to identify and quantify the concepts contained in these problems using 
the ICF as a reference. Since the ICF was developed to facilitate communication 
between different groups of people and to be used globally, the aim is to include 
experts from all six WHO regions: Eastern Mediterranean, South-East Asia, Western 
Pacific, The Americas, Africa and Europe. To maximize the number and range of 
ideas and opinions, the aim is to include experts from different health professions 
including neurosurgeons, orthopedic surgeons, plastic surgeons, rehabilitation 
physicians, neonatologists, neurologists, pediatricians, physical therapists, 
occupational therapist, nurses and social workers. The health professionals have to 
be experienced in the treatment of OBPI for at least two years and have to be fluent 
in English to contribute to the survey. In the expert survey a 5 item open-ended 
questionnaire is used which requests that experts list all body structures, functions, 
Table I: Summary of the methods for the development of International Classification of 








standards, like the 
Short Form-36
To study the content 
validity and feasibility of the 
Comprehensive and the Brief 
ICF Core Sets for OBPI
A network of organizations 
and institutions from all 
over the world which 
are interested in the 
implementation and testing 





activities and participation aspects in which patients with OBPI encounter problems 
as well as all contextual factors which have a facilitation and/or hindering influence 
on the problems of patients with OBPI. The answers of the health professionals 
are linked to the ICF categories and the frequency of ICF categories are reported.
Cross sectional study: To obtain the clinical perspective, a multi-center cross-sectional 
study will be conducted. The aims of this study are (a) to describe functioning and 
health of patients with OBPI, (b) to identify the most common problems using the ICF 
and (c) to identify the categories that explain most of the variance outcome measures 
currently used. This multi-center study will be conducted in the different WHO regions 
and patients with OBPI who are literate in the primary language of the study site 
will be consecutively included in the study. Data will be collected with a case record 
form (CRF), which is made up of two parts. The first part is an ICF checklist, which 
consists of the 31 1st level categories and a selection of 123 from the in total 362 2nd 
level categories of the whole ICF classification system. It provides a relatively simple 
questionnaire, which can be filled out by the physician or other health professional. 
The ICF checklist makes it possible to classify the most important ICF categories in 
clinical practice. The second part includes the EuroQol (EQ-5D) 30, five questions 
of the WHO Quality of Life Questionnaires (WHOQoL) to assess the subjective 
appraisal of health and well-being 31, the SF-36 Health Survey 32, the Disability of 
Arm, Shoulder and Hand Questionnaire (DASH) 33, and the self-administered Co-
morbidity Questionnaire (SCQ) 34. Furthermore, sociodemographic variables will 
be collected. For the ICF components body functions, body structures, activities 
and participation, absolute frequencies and relative frequencies of impairment will 
be reported along with their 95% confidence intervals. For environmental factors, 
absolute frequencies and relative frequencies of persons who regarded a specific 
category as either barrier or facilitator are reported.
Consensus conference
The results of the preparatory phase will be presented at an international 
consensus conference. At this conference, experts in the field of OBPI will work 
actively together to deal with the complex problem of arriving at an international 
consensus on the most adequate ICF categories to be included on the ICF Core 
Sets for OBPI. The “Nominal-Group Technique” will be applied to regulate the 
group dynamic and the teamwork during the conference 35. Since the results of 
the preliminary studies are all expressed in ICF language, they can be compiled 
in tables that contain for each category addressed the percentage with which the 
categories were named in the preparatory studies. First, the experts will be asked 
to select ICF categories for the comprehensive ICF Core Sets, which is a list of 
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ICF categories long enough to describe the prototypical spectrum of functioning 
and health of patients with OBPI. Second, the experts will be asked to select from 
the comprehensive ICF Core Sets lists the ICF categories, which are enough to 
describe the prototypical spectrum of functioning of patients with OBPI, but this 
list needs to be short enough to be feasible to use in clinical practice. This process 
will lead to a brief list of ICF Core Sets. 
Validation phase
The next step is to test the validity and feasibility of the proposed brief and 
comprehensive ICF Core Sets for patients with OBPI. This will be conducted in a 
multicenter cohort study at a network of cooperating organizations. The objectives 
are to analyze the frequency of patients’ problems in different subsets, including 
nationality, socioeconomic factors, age, gender, the severity of brachial plexus 
injury and co-morbidities. The results will be used to identify the categories that 
explain most of the variance of external standards, as well as to analyze to what 
extent the entire severity spectrum of problems in functioning reported by patients 
with OBPI is represented in the comprehensive ICF Core Sets.
DIScuSSIon
In this paper we have described the proposed process to develop ICF Core Sets for 
OBPI. The ICF has been proposed by the World Health Organization to describe 
comprehensively limitations in functioning and relevant environmental factors 16. 
The ICF offers a framework and classification for the patient and clinical perspective 
both at the individual and the population level. It integrates long known concepts 
and provides a universal and standardized language. ICF Core Sets are necessary 
to make the ICF useful to describe functional limitations and disabilities of patients 
with OBPI. 
Currently, ICF Core Sets have been, or are being developed for more than 20 
health conditions, including neurological traumas and musculoskeletal diseases 
like traumatic brain injuries, spinal cord injuries, osteoarthritis and low back 
pain 19-25. ICF Core Sets may well serve as the basis for multi-professional patient 
assessment, goal setting, intervention management and evaluation 36. For a 
correct interpretation of the patient’s problems, it is important to first describe the 
concerns of the patient and/or parents in their own words. Physicians can use the 
ICF Core Sets to describe and classify patients’ symptoms and findings of clinical 
examinations. Professionals could describe at least all categories from a brief Core 
Set and use the comprehensive Core Set as a source of additional relevant items. 
Using the ICF Core Sets supports multidisciplinary and comprehensive assessment 




aspect of functioning of a patient. The use of ICF Core Sets can assist health care 
professionals in explaining the necessity of a certain procedure for a patient and for 
their parents thereby creating more insight into the health problems and treatment. 
It is by no means the aim of the ICF to replace validated existing instruments. In 
contrast, it is likely that they will have an essential role to measure particular parts 
of the ICF. Most measurement instruments do however cover only a limited number 
of ICF categories.
Next to the clinical application, ICF Core Sets will be used by researchers and 
healthcare providers in many ways. ICF Core Sets make it possible to classify and 
describe an individual’s functioning using widely accepted terminology, which 
facilitates comparability of international studies. It can also be used to rate the 
content validity of health-status measures and to select appropriate instruments 
for the specific needs for patients with OBPI. In the future, ICF and the ICF Core 
Sets may become the new basis not only for the further development of such 
measures, but also for the creation of an item list with parameters relevant to 
patients with OBPI. Furthermore, ICF facilitates linking medical data across different 
conditions or interventions for efficient, transparent and cost-effective health 
care. Other benefits could also rise from compiling a functionality assessment for 
OBPI from a common set of indicators (a common bio-psycho-social framework) 
used for all health conditions. For example, a common language would facilitate 
communication among health professionals and also between health professionals 
and patients with OBPI, as well as their family caregivers. In addition, because the 
ICF is etiologically neutral, it is easily possible to combine the ICF Core Sets for 
OBPI with other ICF Core Sets in a non-redundant and useful way when describing 
and classifying functioning and disability of persons with more than one condition. 
Worldwide comparisons will also be possible for any health condition, not only 
for OBPI. This will enable policy makers to make informed decisions with regard 
to such issues as resource allocation, new legislation and modification of care 
provision policies. 
A few limitations have to be resolved during the developmental process of ICF 
Core Sets. The assessment of functioning and quality of life data is highly sensitive 
to ethno-cultural differences 37, 38. In order to come up with a first version of ICF 
Core Sets for OBPI that integrates information from different cultural backgrounds, 
the preparatory studies will gather data on patients being treated at centers 
from different countries and from professionals in an international expert survey. 
Another limitation could be that the preparatory studies collect information only 
from published papers in English and English speaking participants. This is done 
to ease comparability of results from different countries, but on the other hand 
will contain a structural bias for countries where English is not the native language. 
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The extent and relevance of this issue will be addressed in the validation phase 
following the consensus conference. An issue to be addressed is the possible need 
for stratification by a number of variables including the extent of brachial plexus 
injury and the age of the growing children. The preliminary studies will provide 
the necessary information to guide these decisions. It is important to realize that 
the ICF Core Sets Consensus Conference will provide only a first, best possible 
version of ICF Core Sets for OBPI, which will then need to be tested worldwide.
In conclusion, this is a big step forward in the development of an internationally 
acceptable and standardized tool for assessing disability in OBPI.  Establishing 
standardized ICF Core Sets will be useful for research, clinical practice and 
teaching. The ICF Core Sets will then also form the basis for the development of 
assessment instruments to quantify the severity of OBPI to measure change over 
time and the effectiveness of interventions. They could also serve as the basis for 
setting clinical significance thresholds in diagnostic assessment systems. Finally, it 
is our hope that such research will lead to interventions and accommodations that 
improve the restoration and maintenance of functioning and minimize disability 
among patients with OBPI throughout the world.
InvItatIon foR PaRtIcIPatIon
The development of the ICF core sets is an inclusive and open process. Therefore, 
the authors of this paper encourage clinical experts and patients to actively 
participate in the process. Anyone who wishes to actively participate is invited to 
contact the Leiden ICF brachial plexus team (brachialplexus@lumc.nl). Individuals, 
institutions and associations can be formally associated as partners of the project. 
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Background: Assessment of muscle atrophy and fatty degeneration in brachial 
plexus injury (BPI) could yield valuable insight into pathophysiology and could be 
used to predict clinical outcome. The objective of this study was to quantify and 
relate fat percentage and cross-sectional area (CSA) of the biceps to range of 
motion and muscle force of traumatic brachial plexus injury (BPI) patients.
Methods:  T1- weighted TSE sequence and three-point Dixon images of the affected 
and non-affected biceps brachii were acquired on a 3 Tesla magnetic resonance 
scanner to determine the Goutallier score, fat percentage, total and contractile 
CSA of 20 adult BPI patients. Regions of interest were drawn by two independent 
investigators to determine the inter-observer reliability. Paired Students’ t-test and 
multivariate analysis were used to relate fat percentage, total and contractile CSA 
to active flexion and biceps muscle force.
Results: The mean fat percentage 12 ± 5.1% of affected biceps was higher than 
6 ± 1.0% of the non-affected biceps (p < 0.001). The mean contractile CSA 8.1 ± 
5.1 cm2 of the affected biceps was lower than 19.4 ± 4.9 cm2 of the non-affected 
biceps (p < 0.001). The inter-observer reliability was excellent (ICC 0.82 to 0.96). 
The Goutallier score was strongly associated with fat percentage (Spearman’s rho 
0.87, p < 0.001), however it gave an overestimation in those classified with a high 
grade Goutallier. The contractile CSA contributed most to the reduction in active 
flexion and muscle force.
Conclusion: Quantitative measurement of fat percentage, total and contractile CSA 
using three-point Dixon sequences provides an excellent reliability and relates with 
active flexion and muscle force in BPI.
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IntRoDuctIon
Brachial plexus injury (BPI) results in severe nerve damage affecting the upper 
extremity. Despite partial natural recovery, nerve and/or secondary surgery, both 
traumatic BPI patients and neonatal brachial plexus palsy patients do not regain 
normal upper extremity function and are impaired in muscle force and range 
of motion of the shoulder, elbow, wrist and/or hand 1-7. Long-term denervation 
results in muscle degeneration including muscle atrophy, fatty degeneration and 
interstitial fibrosis in the muscle. Quantitative tools which assess the decrease in the 
amount of muscle tissue could improve insight in the extent of muscle degeneration 
and could facilitate a better treatment strategy. The current literature on muscle 
degeneration in the upper extremity of BPI focuses on total muscle cross sectional 
area (CSA) and on a qualitative assessment of muscle fatty degeneration using 
the Goutallier score on T1 weighted Turbo Spin Echo (TSE) magnetic resonance 
(MR) images as well as at computed tomography (CT) scans 4, 7-13. The current 
literature has limitations as the inter-observer reliability of the Goutallier score is 
moderate even in experienced hands 14, 15. Furthermore, a qualitative assessment 
of fatty degeneration is less sensitive in detecting small differences compared 
to a quantitative assessment 16-18. Finally, an overall qualitative muscle score 
(i.e.  Goutallier score) and assessments of total muscle CSA measure both  fatty 
degeneration as well as contractile muscle tissue, whereas only the latter is the 
true functional part of the muscle 4, 7-13. 
The three-point Dixon sequence can be applied to quantify intramuscular fat 
(i.e. indirect contractile muscle tissue). This sequence uses a chemical shift based 
approach which relies on the difference in resonance frequency between water 
and fat. Previously, the Dixon sequence has been used extensively to measure 
intramuscular fat in different conditions, including rotator cuff tears 19, 20, lean and 
obese children 21, diabetes 22, 23 and the muscular dystrophies  17, 18, 24-30. However, 
the extent of muscle fatty degeneration as an indirect measure and the amount of 
contractile tissue in BPI is currently unknown. 
The first objective of this study was to quantify intramuscular fat, the total 
and contractile CSA in BPI patients and to assess the inter-observer reliability 
and the variability using three-point Dixon MRI. The second objective was to 
correlate the qualitatively assessed intramuscular fat with the Goutallier score 
on a T1 weighted TSE sequence with the quantitatively obtained value. The 
final objective was to assess whether intramuscular fat, the total and contractile 







An observational study was performed including 20 adult BPI patients recruited 
from the peripheral nerve injury unit of the Leiden University Medical Center. 
Inclusion criteria were an age > 18 years old and a traumatic BPI. To create a 
uniform group of patients who are at the end stage of neural regeneration, all 
patients had to be minimum two years after trauma and/or nerve surgery for the 
biceps muscle. Patients were excluded if they had a fracture of the humeral bone, 
bilateral brachial plexus lesion, secondary surgery around the shoulder or elbow, 
or contra-indications for MRI. The medical ethical review board of the Leiden 
University Medical Center approved the protocol of this study and all patients 
signed informed consent. This study was registered in the Netherlands Trial 
Register, number NTR2524. 
MRI
MR imaging was performed on a 3 Tesla MR machine (Philips Achieva, Philips 
Medical Systems, Best, the Netherlands) in supine position, with the arm as much in 
the center of the magnet bore as possible and the patient’s arms placed alongside 
of the body with the thumbs directed upwards. Both arms were imaged separately. 
A 14-cm two-element receive coil was used for signal reception. The receive coil 
elements were positioned on the anterior and posterior side in the middle of the 
upper arm using the humeral head and olecranon as palpable bony reference. The 
scan protocol consisted of axial T1-weighted TSE sequence (16 slices of 7.5 mm 
thickness, 0.75 mm gap, repetition time (TR) 600 ms, echo time (TE) 16 ms, field 
of view (FOV) 180 x 180 mm, voxel size 0.6x0.6 mm2, TSE factor 5, acquisition time 
5:20 minutes) and a 3-point gradient echo Dixon sequence (16 slices of 7.5 mm 
thickness, 0.75 mm gap, TR 400 ms, first TE 4.41 ms, echo spacing 0.76 ms, flip 
angle 8°, FOV 180x180 mm, (voxel size 0.9x0.9 mm2), acquisition time 6:30 minutes) 
of the affected and non-affected upper arm. The T1 and Dixon sequences were 
planned using a survey scan, around the distal 2/3 of the humeral bone using 
the humeral head and epicondyles of the distal humeral bone as bony landmark. 
Representative examples of T1, Dixon fat and Dixon water images of the non-
affected and affected arm are shown in figure 1.
Data analysis
The three-point Dixon images were reconstructed with multipeak correction as 
described before, with frequencies fp= [94, -318, -420] Hz and amplitudes AP= [0.08, 
0.15, 0.78], to account for the multiple peaks of the fat spectrum 28. No corrections 
were made for partial saturation due to T1, T2 or T2* relaxation. Regions of interest 
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(ROIs) were drawn manually on every slice by two independent investigators (B.J.D. 
and J.F.H.), blinded for patient details using the Medical Image Processing, Analysis 
and Visualization software package (http://mipav.cit.nih.gov) on T1-weighted 
images in the biceps and triceps brachii of the affected and non-affected arm. Five 
consecutive slices with the largest cross sectional area of the biceps and triceps 
brachii were used to calculate the mean fat percentage, the total CSA (i.e. the CSA 
including muscle tissue and intramuscular fat tissue), and the contractile CSA which 
was calculated from the mean fat percentage and the total CSA (contractile CSA = 
total CSA (100 - mean fat percentage) / 100). The mean fat percentage per muscle 
was computed using the co-registered contours from the T1 weighted images on 
the Dixon images and calculated by averaging all pixels assigned to that muscle. 
Next, the mean fat percentage was calculated by: signal intensity on fat image 
/ (signal intensity on fat image + signal intensity at water image). The Goutallier 
grading was scored by two experienced musculoskeletal radiologists (CSPR and 
MR) in consensus: 0 ‘no fat’, 1 ‘some fatty streaks’, 2 ‘less fat than muscle’, 3 ‘as 
much fat as muscle’ and 4 ‘more fat than muscle’. Furthermore, the affected biceps 
and triceps brachii were scored for the presence of atrophy compared to the non-
affected biceps and triceps brachii of the contra lateral arm. 
Clinical parameters
The age, gender, affected side, severity of the lesion according to Narakas and 
type of nerve and/or secondary surgery was recorded 31. The passive and active 
elbow range of motion (flexion, extension, supination and pronation) was measured 
using a hand held goniometer. Muscle force was measured (semi) quantitatively 
of both elbow flexion and elbow extension using the medical research council 
(MRC) scale and a hand-held dynamometer (MicroFET2, Biometrics, Almere, the 
Netherlands) in a standardized arm positions (90° flexion and 90° supination). 
Muscle quality was determined by calculating the specific muscle force i.e. muscle 
force in Newton per cm2 of contractile CSA. The self assessment questionnaires 
disability of the arm, shoulder and hand (DASH), the short form-36 (SF-36) and 
visual analogue score (VAS) for pain (0-10) were used to assess the quality of life 
of the BPI patients.
Statistical analysis
The paired Student’s t-test was used to study differences in fat percentage, total 
CSA, contractile CSA and specific muscle force between the affected and the 
non-affected biceps and triceps brachii. The intraclass correlation coefficient 
(ICC) of fat percentage, total and contractile CSA was calculated to determine the 
reliability between two independent observers and potential variability between 5 




Figure 1: Example of T1, Dixon fat and Dixon water images of the non-affected and affected 
arm. Regions of interest are drawn in red for the biceps and green for the triceps brachii.
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Figure 1: Example of T1, Dixon fat and Dixon water images of the non-affected and affected arm. 
Regions of interest are drawn in red for the biceps and green for the triceps brachii. 
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For interpretation, the criteria formulated by Cicchetti and Sparrow were used: 0.00 
to 0.39, poor; 0.40 to 0.59, fair; 0.60 to 0.74, good; or 0.75 to 1.00, excellent 33. 
The Spearman’s rho correlation coefficient was used to investigate the presence of 
correlation between the percentages of fat using Dixon with the Goutallier score 
of the T1w images. Univariate linear regression analysis was employed to study 
the association between fat percentage, total and contractile CSA with range 
of motion and muscle force in Newton. Logistic regression analysis was used to 
associate fat percentage, total and contractile CSA to muscle force in MRC 0 to 
3 versus MRC 4 and 5.  In the multivariate analysis, age and elapsed time since 
the trauma were used. For statistical analysis a SPSS software package was used 
(version 23.0, IBM Inc., Armonk, New York, USA). All analyses were two tailed and 
p-values < 0.05 were considered significant. 
ReSultS
Patients
The patient characteristics are summarized in table I. In one patient, the non-
affected arm could not be scanned due to claustrophobia of the patient after 
scanning the affected arm. The mean fat percentage was 12 ± 5.1 % in the affected 
biceps brachii which was significantly higher than 6 ± 1.0 % in the non-affected 
biceps brachii (p < 0.001) as shown in figure 2. The mean fat percentage was 10 ± 
4.3 % in the affected triceps brachii, compared to 6 ± 1.6 % of the non-affected 
triceps brachii (p = 0.001). The mean total CSA of the affected biceps brachii was 
9.0 ± 5.3 cm2 which was lower than a mean of 20.7 ± 5.2 cm2 of the non-affected 
biceps brachii (p = 0.001). The mean contractile CSA was lower in the affected 
biceps brachii 8.1 ± 5.1 cm2, compared to a mean of 19.4 ± 4.9 cm2 in the non-
affected biceps brachii (p < 0.001). The total and contractile CSA were also lower 
in the affected triceps brachii compared to the non-affected triceps brachii as 
shown in table II. 
Reliability
The interobserver reliability was excellent for fat percentage, total CSA and 
contractile CSA in both the biceps and the triceps brachii (table III). To measure 
the homogeneity between the MRI slices, the ICC of 5 consecutive MRI slices was 
calculated. The ICC was excellent for fat percentage, total and contractile CSA of 




Figure 2: Fat percentage of the affected en non-affected biceps and triceps 
Table I: Patient characteristics
N = 20
Sex * (male) 17 
Age † (years) 37 ± 11.1
Body mass index† (kg/m2) 25 ± 3.8
Dominancy before trauma * (right / left / both) 16 / 3 / 1
Brachial plexus injury
Age at trauma † (years)
Side * (right / left)
Narakas type* (C5-C6 / C5-C7 / C5-C8 / C5-T1)
31 ± 10.8
10 / 10
5 / 1 / 3 / 11
Primary treatment
Conservative / neurolysis / nerve transplantation *
Age at neurosurgery † (years)
Type of nerve transplantation *
Anterior division superior trunk 











SF36 questionnaire †# 72 ± 18.1
DASH questionnaire †‡ 23 ± 17.6
Employed *# 16
Playing sport / instrument*# 9
VAS for pain †# 3.5 ± 3.06
*The values are given as the number of patients. † Values are given as mean with standard 
deviation #data was obtained from 19 patients, ‡data was obtained from 18 patients. SF36: 
Short-Form 36. DASH: Disability of the arm, shoulder and hand. VAS: Visual analogue scale with 






















Table II: Results of fat percentage, total and contractile CSA in the affected and non-affected 






Mean difference  
(95 % CI) 





12 ± 5.1 
10 ± 4.3 
 
6 ± 1.0 
6 ± 1.6 
 
-5 ( -3 to -7) 








9.0 ± 5.3 
10.3 ± 6.6) 
20.7 ± 5.2 
20.2 ± 4.8 
-11.5 (-15.0 to -7.9) 










19.4 ± 4.9 
18.9 ± 4.5 
-11.1 (-14.5 to -7.7) 




*The CSA including muscle tissue and intramuscular fat tissue, #contractile CSA = total CSA (100 - mean fat percentage) / 
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Table II: Results of fat percentage, total and contractile CSA in the affected and non-














-5 ( -3 to -7)
-3 (-2 to -5)
< 0.001
0.001







-11.5 (-15.0 to -7.9)
-9.5 (-12.7 to -6.4)
< 0.001
< 0.001







-11.1 (-14.5 to -7.7)
-9.1 (-12.1 to -6.2)
< 0.001
< 0.001
*The CSA including muscle tissue and intramuscular fat tissue, #contractile CSA = total CSA (100 
- mean fat percentage) / 100, CI: confidence interval, CSA: cross sectional area.
Table III: Intraclass correlation coefficients of 2 independent observers and 5 consecutive 
MRI slices
2 independent observers 5 consecutive MRI slices














































*The CSA including muscle tissue and intramuscular fat tissue, #contractile CSA = total CSA 
(100 - mean fat percentage) / 100. MRI: magnetic resonance imaging, ICC: interclass correlation 






mean total CSA of the triceps brachii which were scored as ‘not atrophic’, was not significantly 
different between the affected and the non-affected arm (mean difference -2.9 cm2, 95% CI -7.7 to 
2.0, p = 0.18). The mean total CSA of biceps brachii which were scored ‘atrophic’ was significantly 
smaller in the affected compared to the non-affected biceps (mean difference -15.0 cm2, 95% CI 
-17.7 to -12.3, p < 0.001). The same results were observed for the triceps brachii (mean difference 
-11.9 cm2, 95% CI -15.1 to -8.7, p < 0.001). 
 
 
Figure 3: Association of quantitative fat 
percentage on Dixon with qualitative 
Goutallier score on T1 of the affected and 










Figure 4: Association of total cross sectional 
area with atrophy of the affected and non-










Figure 3: Association of quantitative fat percentage on Dixon with qualitative Goutallier score 
on T1 of the affected and non-affected biceps and triceps




mean total CSA of the triceps brachii which were scored as ‘not atrophic’, was not significantly 
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2.0, p = 0.18). The mean total CSA of biceps brachii which were scored ‘atrophic’ was significantly 
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Qualitative versus quantitative fat scores
The quantitative fat percentage was strongly associated with the qualitative Goutallier 
score with a Spearman’s rho correlation coefficient of 0.87 for the biceps (p < 0.001) 
and 0.78 for the triceps (p < 0.001), as depicted in figure 3. However, the Goutallier 
score overestimates the fat percentage as patients graded with score 3 or 4 (i.e. fat 
percentage of 50% or higher) had a three-point Dixon fat percentage range from 
9 to 19%. The qualitative score of atrophy was compared to the quantitative score 
of total CSA, as shown in figure 4. In the patients where the mean total CSA of the 
biceps brachii was visually scored as ‘not atrophic’, there was indeed no significant 
difference between the affected and the non-affected arm (mean difference -1.6 cm2, 
95% CI 4,8 to 1.6, p = 0.23). Also the mean total CSA of the triceps brachii which were 
scored as ‘not atrophic’, was not significantly different between the affected and the 
non-affected arm (mean difference -2.9 cm2, 95% CI -7.7 to 2.0, p = 0.18). The mean 
total CSA of biceps brachii which were scored ‘atrophic’ was significantly smaller in 
the affected compared to the non-affected biceps (mean difference -15.0 cm2, 95% 
CI -17.7 to -12.3, p < 0.001). The same results were observed for the triceps brachii 
(mean difference -11.9 cm2, 95% CI -15.1 to -8.7, p < 0.001).
Relation to clinical outcome
The association of fat percentage, total and contractile CSA of the affected and 
non-affected biceps and triceps brachii with muscle force in MRC is shown in 
figure 5. Clinical results of passive and active range of motion and muscle force are 
shown in table IV. The specific muscle force was lower in the affected biceps brachii 
(mean 10 ± 5.4 N/cm2) compared to the non-affected biceps (mean 16 ± 4.8 N/cm2) 
(p = 0.002), while this failed to reach significance in the triceps brachii (mean 12 ± 
4.9 N/cm2 in the affected versus 14 ± 3.6 N/cm
2 in the unaffected arm (p = 0.078). 
Univariate and multivariate regression analyses are described in tables V to VII. 
Multivariate regression analysis showed that contractile CSA of the biceps brachii 
was most significantly related to several clinical outcome parameters including 
elbow flexion (7.1°, 95% CI 2.8 to 11.5, p = 0.003), supination (5.5°, 95% CI 0.6 to 
10.4, p = 0.030), muscle force in MRC (odds ratio 2.6, 95% CI 1.1 to 6.1) and muscle 
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Figure 5: Association of fat percentage (A), total CSA (B) and contractile CSA (C) with muscle 




Figure 5: Association of fat percentage (A), 
total CSA (B) and contractile CSA (C) with 
muscle force of the affected and the non-































Table V: Linear regression for active range of motion
Regression coefficient  95% CI p - value
Active flexion univariate models for the affected biceps brachii 
Fat percentage -6.0 -10.8 to -1.2 0.017
Total CSA * 7.0 2.8 to 11.2 0.003
Contractile CSA # 7.3 2.9 to 11.7 0.003
Active flexion multivariate models for the affected biceps brachii
Fat percentage -5.9 -10.9 to -0.8 0.025
Total CSA * 6.8 2.6  to 11.0 0.004
Contractile CSA # 7.1 2.8 to 11.5 0.003
Active extension univariate models for the affected triceps brachii
Fat percentage -0.9 -1.8 to 0.05 0.061
Total CSA * 0.6 -0.03 to 1.2 0.062
Contractile CSA # 0.6 -0.02 to 1.2 0.058
Active extension multivariate models for the affected triceps brachii
Fat percentage -1.0 -1.8 to 0.1 0.029
Total CSA * -0.4 -0.2 to 1.0 0.159
Contractile CSA # 0.5 -0.2 to 1.1 0.150
Active supination univariate models for the affected biceps brachii
Fat percentage -3.2 -8.0 to 1.7 0.186
Total CSA * 4.8 0.5 to 9.1 0.031
Contractile CSA # 5.0 0.5 to 9.4 0.032
Active supination multivariate models for the affected biceps brachii
Fat percentage -3.8 -9.2 to 1.7 0.164
Total CSA * 5.2 0.6 to 9.9 0.030
Contractile CSA # 5.5 0.6 to 10.4 0.030
*The CSA including muscle tissue and intramuscular fat tissue, #contractile CSA = total CSA 
(100 - mean fat percentage) / 100. Univariate linear regression models evaluated the associate 
fat percentage, total CSA or contractile CSA of the affected biceps or triceps brachii to active 
range of motion. The multivariate models were used to correct for age and time after trauma.  CI: 
confidence interval, CSA: cross sectional area.
50
3
Quantitative MRi foR Muscle atRophy and fatty degeneRation 
Table VI: Logistic regression for muscle force in MRC
Odds ratio 95% CI p - value
Univariate models for the affected biceps brachii
Fat percentage -0.17 -0.31 to -0.04 0.012
Total CSA * 0.16 0.02 to 0.29 0.024
Contractile CSA # 0.17 0.03 to 0.32 0.021
Multivariate models for the affected biceps brachii
Fat percentage 0.7 0.55 to 0.99 0.045
Total CSA * 2.4 1.1 to 5.6 0.034
Contractile CSA # 2.6 1.1 to 6.1 0.029
Univariate models for the affected triceps brachii
Fat percentage -0.36 -0.60 to -0.12 0.004
Total CSA * 0.30 0.09 to 0.50 0.005
Contractile CSA # 0.33 0.10 to 0.55 0.005
*The CSA including muscle tissue and intramuscular fat tissue, #contractile CSA = total CSA 
(100 - mean fat percentage) / 100. Univariate logistic regression models evaluated the contribution 
of fat percentage, total CSA or contractile CSA of the affected biceps or triceps brachii to the 
muscle force in MRC 0 to 3 versus MRC 4 and 5. The multivariate models were used to correct 
for age and time after trauma. Multivariate models of the affected triceps brachii are not shown 
because of invalid model due zero frequencies. MRC: medical research council, CI: confidence 
interval, CSA: cross sectional area.
Table VII: Linear regression for muscle force in Newton (continued)
Outcome variable Regression coefficient 95% CI p - value
Univariate models for the  affected biceps brachii*
Fat percentage -10.3 -15.8 to -4.9 0.001
Total CSA * 12.3 8.5 to 16.1 < 0.001
Contractile CSA # 13.0 9.2 to 16.8 < 0.001
Multivariate models for the affected biceps brachii*
Fat percentage -10.3 -16.4 to 4.2 0.003
Total CSA * 12.2 8.1 to 16.3 < 0.001
Contractile CSA # 13.0 8.9 to 17.1 < 0.001
Univariate models for the affected triceps brachii*
Fat percentage -15.0 -23.2 to -6.7 0.001
Total CSA * 11.1  6.4 to 15.7 < 0.001




Table VII: Linear regression for muscle force in Newton (continued)
Outcome variable Regression coefficient 95% CI p - value
Multivariate models for the affected triceps brachii*
Fat percentage -15.4 -24.4 to -6.4 0.002
Total CSA * 12.6 8.3 to 16.9 < 0.001
Contractile CSA # 13.2 8.8 to 17.6 < 0.001
Univariate models for the non-affected biceps brachii
Fat percentage -13.4 -41.0 to 14.3 0.323
Total CSA * 7.4 3.6 to 11.2 0.001
Contractile CSA # 7.8 3.8 to 11.8 0.001
Multivariate models for the non-affected biceps brachii
Fat percentage -11.9 -40.9 to 17.1 0.396
Total CSA * 7.5 3.5 to 11.5 0.001
Contractile CSA # 7.9 3.6 to 12.1 0.001
Univariate models for the non-affected triceps brachii
Fat percentage -1.2 -21.9 to 19.4 0.902
Total CSA * 6.0 -1.0 to 13.0 0.086
Contractile CSA # 6.4 -1.0 to 13.8 0.087
Multivariate models for the non-affected triceps brachii
Fat percentage -11.6 -32.2 to 8.9 0.245
Total CSA * 4.1 -3.6 to 11.7 0.270
Contractile CSA # 4.4 -3.4 to 12.3 0.247
*The CSA including muscle tissue and intramuscular fat tissue, #contractile CSA = total CSA 
(100 - mean fat percentage) / 100. Univariate linear regression models evaluated the contribution 
of fat percentage, total CSA or contractile CSA of the affected or non-affected biceps or triceps 
brachii to the muscle force in Newton. *Only n=12 patients were included in these regression 
models because these patients were able to give muscle force against resistance, i.e. Muscle 
Research Council (MRC) 4 or 5. The multivariate models were used to correct for age and time 
after trauma. CI: confidence interval, CSA: cross sectional area.
DIScuSSIon
The three-point Dixon MRI quantifies intramuscular fat, total and contractile CSA 
with an excellent inter-observer reliability in BPI patients. The fat percentage, total 
and contractile CSA was shown to be homogenous among consecutive MRI slices. 
The fat percentage of both the biceps and the triceps brachii showed a strong 
association with the Goutallier score, but the Goutallier score overestimated the 
fat percentage compared to the Dixon technique. Contractile CSA of the affected 
biceps brachii contributed most to the reduction in active elbow flexion, active 
supination and muscle force.
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Long-term denervation results in muscle degeneration including muscle 
atrophy and fatty degeneration. Previous studies in brachial plexus injury used 
only qualitative methods to score muscular fatty degeneration 4, 9. Contrary, with 
quantitative measurement methods comparisons between but also within patient 
groups during follow-up are more objective. Quantitative MRI has previously 
been used in patients with rotator cuff tears, in aging and Duchene muscular 
dystrophy. The values of control patients in literature are comparable with our 
observation of fat percentage of 6 ± 1.0 % in the non-affected biceps brachii 28, 34. 
As hypothetically expected, but never been proved in a clinical setting, contractile 
CSA was also associated with muscle force of the non-affected biceps brachii 
indicating a consistent measurement method. Using both quantitative MRI and 
quantitative muscle force, we calculated the specific muscle force. This excluded 
the non-functional fat inside the muscle compartment. The specific muscle force 
was significantly lower in the affected compared to the non-affected biceps brachii, 
indicating a lower muscle quality in the affected muscle. In BPI, the limited capacity 
of muscle fibers to contract could be due to the partial denervation, but also 
muscle stiffness or disorganization of the muscle fibers could influence the capacity 
of the muscle fibers to generate force 35, 36. 
The quantitative three-point Dixon method showed a good correlation with 
the qualitative T1 measurements of fat using the Goutallier score. As previously 
described, the Goutallier score gave an overestimation of the intramuscular fat 19. 
Other quantitative techniques used to assess fatty degeneration in BPI include 
ultrasound and computed tomography. However these techniques result in a value 
for muscle attenuation without the possibility to distinguish between muscle and fat 
tissue 13, 37. This is the first study using a quantitative assessment of contractile CSA 
in BPI patients. Five consecutive MRI slices showed a homogeneous distribution of 
intramuscular fat, total and contractile CSA. It is not known whether this distribution 
is also homogeneous along the total length of the muscles as the proximal and 
distal end of the muscles were not included in the MRI scans in this study. 
Strength of this study is the use of the non-affected arm as a control and the 
association of quantitative MRI data with clinical parameters as range of motion 
and muscle force. A limitation of this study is a lack of histology; however literature 
shows an excellent correlation of fat fraction obtained by MRI and histology 38. 
Measurements of fat percentage, total and contractile CSA may give more 
insight into the pathophysiology of contractures and muscle weakness in traumatic 
BPI as well as neonatal BPI. It could be used to predict which patients are more 
likely to progress to a worse outcome due to bony deformities and assist at the 
timing of surgery.  Dixon MRI may also improve treatment of BPI by determining 




transfers and osteotomies. Measurement of contractile CSA may be used to assess 
the muscle imbalance around the shoulder in neonatal brachial plexus palsy which 
causes glenohumeral deformities 4, 10, 12. Knowledge on this muscle imbalance could 
assist at decision making on the timing and what kind of operation to perform to 
prevent glenohumeral deformities. Furthermore, quantitative assessment of fat 
percentage, total and contractile CSA might be useful in longitudinal follow-up 
and for research purposes 13.  The contractile CSA of the affected biceps brachii 
contributed most to the reduction in active flexion, active supination and muscle 
force. The fat percentage also contributed to clinical outcome, although this 
contribution was less strong compared to atrophy. As contractile CSA contributed 
most to clinical outcome, we favor measurement of both the fat percentage and 
the total CSA to be able to calculate the contractile CSA. Contractile CSA may be 
the best parameter to quantify muscle atrophy and fatty degeneration, however 
this will need to be confirmed in future research.
concluSIonS
This study showed that the intramuscular fat, the total and contractile CSA of the 
biceps and triceps brachii can be assessed in BPI with an excellent reliability. The 
quantitative scoring of the three-point Dixon sequences was significantly correlated 
with the qualitative Goutallier score on T1 weighted TSE sequences, however the 
Goutallier score gave an overestimation. The contractile CSA of the affected biceps 
contributed most to the reduction in active flexion, active supination and muscle 
force. Assessment of contractile CSA will yield valuable insight in pathophysiology 
and predict the outcome of conservative and surgical procedures. 
acknowleDgeMentS
This study was funded by the Dutch Arthritis Association (LLR13) and the Program 
Translational Research of ZonMw, the Netherlands organization for health research 
and development (project number 95100105), which did not play a role in the 
investigation. We would like to thank Beatrijs H.A. Wokke for assistance at MRI 




Quantitative MRi foR Muscle atRophy and fatty degeneRation 
RefeRenceS
1. Kim DH, Cho YJ, Tiel RL, Kline DG. Outcomes of surgery in 1019 brachial plexus lesions 
treated at Louisiana State University Health Sciences Center. J Neurosurg 2003; 98:1005-
1016.
2. Malessy MJ, de Ruiter GC, de Boer KS, Thomeer RT. Evaluation of suprascapular nerve 
neurotization after nerve graft or transfer in the treatment of brachial plexus traction 
lesions. J Neurosurg 2004; 101:377-389.
3. Krishnan KG, Martin KD, Schackert G. Traumatic lesions of the brachial plexus: an analysis 
of outcomes in primary brachial plexus reconstruction and secondary functional arm 
reanimation. Neurosurgery 2008; 62:873-885.
4. Hogendoorn S, van Overvest KL, Watt I, Duijsens AH, Nelissen RG. Structural changes 
in muscle and glenohumeral joint deformity in neonatal brachial plexus palsy. J Bone 
Joint Surg Am 2010; 92:935-942.
5. Hale HB, Bae DS, Waters PM. Current concepts in the management of brachial plexus 
birth palsy. J Hand Surg Am 2010; 35:322-331.
6. Malessy MJ, Pondaag W. Neonatal brachial plexus palsy with neurotmesis of C5 and 
avulsion of C6: supraclavicular reconstruction strategies and outcome. J Bone Joint 
Surg Am 2014; 96:e174.
7. Eismann EA, Little KJ, Laor T, Cornwall R. Glenohumeral abduction contracture in children 
with unresolved neonatal brachial plexus palsy. J Bone Joint Surg Am 2015; 97:112-118.
8. Poyhia TH, Nietosvaara YA, Remes VM, Kirjavainen MO, Peltonen JI, Lamminen AE. MRI 
of rotator cuff muscle atrophy in relation to glenohumeral joint incongruence in brachial 
plexus birth injury. Pediatr Radiol 2005; 35:402-409.
9. Poyhia TH, Koivikko MP, Peltonen JI, Kirjavainen MO, Lamminen AE, Nietosvaara AY. 
Muscle changes in brachial plexus birth injury with elbow flexion contracture: an MRI 
study. Pediatr Radiol 2007; 37:173-179.
10. Waters PM, Monica JT, Earp BE, Zurakowski D, Bae DS. Correlation of radiographic 
muscle cross-sectional area with glenohumeral deformity in children with brachial plexus 
birth palsy. J Bone Joint Surg Am 2009; 91:2367-2375.
11. VAN Gelein Vitringa VM, Jaspers R, Mullender M, Ouwerkerk WJ, van der Sluijs JA. Early 
effects of muscle atrophy on shoulder joint development in infants with unilateral birth 
brachial plexus injury. Dev Med Child Neurol 2010.
12. Ruoff JM, van der Sluijs JA, van Ouwerkerk WJ, Jaspers RT. Musculoskeletal growth in the 
upper arm in infants after obstetric brachial plexus lesions and its relation with residual 
muscle function. Dev Med Child Neurol 2012; 54:1050-1056.
13. Hogendoorn S, Duijnisveld BJ, van Duinen SG, Stoel BC, van Dijk JG, Fibbe WE, Nelissen 
RG. Local injection of autologous bone marrow cells to regenerate muscle in patients 
with traumatic brachial plexus injury: a pilot study. Bone Joint Res 2014; 3:38-47.
14. Slabaugh MA, Friel NA, Karas V, Romeo AA, Verma NN, Cole BJ. Interobserver and 
intraobserver reliability of the Goutallier classification using magnetic resonance imaging: 
proposal of a simplified classification system to increase reliability. Am J Sports Med 
2012; 40:1728-1734.
15. Jain NB, Collins J, Newman JS, Katz JN, Losina E, Higgins LD. Reliability of Magnetic 
Resonance Imaging Assessment of Rotator Cuff: The ROW Study. PM R 2015; 7:245-254.
16. Fischmann A, Hafner P, Fasler S, Gloor M, Bieri O, Studler U, Fischer D. Quantitative 





17. Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, Eagle M, 
Mayhew A, de Sousa PL, Dewar L, Morrow JM, Sinclair CD, Thornton JS, Bushby K, 
Lochmuller H, Hanna MG, Hogrel JY, Carlier PG, Vissing J, Straub V. Quantitative muscle 
MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre 
longitudinal study. PLoS One 2013; 8:e70993.
18. Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, Eagle 
M, Mayhew A, de Sousa PL, Dewar L, Morrow JM, Sinclair CD, Thornton JS, Bushby 
K, Lochmuller H, Hanna MG, Hogrel JY, Carlier PG, Vissing J, Straub V. Quantitative 
magnetic resonance imaging in limb-girdle muscular dystrophy 2I: a multinational cross-
sectional study. PLoS One 2014; 9:e90377.
19. Nardo L, Karampinos DC, Lansdown DA, Carballido-Gamio J, Lee S, Maroldi R, Ma CB, 
Link TM, Krug R. Quantitative assessment of fat infiltration in the rotator cuff muscles 
using water-fat MRI. J Magn Reson Imaging 2014; 39:1178-1185.
20. Lee S, Lucas RM, Lansdown DA, Nardo L, Lai A, Link TM, Krug R, Ma CB. Magnetic 
resonance rotator cuff fat fraction and its relationship with tendon tear severity and 
subject characteristics. J Shoulder Elbow Surg 2015.
21. Kovanlikaya A, Mittelman SD, Ward A, Geffner ME, Dorey F, Gilsanz V. Obesity and fat 
quantification in lean tissues using three-point Dixon MR imaging. Pediatr Radiol 2005; 
35:601-607.
22. Karampinos DC, Baum T, Nardo L, Alizai H, Yu H, Carballido-Gamio J, Yap SP, Shimakawa 
A, Link TM, Majumdar S. Characterization of the regional distribution of skeletal muscle 
adipose tissue in type 2 diabetes using chemical shift-based water/fat separation. J Magn 
Reson Imaging 2012; 35:899-907.
23. Alizai H, Nardo L, Karampinos DC, Joseph GB, Yap SP, Baum T, Krug R, Majumdar S, Link 
TM. Comparison of clinical semi-quantitative assessment of muscle fat infiltration with 
quantitative assessment using chemical shift-based water/fat separation in MR studies 
of the calf of post-menopausal women. Eur Radiol 2012; 22:1592-1600.
24. Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat quantification 
of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: 
preliminary study. AJR Am J Roentgenol 2008; 190:W8-12.
25. Wokke BH, Bos C, Reijnierse M, van Rijswijk CS, Eggers H, Webb A, Verschuuren JJ, Kan HE. 
Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration 
in duchenne muscular dystrophy patients. J Magn Reson Imaging 2013; 38:619-624.
26. van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, van 
Deutekom JC, Aartsma-Rus A, Kan HE, Verschuuren JJ. Dystrophin levels and clinical 
severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry 2014; 
85:747-753.
27. Triplett WT, Baligand C, Forbes SC, Willcocks RJ, Lott DJ, DeVos S, Pollaro J, Rooney 
WD, Sweeney HL, Bonnemann CG, Wang DJ, Vandenborne K, Walter GA. Chemical 
shift-based MRI to measure fat fractions in dystrophic skeletal muscle. Magn Reson Med 
2014; 72:8-19.
28. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, Webb AG, van Zwet EW, 
Aartsma-Rus A, Verschuuren JJ, Kan HE. Quantitative MRI and strength measurements 
in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul 
Disord 2014; 24:409-416.
29. Carlier PG, Azzabou N, de Sousa PL, Hicks A, Boisserie JM, Amadon A, Carlier RY, Wary C, 
Orlikowski D, Laforet P. Skeletal muscle quantitative nuclear magnetic resonance imaging 
follow-up of adult Pompe patients. J Inherit Metab Dis 2015; 38:565-572.
56
3
Quantitative MRi foR Muscle atRophy and fatty degeneRation 
30. Wary C, Azzabou N, Giraudeau C, Le LJ, Montus M, Voit T, Servais L, Carlier P. Quantitative 
NMRI and NMRS identify augmented disease progression after loss of ambulation in 
forearms of boys with Duchenne muscular dystrophy. NMR Biomed 2015.
31. Narakas AO. Obstetrical brachial plexus injuries. In: Lamb D, editor. The paralysed hand. 
Edinburgh: 1987. p 116-135.
32. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol 
Bull 1979; 86:420-428.
33. Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of 
specific items: applications to assessment of adaptive behavior. Am J Ment Defic 1981; 
86:127-137.
34. Hogrel JY, Barnouin Y, Azzabou N, Butler-Browne G, Voit T, Moraux A, Leroux G, Behin 
A, McPhee JS, Carlier PG. NMR imaging estimates of muscle volume and intramuscular 
fat infiltration in the thigh: variations with muscle, gender, and age. Age (Dordr ) 2015; 
37:9798.
35. Galban CJ, Maderwald S, Uffmann K, de GA, Ladd ME. Diffusive sensitivity to muscle 
architecture: a magnetic resonance diffusion tensor imaging study of the human calf. 
Eur J Appl Physiol 2004; 93:253-262.
36. Chan S, Head SI, Morley JW. Branched fibers in dystrophic mdx muscle are associated 
with a loss of force following lengthening contractions. Am J Physiol Cell Physiol 2007; 
293:C985-C992.
37. van de Sande MA, Stoel BC, Obermann WR, Lieng JG, Rozing PM. Quantitative 
assessment of fatty degeneration in rotator cuff muscles determined with computed 
tomography. Invest Radiol 2005; 40:313-319.
38. Gaeta M, Scribano E, Mileto A, Mazziotti S, Rodolico C, Toscano A, Settineri N, Ascenti 
G, Blandino A. Muscle fat fraction in neuromuscular disorders: dual-echo dual-flip-angle 





Serial casting for elbow flexion 
contractures in obstetric 
brachial plexus injury
B.J. Duijnisveld 1, D. Steenbeek 2, R.G.H.H. Nelissen 1
1. Department of Orthopaedics, Leiden University Medical Center 
2. Department of Rehabilitation, Leiden University Medical Center





Background: The objective of this study was to evaluate the effectiveness of serial 
casting of elbow flexion contractures in obstetric brachial plexus injury.
Methods: A prospective consecutive cohort study was performed with a median 
follow-up of 5 years. Forty-one patients with elbow flexion contractures ≥30° were 
treated with serial casting until the contracture was ≤10°, for a maximum of 8 weeks. 
Range of motion, number of recurrences and patient satisfaction were recorded 
and analyzed using Wilcoxon signed-rank and Cox regression tests.
Results: Passive extension increased from a median of -40° (IQR -50 to -30) to -15° 
(IQR -10 to -20, p < 0.001). Twenty patients showed 37 recurrences. The baseline 
severity of passive elbow extension had a hazard ratio of 0.93 (95% CI 0.89 to 0.96, 
p < 0.001) for first recurrence. Median patient satisfaction was moderate. Four 
patients showed loss of flexion mobility and in two patients serial casting had to 
be prematurely replaced by night splinting due to complaints.
Conclusion: Serial casting improved elbow flexion contractures, although 
recurrences were frequent. The severity of elbow flexion contracture is a 
predictor of recurrence. We recommend more research on muscle degeneration 
and determinants involved in elbow flexion contractures to improve treatment 
strategies and prevent side-effects.
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IntRoDuctIon
Obstetric brachial plexus injury (OBPI) is caused by trauma to the brachial plexus 
during delivery, resulting in axonotmesis, neurotmesis and/or avulsion of some or 
all of the C5 through T1 nerve roots and/or trunks. The incidence varies between 
0.4 and 4.6 per 1000 live births 1-3. The natural course is diverse and depends on 
the extent and severity of the nerve lesions. Most children show full neurological 
recovery, but 20 to 35% have residual deficits for which reconstructive nerve surgery 
is indicated 4-8. Despite improved function after natural recovery and nerve surgery, 
up to 35% of OBPI patients have residual muscle weakness, contractures and/or 
joint deformities and require additional treatments to further improve the function 
of the upper extremity, including soft-tissue releases, muscle tendon transfers and 
osteotomies 7, 9-11. 
The main sequela of upper OBPI (C5-C6) at the elbow joint is flexion 
contracture, with a prevalence of 50 to 90%. In most cases, flexion contractures 
are limited to 10° to 30° and can be treated by range-of-motion exercising and 
nighttime splinting. In a minority of cases, however, the contracture exceeds 30°, 
and additional treatment is needed. An elbow flexion contracture greater than 
30° has a severe impact on function in terms of the international classification 
of functioning, disability and health (ICF) activity and participation categories, 
since most daily living activities are executed in 30° to 130° of elbow flexion 12-14. 
Literature on the management of elbow flexion contractures in patients with OBPI 
is scarce, and authors have proposed both non-surgical and surgical treatments, 
including splinting, serial casting, anterior elbow release and arthrodiatasis 14-19. 
However, the studies all had limited patient numbers and lacked long-term follow 
up. Although serial casting is frequently applied and globally considered to 
be the preferred therapy, literature on the effect of stretching by serial casting 
for contractures is limited. 
The primary objective of the current study was to evaluate whether serial casting 
of elbow flexion contractures would improve elbow extension in patients with OBPI. 
Secondary objectives were to assess the number of recurrences of elbow flexion 
contractures and to examine side-effects, including the effect of serial casting 
on biceps and triceps muscle strength and restrictions of flexion, supination and 
pronation. Patient satisfaction and predisposing patient characteristics influencing 





A prospective consecutive cohort study was performed among children with OBPI 
treated with serial casting because of elbow flexion contracture. 
Patients
Forty-one consecutive patients with OBPI and elbow flexion contracture of ≥30° 
were recruited at the outpatient clinic of the Leiden University Medical Center 
(LUMC). All recruited patients were enrolled in this prospective cohort study, 
as serial casting treatment was the standard treatment protocol for patients with 
≥30° of flexion contracture (i.e. an extension deficit of 30°) despite regular physical 
therapy and nighttime splinting. Serial casting started with two weeks of casting 
in submaximal stretch to enable the child to get used to the cast and to allow for 
muscle accommodation. From the third week on, the serial casting was performed 
in maximal extension to maximize the effect of the casting period. Serial casting was 
only continued if the treatment was tolerated by the patients. This protocol remained 
unchanged throughout the inclusion period. Patients were excluded from this study 
if they had undergone prior surgery of the affected elbow, or if they had radial head 
dislocation. Patients were also excluded if the elbow flexion contracture benefitted 
the functional ability of the arm. For example, an elbow contracture can be functional 
in the case of poor hand function (Raimondi hand function scale scores below 3 20). All 
children and their parents were informed about common discomforts and functional 
burden during the casting period, like the inability to swim. They were also informed 
about side-effects like temporary restriction of active elbow flexion after cast removal.
All patients were treated by one staff member (R.G.H.H.N.), and serial casting 
was performed with weekly casting in maximal elbow extension, until the flexion 
contracture was 10° or less. Serial casting lasted for a maximum of 8 weeks. If the 
maximal extension was reached after serial casting, patients received a nighttime 
splint, using the final cast as a splint. Physical therapy was continued after serial 
casting, using range of motion exercises. The study protocol to prospectively 
evaluate children with OBPI was approved by the LUMC ethics committee.
Clinical parameters
The age, gender, affected side, severity of the lesion according to Narakas, type 
of primary treatment and age at nerve surgery were recorded 21. All patients were 
evaluated at baseline, after serial casting (a median of 4 weeks, interquartile range 
(IQR) 4 to 6) and at annual regular follow-up, including passive elbow extension and 
flexion as well as passive forearm supination and pronation in 90° of elbow flexion. 
Elbow flexion and extension strengths were measured on a Medical Research 
Council (MRC) 0 - 5 scale, as muscle imbalance was considered one of the factors 
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that can influence recurrence after treatment. Active elbow extension, flexion and 
forearm supination and pronation were assessed at follow-up to assess side-effects. 
We also recorded the number of weeks of serial casting, the number of recurrences 
and whether or not patients received additional treatment. Patient satisfaction 
regarding goal attainment was retrospectively assessed by an independent 
pediatric physiatrist, and critically checked by the first author, who subjectively 
examined the neurosurgeon’s, orthopedic surgeon’s and rehabilitation records, 
and rated patient satisfaction using a 5-point Likert scale: 1. very satisfied, 2. 
moderately satisfied, 3. neither satisfied nor dissatisfied, 4. moderately dissatisfied 
and 5. very dissatisfied. No patients were lost to follow-up, and baseline and 
follow-up range of motion data of all patients were available for analysis.
Statistical analysis
The Wilcoxon signed-rank test was used to test the statistical significance of clinical 
outcome parameters, as range of motion data was not normally distributed. Cox 
regression analysis was used to determine whether any of the clinical parameters 
were associated with recurrence of elbow flexion contractures, including age, 
gender, Narakas type, primary treatment, biceps and triceps muscle strength and 




Patient characteristics are shown in table I, showing separate data for each Narakas 
patient category. Clinical results are shown in table II, again showing separate data 
for each Narakas patient category, including passive extension, flexion, supination 
and pronation, number of patients with one or more recurrences, mean number 
of recurrences per patient, time until first recurrence, biceps and triceps muscle 
strength and patient satisfaction. The elbow range of motion for the total patient 
group is shown in figure 1. This total patient group had a median passive elbow 
extension of -40° (IQR -50 to -30) at the start of serial casting. After serial casting 
for a median of 4 weeks (IQR 4 to 6), the median passive extension had increased 
to -15° (IQR -10 to -20, p < 0.001). At follow-up, after an average of 5 years (IQR 
3 to 6), the median passive extension was -25° (IQR -40 to -20, p < 0.001). During 
this period, 20 (49%) patients had a total of 37 recurrences of elbow flexion 
contracture ≥30° and were treated a second time with serial casting, following 
the same procedure. The median time to the first recurrence was 2 years (IQR 
1 to 4). Excluding patients with recurrent elbow flexion contracture, the median 




-25 to -20, p < 0.001) at follow-up. One patient had 7 recurrences of elbow flexion 
contractures and was treated with multiple serial castings. At an age of 5 years, this 
patient underwent anterior capsule release because of an elbow flexion contracture 
of 70°. After 12 years of follow-up, the patient’s elbow flexion contracture was 
50°. Patient satisfaction was scored at a median value of 2, indicating ‘moderately 
satisfied’ (IQR 1 `very satisfied´ to 2 ´moderately satisfied´). 
Side-effects / complications: elbow flexion, supination and pronation
Two participants scored 5 on the satisfaction scale, indicating ‘very dissatisfied’ 
as regards goal attainment, in both cases due to loss of elbow flexion. Two 
participants reported greater than expected discomfort in the first week of serial 
casting, including pain and hand edema. In both of these children, the serial casting 
had to be prematurely replaced by splinting as a result of complaints. The median 
baseline passive elbow flexion was 150° (IQR 145 to 150). After serial casting for 
Table I: Patient characteristics
Narakas type






Sex (male) 5 8 6
Age at baseline measurement # * (years) 6.8 (4.71) 7.1 (4.36) 10.9 (4.68)
Side (right / left) 7 / 4 10 / 11 4 / 5
Age at primary treatment § * (years) 0.5 (0.26) 0.5 (0.17) 0.4 (0.24)
Conservative / neurolysis / nerve transplantation
Anterior division of superior trunk 
Posterior division of superior trunk 
Medial trunk
Suprascapular nerve
















Shoulder external rotation surgery
Pronation osteotomy of the ulna and/or radius
Wrist extension surgery
Botulinum toxin injection subscapularis
Botulinum toxin injection triceps
Botulinum toxin injection biceps and brachialis †
Biceps rerouting surgery †
Elbow manipulation in narcosis †




























Casting ‡ (weeks) 6 (3 to 7) 4 (3 to 5) 6 (4 to 6)
Follow-up * (years) 5.4 (4.15) 5.6 (3.03) 3.0 (2.97)
#This is the age at the start of serial casting treatment. *The values are given as mean with 
standard deviation. §This is the age at neurosurgical intervention. †Secondary procedure 
performed after inclusion. ‡The values are given as median and interquartile range. 
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-30 (-40 to -30)
-20 (-20 to -14)
-25 (-30 to -20)
-40 (-48 to -30)
-15 (-20 to -10)
-25 (-40 to -20)
-45 (-50 to -38)
-13 (-20 to -6)
-30 (-40 to -18)




150 (145 to 150)
143 (101 to 150)
143 (130 to 150)
150 (145 to 150)
140 (120 to 150)
145 (140 to 150)
150 (143 to 150)
140 (100 to 150)
145 (140 to 150)




90 (88 to 90)
90 (90 to 90)
90 (78 to 90)
90 (74 to 90)
90 (90 to 90)
70 (30 to 90)
90 (85 to 100)
90 (90 to 96)
90 (10 to 90)




90 (80 to 90)
90 (90 to 90)
90 (80 to 90)
90 (38 to 90)
65 (39 to 83)
80 (60 to 90)
30 (5 to 90)
10 (-11 to 90)
70 (0 to 90)
Patients with recurrence
Recurrences per patient #*










Biceps muscle strength ‡ (MRC) 4 (4 to 4) 4 (4 to 5) 4 (3 to 4)
Triceps muscle strength ‡ (MRC) 5 (5 to 5) 4 (3 to 5) 4 (3 to 4)
Patient satisfaction ‡ 2 (1 to 3) 2 (1 to 2) 2 (2 to 3)
‡The values are given as median and interquartile range. # The mean number of recurrences of 
elbow flexion contracture per patient after the initial serial casting treatment.  *The values are 
given as mean with standard deviation. 
a median of 4 weeks (IQR 4 to 6), the median passive flexion had decreased to 
140° (IQR 120 to 150, p = 0.001) and at a mean follow-up of 5.0 years (SD 3.29) it 
had increased again to 145° (IQR 140 to 150, p = 0.006) as shown in figure 1. Four 
patients showed a loss of elbow flexion of 50° or more. One child with a severe 
decrease in elbow flexion, to 85°, had to be treated two times with manipulation 
under general anesthesia, after which the elbow flexion stabilized at 130°. During 
follow-up, six patients were treated with pronation osteotomy of the ulna and/or 
radius, including three patients who were additionally treated with biceps tendon 
transfer at a mean of 5.3 years (SD 1.05) after the start of serial casting. However, 
these supination contractures had no relation with the serial casting. When these 
six patients are excluded, there was no change in the median passive supination at 
follow-up (p = 0.13). The median baseline passive pronation was 90° (IQR 30 to 90) 








Figure 1: Clinical results 
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biceps muscle strength in the total patient group was MRC 4 (IQR 4 to 4) and the 
median triceps muscle strength was MRC 4 (IQR 3 to 5), both of which did not 
change during follow-up. As expected, the median triceps muscle strength was 
lower in patients with C7 involvement (MRC 4, IQR 3 to 5) than in patients with a 
C5-C6 lesion (MRC 5, IQR 5 to 5, p = 0.02). The median biceps muscle strength 
(MRC 4, IQR 4 to 4) was lower than the median triceps muscle strength (5, IQR 5 to 
5) in patients with a C5-C6 lesion (p = 0.025). Biceps and triceps muscle strengths 
were comparable in patients with a C7 involvement (p = 0.34). The median passive 
elbow extension at baseline was lower in patients with C7 involvement (-40°, IQR 
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-50 to -30) than in those with a C5-C6 lesion (-30°, IQR -40 to -30). This difference 
approached significance (p = 0.07). At follow-up, the median active extension was 
-30° (IQR -40 to -20), median active flexion 140° (IQR 135 to 145), median active 
supination 70° (IQR 10 to 90) and median active pronation 80° (IQR 40 to 85).
Predictors of recurrent elbow flexion contractures
Baseline median passive extension was -45° (IQR -60 to -30) in patients with 
recurrence of elbow flexion contracture, compared to -30° (IQR -40 to -30) in 
patients without recurrence, but this difference did not reach statistical significance 
(p = 0.16). Patients whose flexion contracture recurred showed no significant 
difference in passive flexion, supination or pronation at baseline or after serial 
casting, compared to patients without recurrences. However, their median extension 
decreased further during follow-up, despite further serial casting treatments, from 
-20° (IQR -20 to -10) to -40° (IQR -50 to -30, p = 0.001). At follow-up, patients with 
and without recurrence of flexion contracture did not differ in terms of passive or 
active flexion, supination or pronation, or biceps or triceps muscle strength. 
Multivariate cox regression was used to model the time to first recurrence of 
elbow flexion contracture. Severity of passive elbow extension at baseline had a 
hazard ratio of 0.93 (95% CI 0.89 to 0.96, p < 0.001) for first recurrence of elbow 
flexion contracture. The following factors were not associated with recurrence of 
elbow flexion contracture: age, gender, Narakas type, primary treatment, biceps 
or triceps muscle strength and number of weeks of serial casting.
DIScuSSIon
In the present study, serial casting of elbow flexion contractures in children with 
OBPI improved passive elbow extension, although recurrence of elbow flexion 
contractures was frequently observed (49%). Passive elbow flexion was decreased 
after serial casting. Four cases of a severe decrease in elbow flexion (i.e. more 
than 50° loss of elbow flexion) were encountered after casting, for which one 
patient required manipulation under general anesthesia. Although all patients in 
this population recovered during follow-up, the severe decrease in elbow flexion 
should be interpreted as a serious side effect. Passive supination and pronation 
were not affected by serial casting, and no changes were observed in biceps or 
triceps muscle strength. The more severe the contracture was at the start of the 
serial casting, the higher the likelihood of recurrence. 
In terms of the ICF activity and participation levels, elbow flexion contractures 
are generally associated with functional hand positioning limitations, for example 
during balancing, cycling, or activities like carrying a bag or leaning on a 




the clinical relevance of treating elbow flexion contractures. A study by Morrey 
demonstrated that most daily living activities are executed in the 30° to 130° range 
of motion of elbow flexion 13, and skills such as carrying a bag require even more 
elbow extension. These arguments prompted us to treat patients with persistent 
elbow flexion contractures ≥30° with serial casting. Treatment goals in our study 
also related to cosmetic issues. Patients with elbow flexion contractures below 30° 
are generally treated with physical therapy and night splinting only. 
Literature on the treatment of elbow flexion contractures ≥30° is limited. In a recent 
study by Sheffler et al., 9 patients with elbow flexion contractures ≥30° were treated 
with serial casting 14. They showed an improvement in passive elbow extension from 
-49° to -30°, which is less favorable than the results in the present study, which found 
an improvement in passive elbow extension from -40° to -15°. The more favorable 
outcome in our population (passive elbow extension -15° versus -30°) could be the 
result of an earlier start of the serial casting and the duration of serial casting, which 
was not reported by Sheffler et al. 14. These authors found a further deterioration of 
the elbow flexion contracture of 4.4% a year during 27 months of follow-up, which 
is consistent with our finding of 10° of deterioration over 5 years of follow-up. Ho et 
al. treated 19 patients non-surgically for elbow flexion contractures, and found an 
improvement in passive elbow extension from -48° to -17°. However, their results 
included patients treated with serial casting as well as those treated with splinting 17. 
The etiology of flexion contracture of the elbow in children with OBPI is unknown and 
needs further elucidation 10. Current hypotheses in the literature include reinnervation 
of the elbow flexors prior to that of the elbow extensors, leading to muscle imbalance, 
and/or co-contraction as a cause of elbow flexion contractures 12. Our study found no 
differences in biceps and triceps muscle strength of patients with lesions of both C5-C6 
and C7. Patients with lesions only of C5-C6 developed an elbow flexion contracture 
despite stronger triceps than biceps muscles. Thus, the results of our study do not 
support muscle strength imbalance as the cause of elbow flexion contractures. Other 
hypotheses include changes in the partially denervated muscle itself as a cause of 
elbow flexion contracture, including muscle atrophy, fattening and fibrosis 22. It is also 
possible that elbow flexion contractures could be caused by positional preferences 
of the arm in brachial plexus injury. A mild elbow flexion contracture could facilitate 
the weak elbow flexors, as limitation of elbow flexion leads to greater impairment of 
daily activities 13. This, in conjunction with the internal rotation contracture present in 
the shoulder, attenuates the flexion position of the elbow even further.
Strengths of this study include that it is the largest case series so far on the 
treatment outcome of OBPI patients with severe elbow flexion contractures. We 
present clinical outcomes and complication rates, giving further clues about the 
etiology of elbow flexion contractures. To our knowledge there have not been any 
68
4
Serial caSting for elbow flexion contractureS
reports of serial casting studies using a 5-year follow-up. A limitation of this study 
is the lack of control groups to compare different treatment modalities, making 
it a prospective consecutive cohort study. The global use of the therapy and its 
presumed effect make it difficult to obtain ethical approval for including control 
groups and to motivate parents to participate in a randomized controlled trial. 
One of our messages is that the effect should not be overestimated, and we 
strongly recommend that randomized controlled trials be organized. Another 
limitation is that therapy compliance regarding night splinting and co-interventions 
like physical therapy were not recorded, which might have influenced recurrences 
of elbow flexion contracture. A third limitation concerns a lack of reproducibility 
as a result of individual variation in therapy. The maximum stretch force applied 
during serial casting depends on the interaction with and tolerance of the child and/
or parent and therefore might have influenced the outcome of the serial casting 
treatment. On the other hand, a strength of this study is that the intervention 
performed was usual care, and therapy did not change because of participation in 
the study. This was also the reason why we had not expected the dissatisfaction that 
we found, and we therefore had to assess patient satisfaction retrospectively. Future 
studies should assess the patient satisfaction and goal attainment prospectively.
In conclusion, this study demonstrates that serial casting can improve elbow 
flexion contractures in children with OBPI. Complications include temporary 
decrease of elbow flexion and a high rate of recurrence of elbow flexion 
contractures, stressing the importance of close follow-up. The severity of the 
elbow flexion contracture at the start of serial casting is a predictor of recurrence 
of the elbow flexion contracture. Further research into the etiology and treatment 
strategies could optimize the management of elbow flexion contractures in 
OBPI. This could include studies on the many recent developments in dynamic 
splinting techniques. As including an untreated control group is hardly feasible, we 
recommend randomized controlled trials comparing generally accepted therapy 
strategies such as serial casting and dynamic splinting. More research is needed to 
evaluate serial casting of elbow flexion contractures at the ICF level of activity and 
participation. In order to prevent side-effects, we recommend a close follow-up, 
careful physical examination during the cast changes and critical estimation of the 
casting period, which should be as short as possible.
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Background: Obstetric brachial plexus injury (OBPI) is frequently associated with 
internal rotation contractures of the shoulder as a result of muscle imbalance. The 
purpose of this study is to assess the effect of botulinum toxin A (BTX-A) injection 
in the subscapular muscle on external rotation and the need for tendon transfer 
for external rotation of the shoulder.
Methods: A prospective comparative study was performed including 15 consecutive 
patients treated with BTX-A and a historic control group of 67 patients with mean 
age 30 months (SD 10). The BTX-A injection (2 IU/kg body weight) was performed 
immediately following MRI under general anesthesia in the subscapular muscle. 
Passive external rotation, the need for tendon transfer surgery, glenohumeral 
deformity and muscle degeneration were evaluated. The hazard ratio for no 
relapse of internal rotation contracture after BTX-A injection compared to no BTX-A 
injection was calculated.
Results: In the BTX-A group, the passive external rotation in adduction increased 
from -1° (95% CI -10 to 8) to 32° (95% CI 17 to 46) at 3 months and 6 patients were 
indicated for surgery compared to a decline from -2° (95% CI -7 to 3) to -11° (95% 
CI -17 to -6) in the control group with 66 indications for surgery. At 5 years follow-
up, 10 patients in the BTX-A group were indicated for surgery with a hazard ratio 
of 4.0 (95% CI 1.9 to 8.4). 
Conclusions: BTX-A injection in the subscapular muscle of OBPI patients can 
reduce internal rotation contractures and subsequently the need for tendon transfer 
surgery. At 5 years follow-up a relapse was seen in 67% of the patients treated with 
BTX-A. Since at MRI less SC degeneration was found in the good responders on 
BTX-A treatment, this group seems to be the best target group. Further research is 
needed on patient selection for BTX-A injection including glenohumeral deformity, 
subscapular degeneration as well as doses of BTX-A to be used.
Level of Evidence: Level II - prospective comparative study.
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IntRoDuctIon
Obstetric brachial plexus injury (OBPI) patients often develop internal rotation 
contractures with a prevalence of up to 39% depending on the extent and severity 
of the brachial plexus injury 1, 2. Several theories on the origin of an internal rotation 
contracture in OBPI patients exist. The muscle imbalance theory states that OBPI 
leads to muscle imbalances around the shoulder, in which internal rotators are 
stronger resulting in an internal rotation contracture 3, 4. But also posture by which 
the injured extremity is held close to the body to enable easier bimanual activities, 
will cause a contracture if this position is unopposed by active external rotation. 
Recently an animal study has shown that selective denervation of the subscapular 
muscle (SC) alone leads to SC atrophy and internal rotation contracture indicating 
that weakness of the external rotators are not solely responsible for the muscle 
imbalance causing internal rotation contracture 5. Furthermore, excision of the 
external rotators in mice without brachial plexus injury caused no contractures or 
shortening of the SC muscle 6. Previously, MRI studies have shown that upon brachial 
plexus injury the muscle degeneration was most prominent in the SC muscle 7.
Treatments of internal rotation contractures include surgical SC release. These 
techniques are combined with transfer of a latissimus dorsi and/or teres major 
tendon to the rotator cuff to create active external rotation to improve arm function 
and quality of life 8-10. Disadvantages of SC release and/or tendon transfer include 
weaker adduction and potential partial power loss of internal rotation with a 
subsequent risk for an external rotation contracture of the shoulder. A less invasive 
method to address the internal rotation contracture is the injection of botulinum 
toxin A (BTX-A) 10-12. There have been some reports on BTX-A injections but no 
clear conclusions can be drawn from these studies since the heterogeneity was 
large (ie number of BTX-A injections, variety of muscles, combination with tendon 
transfer surgery) 13-18. 
Our hypothesis is that injection of BTX-A into the SC muscle alone could 
temporarily weaken its function to open a time window primarily for the treatment 
of the internal rotation contracture with intensive physical therapy, but also to give 
the external rotation movement time to get “learned” (i.e. cerebral plasticity) again 
during global movement of the upper extremity. There have been no reports on 
BTX-A injection in the SC to treat internal rotation contracture of OBPI children 
without tendon transfer surgery. 
The primary objective of the present study was to assess the efficacy of BTX-A 
injection in the SC on the passive external rotation (PER) in children with OBPI. 
Because of a potential increase of PER, the need of tendon transfer could decrease 
after BTX-A treatment. Therefore the second objective was to assess the effect 








A prospective comparative study was performed with at least five year follow-up 
on 15 OBPI patients with an internal rotation contracture treated with BTX-A in 
the SC muscle.  Clinical outcome of these BTX-A OBPI patients were compared 
to a historic prospective control group of 67 patients with an internal rotation 
contracture. BTX-A was used after written informed consent was obtained from 
the parents. 
Between 1997 and 2009 all patients with OBPI were seen at the outpatient clinic 
of the Leiden University Medical Center. Only those patients with a progressive 
internal rotation contracture were included in the present study, regardless 
whether the OBPI lesion was initially treated conservatively or by nerve surgery. 
From 2007 onwards, all patients younger than 48 months old were injected with 
2 IU/kg BTX-A (Botox ®, Allergan Inc.) in the two parts of the SC muscle. Patients 
treated before 2007 were used as a historical control group. Management of all 
patients, both the historical control group and the BTX-A group, consisted of 
daily stretching exercises supervised by a trained physical therapist for at least 
3 months. A progressive internal rotation contracture was defined as an external 
rotation in adduction of less than 30 degrees. In all patients, the passive external 
rotation (PER) range of motion was reduced to 30° or less, and the Mallet functional 
shoulder score was 3 or less for the subsets hand-to-mouth and/or hand-to-head 
movement 19. A standardized MRI of the shoulder was performed under anesthesia, 
which is part of the preoperative work-up for children eligible for an external 
rotation tendon transfer in our clinic 7. In the control group, all patients eligible 
for MRI were considered to have a surgical contracture release and a tendon 
transfer after the MRI. The time elapsed between MRI and surgery depended on 
the surgical waiting list. 
To reduce any potential sources of bias, consecutive patients were included. 
Furthermore, in both the historical patient group and the BTX-A group, patients 
were excluded if a complete posterior dislocation of the humeral head was present 
at MRI. A complete dislocation was defined as a smaller than 10% part of the 
humeral head being anterior to the longitudinal axis of the scapula (PHHA) 20. These 
dislocated shoulders were considered to be beyond the point of a correctable joint. 
Patients with prior secondary orthopedic surgery or Raimondi hand function scale 
less than 3 were excluded as well 21. 
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The affected side, severity of the lesion according to Narakas, type of primary 
treatment and age at nerve surgery was recorded 22. All patients were evaluated at 
3 months and yearly after the BTX-A injection at the outpatient clinic. All patients 
completed 5 year follow-up and were included in the data analysis. If a tendon 
transfer was not indicated, then patients were scheduled for clinical follow-up. The 
medical ethical review board of the Leiden University Medical Center approved for 
the prospective database of orthopedic interventions of OBPI patients. 
Clinical assessment
The PER of the glenohumeral joint was assessed in adduction and 90° abduction 
using a hand held goniometer. The passive external rotation range of motion 
was measured with the elbow flexed to 90° and with the hand of the examiner 
holding the scapula (i.e. the acromion). True glenohumeral external rotation range 
was measured at the position where the first sign of resistance (i.e. movement of 
scapula with respect to the humeral bone) while external rotating the arm was 
felt. No force was exerted on the arm in order to avoid a shift of the scapula 
which introduces a thoracoscapular component in the total external rotation range. 
Negative degrees denote internal rotation from neutral position. Furthermore, the 
passive glenohumeral abduction was measured and the passive internal rotation 
was measured in 90º abduction.  The Mallet score was used to assess global active 
shoulder function 19. 
BTX-A injection
The BTX-A injection was performed immediately following the MRI under general 
anesthesia in fifteen patients. In one patient the BTX-A injection was performed 
two months after the MRI was performed under general anesthesia. Patients were 
put in the lateral decubital position with the affected arm in maximum internal 
rotation and adduction to reach winging of the medial edge of the scapula. A flacon 
of 100 IU BTX-A was diluted in 10 ml 0.9% NaCl. In total, 2 IU per kg was injected 
per patient. A nine cm 22 gauge slightly bowed needle was inserted anterior of 
the medial scapular edge at one- and at two-thirds of the distance between the 
angulus superior and inferior of the scapula to block the motor endplates of the 
upper subscapular and the lower subscapular nerves. When the needle touched 
the scapular bone, the needle was retracted a few millimeters to ensure that the 
BTX-A was injected in the SC 23. Slightly bowing the needle did never result in 
breaking. Furthermore, neurovascular injury or pneumothorax did not occur. After 
BTX-A injection parents were instructed to continue the daily stretching exercises 
just as before the BTX-A injection supervised by a trained physical therapist. 






The MRI images were acquired using a 1.5 Tesla magnet (Philips Healthcare Inc.). 
T1 images were made in the transverse plane of the shoulder. For all sequences, 
the slice thickness was 4.0 mm with a 0.4 mm spacing gap. The degree of glenoid 
version and PHHA were measured in a transverse plane of the shoulder at 
midglenoid level, as previously described 7, 20, 24. The degree of SC degeneration 
was measured on a 3-point visual scale. The SC was graded as normal if the 
diameter of the SC of the affected and the contra lateral shoulder were similar. 
The SC was graded as atrophic if the diameter was smaller. If fatty streaks 
were also present, the SC was graded as atrophic with fatty degeneration 7. To 
measure the interobserver variability, 2 independent observers evaluated the 
PHHA and glenoid version of 15 patients (R.G.H.H.N. and B.J.D.) and the SC 
degeneration of 50 patients (S.H. and B.J.D.). One investigator (B.J.D.) repeated 
the scoring at an interval of two weeks to measure the intraobserver variability. 
The interobserver variability of the MRI variables was excelled for glenoid 
version (ICC 0.87), PHHA (ICC 0.96) and SC degeneration (kappa 0.77) as was 
the intraobserver variability for glenoid version (ICC 0.92), PHHA (ICC 0.96) and 
SC degeneration (kappa 0.79).
Statistical analysis
Statistical differences were tested by the Pearson’s Chi-Square test for nominal 
categorical variables, the Fisher’s exact test for nominal categorical variables if 
more than 20% of the cells had an expected value of less than 5 and the Mann-
Whitney test was used for ordinal categorical variables. The Student independent 
sample t-test was used for continuous variables with 95% confidence intervals (CI). 
Differences in Mallet scores were tested using the Wilcoxon Signed Ranks test. 
Kaplan Meyer analysis was used to calculate survival probability of conservative 
therapy with 95% confidence interval of the BTX-A patient group. The interclass 
correlation coefficient (ICC) was calculated for reliability testing of the PHHA and 
glenoid version, using the 2-way random model with absolute agreement 25. The 
linear weighted kappa was calculated for reliability testing of SC degeneration 26. 
For interpretation, the criteria formulated by Cichetti and Sparrow were used: 0.00 
to 0.39, poor; 0.40 to 0.59, fair; 0.60 to 0.74, good; or 0.75 to 1.00, excellent 27. 
For statistical analysis a SPSS software package was used (SPSS Inc., version 20.0, 
Chicago, Illinois). For the Kaplan Meier analysis R was used (The R foundation 
for statistical computing, version 3.1.2, Austria). All analyses were two tailed and 
p-values < 0.05 were considered significant.  
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ReSultS
Range of motion
The individual characteristics of patients treated with BTX-A and the control group 
are summarized in Table I. No significant differences were found between gender, 
age, affected side, Narakas type and type of primary treatment. No adverse events 
were observed following BTX-A injection. The results of the PER and indications for 
tendon transfer surgery for both groups are summarized in Table II. At baseline, the 
mean PER in adduction was -1° (95% CI -10 to 8) in the BTX-A group and -2° (95% 
CI -7 to 3) in the control group. In the BTX-A group, the mean PER in adduction was 
increased to 32° (95% CI 17 to 46) after 3 months follow-up. In the control group, 
who eventually had surgery, the follow-up time was determined by the waiting 
list for surgery. All patients were assessed at the day before surgery again. The 
mean follow-up time of the control group was 5.7 (SD 2.2) months. These patients 
showed a further decline with a mean PER in adduction to -11° (95% CI -17 to -6). 
The PER in abduction in the BTX-A group increased from 55° (95% CI 45 to 
65) to 65° (95% CI 55 to 80, p = 0.014) after three months. No significant changes 
were observed after 1 or 5 years. The median passive abduction was 90 degrees 
(interquartile range 90-90) and did not change during follow-up. The passive 
internal rotation in abduction increased from 45° (95% CI 35 to 55) to 65° (95% CI 
50 to 85, p = 0.005) after 5 years follow-up. The Mallet score did not significantly 
change for the BTX-A or the control group at follow-up.
Tendon transfer surgery
At follow-up after the BTX-A injections, patients were indicated for tendon transfer 
surgery if the internal rotation contracture persisted (PER in adduction 30° or 
less) in presence of no active external rotation, both indicating a Mallet functional 
shoulder score of 3 or less for the subsets hand-to-mouth and/or hand-to-head 
movement. Survival probability of conservative therapy is shown in the Kaplan 
Meier curve of figure 1. In the BTX-A group, six patients (40%) were indicated for 
tendon transfer after 3 months. Nine patients showed an improvement in PER in 
adduction and were therefore not indicated for tendon transfer surgery. In contrast, 
only one patient in the control group showed (spontaneous) good clinical function 
at follow-up and 66 patients (99%) were indicated for tendon transfer surgery. At 
5 years follow-up, 10 patients (67%) in the BTX-A group showed an internal rotation 
contracture relapse and were therefore indicated for tendon transfer surgery. The 
hazard ratio for no relapse after BTX-A injection compared to no BTX-A injection 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MRI and patient characteristics
MRI characteristics of the BTX-A and the control group are shown in Table I. The 
glenoid version, PHHA and SC degeneration were not different between the 
groups. Of the 5 patients in the BTX-A group with still a good response after 5 
years follow-up, the SC score was normal in 2 patients (40%), atrophic in 1 patient 
(20%) and atrophic with fatty degeneration in 2 patients (40%). Whereas in the 
10 patients who were indicated for tendon transfer surgery, the SC score was 
normal in none of the patients, atrophic in 2 patients (20%) and atrophic with fatty 
degeneration in 8 patients (80%), however this was not significantly different (p = 
0.08). No significant differences were found in age, gender, Narakas type, primary 
treatment, baseline PER, glenoid version or PHHA between the good responder 
group and the patients indicated for tendon transfer surgery. 
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Figure 1: Survival after BTX-A treatment versus control group 
 
Kaplan Meyer curve with survival probability of conservative therapy with 95 % confidence interval of the botulinum toxin A 
(BTX-A) and control group. Tendon transfer surgery was indicated if at follow-up the passive external rotation (PER) range 
of motion persisted at 30° or less and the Mallet functional shoulder score was 3 or less for the subsets hand-to-mouth 




The purpose of the present study was to assess the efficacy of BTX-A injection in the SC to improve 
the PER in children with OBPI. No adverse events were observed, therefore BTX-A injection can be 
considered to be safe and feasible in this patient group with a mean age of 2.5 years old. The results 
of this study show that BTX-A injection increases PER in adduction compared to the control group. 
Addressing internal rotation contracture of the shoulder is important since progressive glenohumeral 
joint deformity occurs after persisting internal rotation contracture in OBPI 7, 20. The reason to focus 
on the SC muscle to treat the contracture was that the SC muscle is the main constrained in 
adduction of the arm and source of internal rotation contracture. The results of this study are 
Figure 1: S ival after BTX-A treatment ersus control group
Kaplan Meyer curve with survival probability of conservative therapy with 95 % confidence interval 
of the botulinum toxin A (BTX-A) and control group. Tendon transfer surgery was indicated if at 
follow-up the passive external rotation (PER) range of motion persisted at 30° or less and the 




BTX-A injecTion for inTernAl roTATion conTrAcTures
DIScuSSIon
The purpose of the present study was to assess the efficacy of BTX-A injection in 
the SC to improve the PER in children with OBPI. No adverse events were observed, 
therefore BTX-A injection can be considered to be safe and feasible in this patient 
group with a mean age of 2.5 years old. The results of this study show that BTX-A 
injection increases PER in adduction compared to the control group. Addressing 
internal rotation contracture of the shoulder is important since progressive 
glenohumeral joint deformity occurs after persisting internal rotation contracture 
in OBPI 7, 20. The reason to focus on the SC muscle to treat the contracture was 
that the SC muscle is the main constrained in adduction of the arm and source of 
internal rotation contracture. The results of this study are clinically relevant since 
the improvement of PER was sufficient to postpone tendon transfer surgery for 
at least five years and prevent tendon transfer surgery in 33% of patients in the 
BTX-A group. These good responders on BTX-A injection showed less SC muscle 
degeneration. This difference did not reach statistical significance, most probably 
due to the low number of patients treated. Lack of effect on BTX-A injection in 
degenerated muscle (fibrosis or fatty degeneration) could be a result of absence 
of a target for the BTX-A, since no or little muscle fibers are present.
In previous studies many different muscles were injected (pectoralis major and 
minor, teres major, SC and latissimus dorsi), in a variety of number of injections 
(1 to 4) and patients with a variety of ages (range 0.3 to 13.5 years old) 13-17. In a 
recent study Michaud et al. found a mean increase of 6° in PER after BTX-A injections 
in the muscles which altered the surgical plan in 4 of the 18 patients, however also 
multiple muscles were injected (pectoralis major, SC and / or latissimus dorsi) in 
patients with variable ages (range 0.5 to 10 years) with short follow-up of 1 year 18. 
The present study is the first controlled study on BTX-A injections in the SC of 
OBPI patients to correct internal rotation contractures. 
In this study the improved clinical effect outlasted the therapeutic time window 
of BTX-A. This phenomenon could be explained by the time window opened by 
the BTX-A injection which causes relaxation of the SC muscle during which physical 
therapy could be more effective. Furthermore, relaxation of the SC muscle reduce 
afferent signals to the brain and gives time for cortical recruitment for the injured 
nerves leading to an altered balance between afferent input and motor output 15, 28. 
Limitations of this study include the lack of long term (beyond five years) effects 
on PER and the need for tendon transfer surgery in the future remain unknown at 
this moment. Because glenohumeral joint morphology and SC degeneration affect 
shoulder functional outcome, we measured the PHHA, glenoid version and the SC 
degeneration of the affected and normal shoulder on MRI.  As previously observed, 




shoulder compared to the normal shoulder 7, 20. This study excluded patients with 
severe glenohumeral deformity and/or complete posterior dislocation of the 
humeral head, since it was considered that this deformity was beyond a passively 
correctable joint. Finally, this study is a non-randomized study, thus confounders 
might be present for example the willingness of the parents to practice the 
external rotation. 
In conclusion, this prospective observational study demonstrates that BTX-A 
injections in the SC of OBPI children with an internal rotation contracture reduces 
the internal rotation contracture and could potentially postpone and in some cases 
prevent external rotation tendon transfer surgery. The beneficial effect of BTX-A 
injection due to relaxation of the SC muscle opens a time window for both intensive 
exercises of external rotation, as well as teaching the child to make this movement 
part of its global movement of the extremity (i.e. cerebral plasticity). Both pathways 
will reduce the internal rotation contracture resulting in a new balance between 
the external and internal rotators of the shoulder. This is however not valid in 
all patients since at minimum 5 years follow-up a relapse of internal rotation 
contracture was seen in 67% of the patients treated with BTX-A. Since at MRI less 
SC degeneration was found in the good responders on BTX-A treatment, this 
group seems to be the best target group. BTX-A injection in multiple injection sites 
of the subcapular muscle could optimize the effectiveness of BTX-A treatment as 
anatomic studies showed variability of the subscapular innervations 29, 30. This study 
focused on patients of 4 years old or younger as young patients may have more 
reinnervation potential and more cerebral plasticity to strengthen the external 
rotators. Future research could focus on patients older than 4 years to investigate 
whether or not the indication for BTX-A treatment could be extended to older 
patients with OBPI. Further research is needed on patient selection for BTX-A 
injection including glenohumeral deformity, SC degeneration as well as doses of 
BTX-A to be used and whether repeating the BTX-A injection could further reduce 
the internal rotation contracture. 
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Introduction: Histological characteristics of age-related muscle wasting are type II 
muscle fiber atrophy, accumulation of oxidative stress-induced lipofuscin granules 
and decreased satellite cell numbers. There is increasing clinical evidence for a 
strong correlation between chronic systemic inflammation and age-related muscle 
wasting. The aim of this study was to determine the impact of chronic systemic 
inflammation on age-related histological muscle characteristics. 
Methods: As a model for chronic systemic inflammation, we included 10 patients 
suffering from rheumatoid arthritis (RA) and 27 control patients suffering from 
osteoarthritis (OA). Biopsies were taken from the vastus medialis muscle. 
Results: No significant differences were found in type II muscle fiber atrophy, 
lipofuscin accumulation, or satellite cell number in RA compared with OA patients. 
Conclusions: These results suggest there is no association between chronic systemic 
inflammation in RA and age-related muscle characteristics. Future research should 
focus on inflammation and satellite cell function. 
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IntRoDuctIon
Age-related loss of skeletal muscle mass (sarcopenia) is a major contributor to 
disability and mortality 1-3. Between the ages of 20 and 80 years the average 
reduction in muscle cross-sectional area amounts to 40 % 4. The size and numbers 
of muscle fibers are under control of satellite cells, the muscle progenitor cells that 
lie inactivated between the basal lamina and the sarcolemma 5. A decline in satellite 
cell number, together with type II muscle fiber atrophy has been reported to occur 
during aging 6, 7. Morphologically, muscle fibers and satellite cells of elderly subjects 
show an accumulation of lipofuscin granules, a marker for oxidative damage 8, 9. 
Despite its clinical importance, the pathophysiological mechanisms behind the 
development of sarcopenia are not yet well known.
A possible cause for sarcopenia is systemic low grade chronic inflammation. 
Increased systemic pro-inflammatory cytokine levels have been observed 
during aging and they have been associated recently with poor muscle strength 
independent of diseases, smoking or physical exercise 10, 11. In patients suffering 
from rheumatoid arthritis (RA) the levels of inflammatory markers are high at middle 
age, despite anti-inflammatory treatment 12, 13. In these patients, muscle strength 
is significantly lower compared with the general population 14, 15.
In this study we aimed to determine the impact of chronic systemic inflammation 
on age-related histological muscle characteristics, type II muscle fiber atrophy, the 
level of lipofuscin accumulation and satellite cell number per fiber. As a model for 
chronic systemic inflammation, we examined muscle biopsies from patients with 
RA who have a significantly higher pro-inflammatory profile when compared with 
patients with osteoarthritis (OA) 12, 16.
MetHoDS
Study Population
The study population included patients suffering from RA (n = 10) and OA as 
controls (n = 27) who underwent elective knee replacement surgery in the period 
2008 to 2010. Patients with knee revision surgery, tumor surgery, acute trauma, 
osteonecrosis, myositis, or ankylosing spondylitis were excluded. RA patients were 
matched with OA patients on gender and age. Height and weight were assessed 
preoperatively, and inactivity (0 to 10) and pain scores (0 to 10) were assessed using 
the Dutch version of the AIMS questionnaire 17. Preoperative blood samples were 
taken for measurement of C-reactive protein (CRP) levels, erythrocyte sedimentation 
rate (ESR) and white blood cell (WBC) concentration. Anti-inflammatory medication 
use, including prednisone, methotrexate and TNF inhibitors during the 5 years 




were collected from medical charts. The study protocol was approved by the 
Medical Ethics Committee of the Leiden University Medical Center.
Muscle Biopsies
A muscle biopsy was taken from the distal part of the vastus medialis muscle 
during elective knee replacement surgery. After embedding in Tissue-Tek (Sakura 
Finetek, the Netherlands) biopsies were frozen in liquid nitrogen and stored at 
−80 °C until further analysis. Muscle biopsies were cut in sections of 10 μm and 
5 μm at −21 °C using a cryostat-microtome (Leica Instruments GmbH, Nussloch, 
Germany) and mounted on uncoated microscope slides (Starfrost, Braunschweig, 
Germany). Immediately after cutting, the sections were evaluated for cross-sectional 
alignment. Biopsies from RA and OA patients were stained simultaneously and 
blinded for patient characteristics.
Fiber Type Staining
To determine muscle fiber type, 10 μm sections were stored at −20 °C for a 
maximum of 1 night. The nonreversed method for ATPase staining as described 
by Round et al. was used 18. Briefly, slides were incubated for 30 min in 10 mg ATP 
(ATP disodium salt, Sigma Chemicals Ltd) and dithiothreitol in buffered calcium 
chloride at pH 9.4 at 37 °C. Second, slides were washed in calcium chloride 1 % 
and incubated in cobalt chloride 2 % for 2 min. Afterward, slides were washed 
very thoroughly in distilled water and incubated in an ammonium sulphide 1 % 
solution for 30 s.
Lipofuscin Staining
Lipofuscin accumulation was determined using two 5-μm sections and the level 
of lipofuscin specific auto-fluorescence was determined 9. To localize the cross-
sectional muscle fibers, the fiber membrane was stained with PC128 (dilution 1:500, 
sheep anti-laminin, The Binding Site, Birmingham, U.K) as primary antibody and 
Cy5 (dilution 1:50) as secondary antibody. Stained sections were stored at 4 °C 
until images were captured.
Satellite Cell Staining
Satellite cells were stained as described earlier by Lindstrom and Thornell 19. Two 
5 μm sections were fixed in 2 % formaldehyde for 8 min and rinsed in 0.01 M 
phosphate buffered saline containing 0.05 % Tween 20 (VWR Prolabo, Fontenay-
sous-bois, France) 3 times for 5 min each. Sections were blocked with IgG-free 
bovine serum antigen 4 % (Jackson Immuno Research, West Grove, Pennsylvania) 
for 90 min (first primary anti-body incubation) and for 60 min (second primary 
antibody incubation). First, sections were incubated with CD56 (dilution 1:3, mouse 
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anti-CD56; BD biosciences, San Jose, CA) overnight at 4 °C followed by incubation 
with FITC (dilution 1:50). Second, sections were incubated with Pax7 (dilution of 
1:10, Mouse anti-PAX-7, Developmental Studies Hybridoma Bank, Iowa City, USA) 
and PC128 (dilution 1:500, Sheep anti-laminin, The Binding Site, Birmingham, 
UK) for 60 min at room temperature. PC128 were labeled with Cy5 (dilution 1:50) 
and Pax7 with Rhodamine Red (dilution 1:200). All secondary antibodies were 
purchased from Jackson Immuno Research, West Grove, Pennsylvania. Nuclei were 
stained with Hoechst 33258 (Molecular Probes, Leiden, The Netherlands) for 5 min 
at room temperature. Sections were washed with PBS 3 times for 5 min each, 
mounted with aqueous mounting medium (Dako, Carpinteria, USA) and covered 
with cover glasses. Slides were stored at 4 °C for a maximum of 3 days until images 
were captured.
Image Capture and Analysis
All images were captured and analyzed blindly for patient characteristics. Slides 
stained for muscle fiber type determination were scanned using a 3Dhistech 
automatic digital slide scanner (Panoramic Midi, 3Dhistech) with a 20× magnification 
(figure 1). For each patient a minimum of 200 (mean 339 for type I fibers and 596 
for type II fibers) muscle fibers were randomly selected. The cross-sectional area 
of muscle fibers was measured using the program HistoQuant (3Dhistech). Fibers 
were counted using Image-J software, version 1.43. We quantified type II fiber 
atrophy by (1) the ratio of the mean area of single type II fibers to that of single type 
I fibers and (2) the number of type II fibers related to the total number of fibers. 
However, in 1 RA and 3 OA patients fiber type measurement was not possible due 
to poor staining quality or low number of muscle fibers.
Two hundred cross-sectional muscle fibers were captured at 40 × magnification 
to quantify lipofuscin accumulation using a conventional Leica DM 5500 B 
fluorescence microscope (Leica, Rijswijk, The Netherlands) together with a 
CoolSnap K4 cooled charge-coupled device camera (Roper Scientific, Evry Cedex, 
France). Contrast was enhanced, and the total gray value was measured using 
Image-J software version 1.43. 
Satellite cells were visualized using the same fluorescence microscope and 
camera as was used for the lipofuscin measurements. At 40 × magnification 
images were captured and analyzed for at least 200 cross-sectional muscle fibers 
per patient. For this procedure the software program Colorproc was used to 
automatically decrease background staining. Satellite cell number was measured 
in 5 RA and 12 OA patients due to limited biomaterial. Cells were identified 
as satellite cells if they were stained by Pax7 or NCAM containing a nucleus 




staining (figure 1). Satellite cells were identified and counted blinded to group 
by 2 independent observers. Disagreement was resolved by consensus. Satellite 
cell number was determined in relation to the number of muscle fibers within an 
image using the formula: number of counted satellite cells/number of counted 
muscle fibers × 100.
Figure 1: Images of muscle cross-sections stained for muscle fiber typing and satellite cell 
identification by multi-labeling
(A) Staining of type I (white) and type II (black) muscle fibers. (B) DAPI staining (blue). (C) N-CAM 
staining (green). (D) Pax7 staining (red). (E) Combination of DAPI, N-CAM, Pax7, and laminin (white). 
The satellite cell is indicated by an arrow. Lipofuscin granules are indicated by an arrowhead.
Statistical analysis
The independent-samples t-test was used to test for differences in age, height, 
weight, inactivity score, pain score, CRP, ESR, and WBC concentration between 
RA and OA patients. Differences in distribution of gender, the use of prednisone, 
methotrexate and TNF inhibitors and peripheral neuropathy and lumbar discopathy 
were tested by use of the Mann-Whitney test. Linear regression models were 
used to test for differences between RA and OA patients and for associations 
between muscle characteristics and CRP, ESR, and WBC concentration. All models 
were adjusted for age, gender, height and weight. Analyses were performed using 
SPSS software (version 16.0 SPSS Inc, Chicago, USA). All p-values below 0.05 were 
considered to be statistically significant.
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ReSultS
The ratio of single type II and type I fiber areas, the percentage of type II fibers, 
the level of lipofuscin accumulation and the number of satellite cells per fiber 
were compared between patients with RA and OA. Patient characteristics are 
given in table I. The mean age of the RA group was 63.6 years (SD 9.1), and it 
was 66.0 years (SD 8.4) in the OA group. The gender distribution and pain scores 
were comparable between the groups. The inactivity score was not significantly 
higher in the RA group compared with the OA group. The mean duration of RA 
disease was 22.6 years (SD 13.0). All markers of inflammation as well as anti-
inflammatory medication use were significantly higher in RA patients compared 
with OA patients.
Table I: Patient characteristics
RA-group OA-group
Characteristic n = 10 n = 27 P - value
Age (years) 63.6 (9.05) 66.0 (8.41) ns
Sex (% female) 80 81 ns
Disease duration (years) 22.6 (13.0) n/a
Height (cm) 169.9 (11.7) 165.3 (6.7) ns
Weight (kg) 85.0 (19.9) 86.4 (17.3) ns
Clinical measurements *
    Inactivity score (0 – 10) 3.9 (2.9) 2.5 (2.0) ns
    Pain score (0 – 10) 5.4 (2.6) 6.6 (2.1) ns
Markers of inflammation
    CRP (mg/l) 11.8 (10.8) 3.3 (4.9) † 0.038
    ESR (mm) 23.8 (14.9) 10.2 (6.3) ‡ 0.020
    WBC (*109/L) 9.4 (2.8) 7.2 (1.5) § 0.042
Anti-inflammatory medication
    Prednisone (%) 3 (30) 1 (4) 0.024
    Methotrexate (%) 8 (80) 0 < 0.001
    TNF inhibitors (%) 3 (30) 0 0.003
Neurologic diseases
   Peripheral neuropathy (%) 0 2 (7) ns
   Lumbar discopathy (%) 1 (10) 1 (4) ns
RA: rheumatoid arthritis, OA: osteoarthritis, CRP: C-reactive protein, ESR: Erythrocyte 
sedimentation rate, WBC: White blood cells, TNF: Tumor necrosis factor, ns: not significant. 
Values are given as mean (SD) if not otherwise stated. Dutch version of the AIMS questionnaire 
was used to assess the inactivity and pain scores. *available for 4 RA and 16 OA patients. †available 




Figure 2 shows the histological characteristics of the muscle tissue in patients 
with RA and OA. The mean ratio of type II and type I single fiber areas was 0.68 (SE 
0.25) in the RA group versus 0.69 (SE 0.23) in the OA group. The mean percentage 
type II fibers was 66.8 % (SE 4.9) in the RA group and 62.7% (SE 1.6) in the OA 
group. The mean lipofuscin value was 0.21 (SE 0.03) in the RA group and 0.16 (SE 
0.01) in the OA group. The number of satellite cells per fiber was 6.1 % (SE 2.9) in 
RA patients and 5.5 % (SE 1.1) in OA patients. After adjustment for gender, age, 
height and weight no significant differences in the ratio of type II and type I single 
fiber areas, the percentage of type II fibers, the level of lipofuscin accumulation 
and the number of satellite cells per fiber were found between RA and OA patients. 
Independent of RA and OA diagnosis, no significant association was found between 
markers of inflammation and histological muscle characteristics (table II).
Figure 2: Ratio of type II and type I single fiber areas, percentage type II fibers, lipofuscin level 
and satellite cell number per fiber in muscle tissue from RA and OA patients
Results are given as mean and standard error. p-values are calculated using linear regression 
analysis adjusted for age, gender, height, and weight. RA: rheumatoid arthritis, OA: osteoarthritis, 
ratio of single type II/I area: ratio of the area of single type II fibers to that of single type I fibers, 
percentage type II fibers: number of type II fibers related to the total number of fibers, TGV: total 
gray value, SC: satellite cell.
DIScuSSIon
Chronic systemic inflammation is suggested to play an important role in muscle 
wasting during aging 15, 20, 21. To test for the impact of chronic systemic inflammation 
on characteristics associated with muscle aging, we compared muscle biopsies 
obtained from patients with an inflammatory disease (RA) and control patients 
(OA). No significant differences were found in type II muscle fiber atrophy, the level 
of lipofuscin accumulation or the number of satellite cells per fiber in patients with 
RA compared with OA patients.
Multiple factors, including age and inactivity, are known to cause type II muscle 
fiber atrophy 4, 22. Both RA and OA are associated with a lower activity level and 
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type II muscle fiber atrophy 23-30. Although the RA group had a slightly higher 
inactivity score compared with the OA group, neither the ratio of type II and type I 
single fiber areas nor the percentage of type II single fibers differed between 
groups. An earlier study compared muscle biopsies from RA and OA patients 
and found a significantly higher cross-sectional area of type II muscle fibers, but 
no significant difference in the ratio of type II and type I single fiber areas in 29 
RA biopsies compared with 16 OA biopsies. The limitation of that study was that 
inactivity and pain levels were not measured 31. We conclude that chronic systemic 
inflammation in RA has no additional contribution to type II muscle fiber type II.
Lipofuscin accumulation levels are a robust marker for past oxidative stress, which 
contributes to decline in muscle function in older adults 9, 32. Reactive oxygen species 
have also been described to play a role in the pathophysiology of RA 33, 34. A lower 
antioxidant enzyme activity and a higher level of oxidative damage products were 
observed in erythrocytes from RA patients compared with OA patients 34. Compared 
with healthy controls, RA patients have a higher number of lipofuscin granules in the 
vastus lateralis muscle, when investigated by electron microscopy 35. We found slightly 
higher levels of lipofuscin accumulation in patients with RA compared with patients 
with OA, but the difference was not statistically significant. It is possible that this 
difference would reach significance if more RA patients were included. Interestingly, 
physical inactivity due to OA has recently been associated with reduced mitochondrial 
function within skeletal muscle cells and with chronic inflammation 30. A contribution 
of sedentary lifestyle to the accumulation of cellular damage cannot be excluded.
Table II: Association between inflammatory markers and muscle characteristics
Ratio single fiber 
type II/I area
Percentage fiber 
type II (%) Lipofuscin (TGV) *






















ESR (mm) 19 -0.002 
(0.006)




0.63 -0.3  
(0.3)
0.50
WBC (*109/L) 28 -0.004 
(0.025)




0.67 -0.7  
(0.6)
0.27
Adjusted for age, gender, height, weight and rheumatoid arthritis and osteoarthritis diagnosis 
by linear regression. Ratio of single type II/I area: ratio of the area of a single type II fibers to 
that of single type I fibers. Percentage type II fibers: number of type II fibers related to the total 
number of fibers. TGV: total gray value, SC: satellite cell, n: number of patients, β: beta, SE: 
standard error, p: p-value, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, WBC: 





During chronological aging the number of satellite cells is known to decline 36. 
Rodent studies have shown that high concentrations of inflammatory cytokines 
stimulate apoptosis of satellite cells in vitro 37. A comparable study analyzing 
human satellite cell characteristics found that inflammatory cytokines stimulate 
the proliferation of satellite cells and inhibit their initiation of differentiation, but 
they do not induce apoptosis 38. In vivo, it has been show that gene transfer of the 
pro-inflammatory factor TNF-alpha in mice causes a significant reduction in number 
and size of regenerating fibers following muscle injury 39. Because RA patients are 
known to have higher concentrations of inflammatory markers compared with OA 
we hypothesized that this would lead to a reduced regenerative potential in RA, 
including a lower number of satellite cells. This is the first time that the number of 
satellite cells per fiber is quantified in patients with RA. Two studies examined RA 
muscle biopsies by electron microscopy. Using this method it is not possible to 
quantify satellite cells in relation to the number of fibers 40. No satellite cells at all 
were found in intrafusal muscle fibers around muscle spindles in 100 RA patients 41. 
Another study found a higher number of satellite cells in muscle biopsies from 
12 RA patients compared with healthy controls 35. We reported no difference in 
the number of satellite cells per fiber in RA and OA patients, indicating that a link 
between chronic systemic inflammation in RA and satellite cell number is unlikely.
Recently, it has been shown that higher CRP levels and a higher ESR in RA 
patients are associated with a lower lean body mass and the presence of sarcopenic 
obesity 42, 43. In this study, we found that type II fiber atrophy, lipofuscin accumulation, 
and satellite cell number per fiber were not significantly associated with ESR, CRP, 
or WBC concentration. Furthermore, it is known that several inflammatory cytokines 
are capable of accelerating muscle proteolysis 44. However, the precise mechanism 
by which this would cause muscle wasting in RA or during the aging process has 
yet to be elucidated 45. 
The strength of this study is the long disease duration and high levels of 
inflammation in RA patients compared with controls. Furthermore, both groups 
showed the same age and gender distribution. A limitation of this study is the 
relatively low number of patients with RA included in the satellite cell measurements. 
The effect of anti-inflammatory medication use like prednisone, methotrexate and 
TNF inhibitors could also have diluted the studied effect. In addition, OA patients 
are known to have higher levels of systemic inflammatory markers compared 
with healthy controls 46. This low-grade inflammation in OA may have caused a 
substantial detrimental effect on skeletal muscle. Using OA as a control group for 
RA patients would therefore underestimate the impact of high-grade systemic 
inflammation on age-related muscle characteristics.
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In conclusion, chronic systemic inflammation in RA is unlikely to be associated 
with type II muscle fiber atrophy, lipofuscin accumulation, or number of satellite 
cells per fiber. Further investigations should focus on chronic inflammation and 
satellite cell function such as activation and proliferation.
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Background: Chronic inflammation is a profound systemic modification of the 
cellular microenvironment which could affect survival, repair and maintenance 
of muscle stem cells. The aim of this study was to define the role of chronic 
inflammation on the regenerative potential of satellite cells in human muscle. 
Methods: As a model for chronic inflammation, 11 patients suffering from rheumatoid 
arthritis (RA) were included together with 16 patients with osteoarthritis (OA) as 
controls. The mean age of both groups was 64 years, with more females in the RA 
group compared to the OA group. During elective knee replacement surgery, a 
muscle biopsy was taken from the distal musculus vastus medialis. Cell populations 
from four RA and eight OA patients were used for extensive phenotyping because 
these cell populations showed no spontaneous differentiation and myogenic purity 
greater than 75 % after explantation.
Results: After mononuclear cell explantation, myogenic purity, viability, proliferation 
index, number of colonies, myogenic colonies, growth speed, maximum number 
of population doublings and fusion index were not different between RA and OA 
patients. Furthermore, the expression of proteins involved in replicative and stress-
induced premature senescence and apoptosis, including p16, p21, p53, hTERT and 
cleaved caspase-3, was not different between RA and OA patients. Mean telomere 
length was shorter in the RA group compared to the OA group. 
Conclusions: In the present study we found evidence that chronic inflammation 
in RA does not affect the in vitro regenerative potential of human satellite cells. 
Identification of mechanisms influencing muscle regeneration by modulation of its 
microenvironment may, therefore, be more appropriate.
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IntRoDuctIon
Muscle weakness is a common clinical feature following injury, in neuromuscular 
diseases and aging leading to disability and increased mortality 1-3. Understanding 
cellular mechanisms that regulate loss and gain of muscle mass is, therefore, crucial 
for treating muscle wasting-associated disorders. The regenerative potential of 
skeletal muscle is determined by muscle stem cells, which are called satellite cells. 
These are quiescent mononucleated cells that are sequestered between the basal 
lamina and the plasma membrane of the myofibers 4. In response to injury, they 
become activated, proliferate, differentiate and fuse to existing muscle fibers or fuse 
together to form new myofibers during regeneration of damaged skeletal muscle 5. 
Potential explanations for the decline in muscle mass and strength are multiple 
factors, including stiffness, immobility, pain, metabolic, hormonal and nutritional 
status 6, 7. These factors could influence muscle regeneration indicated by the 
number of satellite cells and their proliferative capacity, which in humans is limited 
by the mitotic clock 8, 9. Heterochronic parabiosis has been shown to restore the 
regenerative potential of aged satellite cells which suggest that satellite cell activity 
can be modulated by the microenvironment and circulating factors 9. There is 
growing evidence that chronic inflammation can produce a profound systemic 
modification of the cellular microenvironment which could affect survival, repair and 
maintenance of muscle cells 10. Concentrations of pro-inflammatory cytokines have 
been shown to increase with advancing age and result in a higher catabolic rate 
and loss of muscle mass 11, 12. The underlying factors influencing the regenerative 
potential of satellite cells have not yet been identified.
In the present study, we aimed to define the role of chronic inflammation on 
the regenerative potential of satellite cells in human muscle. As a model for in vivo 
chronic inflammation, we have used muscle biopsies obtained from patients suffering 
from rheumatoid arthritis (RA) compared to patients with osteoarthritis (OA), without 
signs of chronic inflammation. Patients with RA have been shown to have a steeper 
decline in muscle mass and strength compared to the general population, which 
might be due to the chronic inflammatory state of these patients 13, 14.
MateRIal anD MetHoDS
Subjects
The total study population included 11 patients with RA and 16 patients with OA as 
controls. After obtaining written informed consent, a muscle biopsy (approximately 
420 mg) was taken from the distal musculus vastus medialis during elective knee 
replacement surgery. Pre-operatively, blood samples were taken for analysis of 




sedimentation rate (ESR) using the Westergren method and the number of 
leucocytes using flow cytometry. The study was approved by the medical ethics 
committee of the Leiden University Medical Center.
Cell cultures
Myoblast explantation, isolation and cell cultures were performed as previously 
described 15-18. Muscle biopsies from the musculus vastus medialis were dissected 
from connective tissue and fat, finely minced and then plated onto non-coated 
Petri dishes with growth medium consisting of Dulbecco’s modified Eagle medium 
(DMEM, 61965, Invitrogen, Carlsbad, CA, USA), 16 % medium 199 (41150, Invitrogen), 
20 % fetal calf serum (FCS, 10270, lot 41Q4096K, Invitrogen) and 50 ng/ml 
gentamicin (15750, Invitrogen) supplemented with 5 ng/ml hepatocyte growth 
factor (PHG0354, Invitrogen). Once mononucleated cells had migrated out from the 
explants, they were removed from the dish by trypsinization, using 0.05 % trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA, 25300, Invitrogen). Mononucleated 
cells were filtered (40 μm) and plated as a mixed culture in growth medium. At the 
time of cell isolation, all cell populations were considered to be at one population 
doubling. All cultures were incubated at 37 °C in a humid air atmosphere containing 
5 % CO2. Cell populations were trypsinized when they reached 80% of confluence. 
Myogenic purity of the populations was determined by immunocytochemistry. To 
improve myogenic purity, cell populations were magnetically labelled by 15 minutes 
incubation with 20 μl CD56-micro beats per 106 cells (130-050-401, Multenyi Biotec, 
Paris, France). Cell populations were washed with buffer consisting of phosphate 
buffered saline (PBS, 20012, Invitrogen), 0.5 % FCS and 2 mM EDTA and CD56 cell 
selection was carried out using the MiniMACS (Multenyi Biotec). After determination 
of the myogenic purity, cell populations were frozen in 90 % FCS and 10% dimethyl 
sulphoxide hybri-max (D2650, Sigma-Aldrich, St. Louis, MO, USA) and preserved at 
-135 °C. Only cell populations with no spontaneous differentiation after trypsinization 
(less than 10 myotubes with more than 2 nuclei in a 100 mm petri dish) and myogenic 
purity greater than 75 % after CD56 cell selection were used for further analysis. To 
optimize the comparison of RA and OA patients, all experiments were performed 
in a highly standardized manner in three batches each containing at least one RA 
and one OA patient. At the early replicative phase (mean 10.3 (SD 1.7) population 
doublings (PDs)), myogenic purity, viability, proliferation index, colony formation 
and growth speed was measured. Protein analysis and telomere length analysis 
were performed at mean 14.4 (SD 3.1) PDs. Myogenic purity was again measured at 
the mid-term replicative phase (mean 24.3 (SD 4.2) PDs) and at the end of life span 
(maximum replicative capacity). The experiments were performed and analyzed 
blinded for patient diagnosis and age.
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Myogenic purity
Myogenic purity of the cell cultures was determined by immunocytochemistry. 
Cells were rinsed in PBS, fixed with ethanol (100 %) and incubated for one hour with 
monoclonal mouse D33 (M0760, 1/50, Dako, Trappes, France) as primary antibody 
specific for desmin, which is only expressed in myogenic cells. Specific antibody 
binding was revealed in fluorescence by Alexa fluor 488 goat anti mouse antibody 
(1/750, A11029, Molecular Probes, Eugene, OR, USA) and nuclei were revealed by 
Hoechst (1/2500, 33258, Sigma-Aldrich) staining. Myogenic purity was calculated 
as the percentage of desmin positive cells divided by the total number of nuclei. 
Growth characteristics
To measure the proliferation index, cells were cultured for 48 hours in culture 
medium supplemented with 10 µg/ml bromodeoxyuridine (BrdU, B5002, Sigma-
Aldrich). Next, the cells were rinsed in PBS and fixed with ethanol (100 %). To render 
incorporated BrdU accessible to antibody, fixed cells were treated with 2 M HCl 
for 30 minutes at room temperature and were then neutralized by three 20-minute 
washes in 50 mM NaCl, 100 mM Tris HCl pH 7.5. Cells were incubated for one hour 
with a monoclonal antibody directed against BrdU (Bu20a, 1/40, M0744, Dako). 
Specific antibody binding was revealed in fluorescence by Alexa fluor 488 goat anti-
mouse antibody and nuclei were revealed by Hoechst staining. The proliferation 
index was calculated as the percentage of BrdU positive cells divided by the total 
number of nuclei. The proliferation index was determined in three experimental 
triplicates counting at least 500 nuclei in each experiment. 
Five hundred myoblasts were seeded on a 100 mm dish (353003, Becton 
Dickinson, Le Pont de Claix, France) and cultured for 14 days in growth medium to 
allow the formation of colonies. During this period the medium was not changed. 
Next, cells were rinsed in PBS, fixed with ethanol (100 %) and stained overnight 
with Giemsa’s azur eosin methylene blue solution (109204, Merck, Darmstadt, 
Germany). Colonies were defined as a cluster of cells containing 16 cells or more. 
The total number of colonies formed was counted in experimental triplicates. The 
percentage of myogenic colonies was detected by immunocytochemistry using 
desmin (M0760, 1/50, Dako).
Growth speed was calculated by the number of PDs per day during the early 
replicative phase. The number of PDs at each passage was calculated as log(N/n)/
log 2 where N is the number of cells counted at the time of passage and n is the 
number of cells initially plated. During long-term culturing, cells were continuously 
fed in a standardized manner by seeding 50,000 cells in a 100 mm dish (353003, 
Becton Dickinson) and serial passaged when they reached 80 % confluence until 




when they failed to divide during three weeks of re-feeding or if the myogenic 
purity was decreased to less than 10 %. 
Fusion index
To induce differentiation of the mononucleated cells into multinucleated myotubes, 
cells were densely seeded in triplicates on a 12-well dish (353043, Becton 
Dickinson, 17,000 cells/cm2). Once confluent, growth medium was replaced by 
differentiation medium consisting of DMEM, 10 μg/ml insulin (I550-250 M, Sigma-
Aldrich), 100 μg/ml transferrin (T4382-IG, Sigma-Aldrich) and 50 ng/ml gentamicin. 
After 120 hours, cells were rinsed in PBS and fixed with ethanol (100 %). To stain 
the myotubes, polyclonal mouse MF20 antibody (1/80, Developmental Studies 
Hybridoma Bank, Iowa City, IA, USA) was used as the primary antibody and Alexa 
fluor 488 goat anti mouse as the secondary antibody (A11029, 1/750, Molecular 
Probes). Nuclei were revealed by Hoechst staining. The fusion index was calculated 
as the percentage of nuclei incorporated into myotubes (> 2 nuclei) to the total 
number of nuclei. The fusion index was determined in three experimental triplicates 
counting at least 500 nuclei in each experiment. 
Protein analysis
Cultures were washed in PBS, scraped in 1 ml ice-cold PBS, centrifuged at 800 
rpm for one minute and cell pellets were stored at -80 °C for further analysis. Cell 
pellets were resuspended in 150 mL of RIPA buffer (150 mM NaCl, 5 mM EDTA, 
50 mM HEPES, 0.5 % sodium deoxycholate, 1 % NP-40, 0.1 % SDS and complete 
mini-protease inhibitor) and protein concentration was determined with the Pierce 
BCA kit (Thermo Fisher Scientific, Rockford, IL, USA), using bovine serum albumin 
as a standard. Sample buffer (4 % SDS, 20 % glycerol, 0.2 M dithioethreitol, 125 mM 
Tris-HCl, pH 6.8) was added to aliquots of cell extracts and boiled for five minutes. 
Twenty μg of protein were loaded on 12 % SDS-polyacrylamide gels (SDS-PAGE). 
Following migration, proteins were transferred to nitrocellulose membranes. The 
proteins immobilized on the membranes were immediately blocked for one hour at 
room temperature with a solution containing 5 % non-fat dry milk in tris buffered 
saline containing 0.1 % tween 20 (PBT). The blocked membranes were then incubated 
with a rabbit polyclonal anti-p16 antibody (1/1000, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and mouse monoclonal anti-beta-tubulin antibody (1/1000, clone 
TUB 2, T4026, Sigma-Aldrich) as the primary antibody and anti-rabbit or anti-
mouse peroxidase conjugated antibody (1/40.000, GE Healthcare, Orsay, France) 
as the secondary antibody. Anti-p16 and anti-tubulin antibodies were visualized 
using the ECL plus Western Blotting Detection System (GE Healthcare). For p21, 
p53, cleaved caspase-3 and hTERT detection, PDVF membranes were stained for 
one minute with 0.1 % Ponceau (Sigma-Aldrich). Mouse anti-p21 antibody (CP74, 
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1/250, kindly provided by A.G. Jochemsen of the Department of Molecular Cell 
Biology, LUMC), mouse anti-p53 antibody (1/500, Santa Cruz Biotechnology), rabbit 
anti-human-cleaved caspase-3 (H269518, 1/250, R&D Systems, Abingdon, UK), 
rabbit anti-hTERT (1531-1, 1/500, Epitomics, Burlingame, CA, USA) and monoclonal 
mouse anti-muscle actin (1/1000, Santa Cruz Biotechnology) were used as primary 
antibodies and fluorochrome conjugated goat anti-mouse or goat anti-rabbit as 
secondary antibodies (1/2000, Licor Biosciences, Lincoln, NE, USA). Quantification 
of protein expression was performed using ImageJ (http://rsb.info.nih.gov/ij/) 
with data obtained from two experiments. Tubulin or Actin signals were used for 
normalization.
Telomere length
Telomere length was measured by flow cytometry using fluorescence in situ 
hybridization with fluorescein-conjugated peptide nucleic acid (PNA) as 
the probe (K5327, Dako) according to the manufacturer’s protocol. In short, 
cultured cells were trypsinized, mixed with the reference cell line (line 1301; 
Banca Biologica e Cell Factory, Genoa, Italy), and hybridized with and without 
Cy3-labeled peptide nucleic acid probe. After labelling the cells with propidium 
iodide (PI) for DNA content, acquisition was performed using a FacsAria flow 
cytometer (Becton Dickinson) equipped with Diva software. The probe signal 
was measured in the FL-1 channel and the propidium iodide signal in the FL-3 
channel. Experimental duplicates were performed and results were analyzed 
according to the manufacturer’s protocol. 
Oxidative stress
Twenty-four hours after seeding, cell cultures were exposed to a single acute oxidative 
stress of 250 μM H2O2 (H-1009, Sigma-Aldrich) diluted in DMEM with 20 % medium 
199 and 50 ng/ml gentamicin for 60 minutes at 37 °C. Next, cell cultures were rinsed 
with PBS and cultured in growth medium. Control and stressed cell cultures of three 
RA and four OA patients followed the same treatment protocol in triplicates with and 
without the addition of H2O2 respectively. During the early replicative phase (mean 
10.3 (SD 1.7) PDs), myogenic purity, viability, proliferation index, colony formation 
and growth speed were measured. The percentage of viable cells was determined 
24 hours after oxidative stress by trypan blue (T8154, Sigma-Aldrich) exclusion.
Statistical analysis
Data are presented as mean and standard deviation. Experimental triplicates or 
duplicates were averaged for statistical analysis. A linear regression model was 
performed with adjustment for age and gender, myogenic purity, number of PDs 




not influence the outcome parameter. All p-values below 0.05 were considered 
statistically significant.
ReSultS
To investigate the regenerative potential of satellite cells in chronic inflammation, 
11 RA patients were included in this study together with 16 OA patients as 
controls who were all scheduled for elective knee replacement surgery (table I). 
The mean age of both groups was 64 years, with more females in the RA group 
(91 %) compared to the OA group (56 %). The mean disease duration in the 
RA group was 16 years (SD 13). Pre-operative blood samples showed a higher 
level of inflammatory markers, including a higher CRP, ESR and leucocyte level 
compared to the OA group. During elective knee replacement surgery, a muscle 
biopsy (approximately 420 mg) was taken from the distal musculus vastus 
medialis. After mononuclear cell explantation, the mean myogenic purity of the 
RA group was 34 % (SD 20) with 18 % spontaneous differentiation in the cell 
cultures compared to 46 % (SD 26) mean myogenic purity in the OA group with 
19 % of the samples showing spontaneous differentiation. Cell strains without 
spontaneous differentiation of satellite cells and myogenic purity greater than 
Table I: Characteristics of patients and satellite cell isolation









Age (years) 64 (12) 64 (9) 65 (9) 64 (9)
Gender (% female) 91 56 75 50
Disease duration (years) 16 (13) - 15 (13) -
CRP (mg/L) 12 (11) 2 (3) 10 (7) 2 (3)
ESR (mm) 28 (13) 11 (6) 28 (15) 11 (7)
Leucocytes (*109/L) 10.5 (2.5) 7.0 (1.6) 9.7 (1.4) 7.2 (1.6) 
Myogenic purity after explantation 
(% desmin positive cells)
34 (20) 46 (26) 46 (13) 58 (26)
Spontaneous differentiation * (%) 18 19 0 0
Sufficient biopsy quality # (%) 36 50 100 100
CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, n: number of subjects, OA: 
osteoarthritis, RA: rheumatoid arthritis. Values are given as mean (SD) if not otherwise stated. CRP 
and leukocyte data were available for 14 and 10 patients in the OA and RA group respectively. ESR 
data were available for 7 patients in OA group and 10 patients in the RA group. *Spontaneous 
differentiation was defined as 10 or more myotubes with more than 2 nuclei in a 100 mm culture 
dish. #Sufficient biopsy quality was defined as no spontaneous differentiation and myogenic 
purity higher than 75 % after CD56 cell selection.
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75 % after CD56 cell selection were considered to be sufficiently pure for further 
experiments. The resulting experimental group included four RA and eight OA 
patients. As shown in table I, this selected study population had the same 
distribution in age, gender, disease duration and inflammatory markers as the 
total study population.
Satellite cell characteristics
To investigate the influence of chronic inflammation on human satellite cell 
regenerative potential, multiple satellite cell characteristics were measured 
(table II, figure 1). During the early replicative phase (mean 10.3 (SD 1.7) PDs) 
myogenic purity, viability, proliferation index, mean number of colonies, 
Figure 1: In vitro characterization of human satellite cells
Representative images of in vitro characterization of cultured myoblasts using 
immunofluorescence with an antibody against desmin (A and B), BrdU (C) and MF20 (D). 
Specific antibody labeling was revealed using Alexa fluor 488 green fluorochrome. Nuclei 
were visualized with Hoechst (blue). Myogenic purity was determined after explantation (A) and 
increased after CD56 selection (B). To determine the proliferation index, cells were cultured 
for 48 hours in culture medium supplemented with 10 µg/ml BrdU (C). To determine the fusion 
index, cells were cultured in differentiation medium for 120 hours (D). Original magnification 




Table II: Characteristics of satellite cell strains obtained from rheumatoid arthritis and 
osteoarthritis patients
Characteristic 
RA      
n = 4 
OA       
n = 8 β 95 % CI
p - 
value
Myogenicity (% desmin positive cells)
After explantation
After CD56 selection
After thawing at early replicative phase *
At mid-term replicative phase #
At maximum replicative capacity































Viability (% alive cells)
At early replicative phase *












Proliferation index ‡  




Maximum replicative capacity (PD)
Proliferation index after oxidative stress †‡ 































Fusion index at early replicative phase *§  
(% of fused myonuclei)
27 (12) 25 (13) -0.01 -26 to 26 0.99

























Relative telomere length * 
(% of ref. cell line 1301)
22 (5) 23 (10) -0.46 -16 to -0.4 0.04
n: number of subjects, OA: osteoarthritis, RA: rheumatoid arthritis. Beta (β). 95 % confidence 
interval (CI) and p-value are shown for linear regression model adjusted for age and gender, 
myogenic purity, number of PDs, and batch. Values are given as mean (SD) if not otherwise 
stated. *Early replicative phase: mean 10.3 (SD 1.7) PDs for myogenic purity, viability, growth 
characteristics and fusion index; mean 14.4 (SD 3.1) PDs for normalized protein expression and 
relative telomere length. #Mid-term replicative phase: mean 24.3 (SD 4.2) PDs. †Myogenic purity, 
viability and proliferation index was measured at early replicative phase, 24 hours after oxidative 
stress (one hour of 250 μM H2O2 at 37 °C) in four OA and in three RA patients. ‡Proliferation index 
was determined as the percentage of bromodeoxyuridine (BrdU) positive cells after 48 hours of 
culture with BrdU. §Fusion index was determined as the percentage of fused nuclei (> 2 nuclei 
per myofiber) in MF20 positive cells.
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myogenic colonies, growth speed and fusion index were not different between 
RA and OA patients as was the myogenic purity at mid-term and at replicative 
senescence. As depicted in figure 2, the growth curves showed no difference 
between the RA group with a mean maximum number of 33.4 (SD 9.7) PDs 
and the OA group with mean maximum of 27.4 (SD 5.5) PDs. After adjustment 
for age, gender, myogenic purity, number of PDs and batch, none of these 
parameters were statistically significantly different between RA and OA patients 
(data not shown). 
Senescence-associated proteins apoptosis and telomere length
To determine whether senescence is induced in satellite cells, the expression 
of hTERT, p53, p21 and p16 proteins was determined at the early replicative 
phase using a Western blot analysis. Averages of normalized protein expression 
did not significantly differ between RA and OA patients (table II, figure 3). In 
addition, none of the samples were positive for cleaved caspase-3 expression. 
Furthermore, the mean relative telomere length was not different between RA 
and OA patients (Table II, Figure 4). After adjustment for age, gender, myogenic 
purity and batch, the mean relative telomere length was lower in the RA group 
compared to the OA group (β = -0.46, 95 % CI -16 to -0.4, p = 0.04). The other 
measurements were not different. The maximum replicative capacity of the 
Figure 2: Growth curve of human satellite cells 
Growth curve from thawing (day 0) until maximum replicative capacity of human satellite cell 





Figure 3: Protein expression of human satellite cells
A: Representative image of hTERT, p53, p21 and p16 expression in human satellite cells from 
patients suffering from rheumatoid arthritis (n = 4) or osteoarthritis (n = 8). Actin and tubulin 
expression was used for normalization. B: Normalized average protein expression and 95 % 
confidence interval of hTERT, p53, p21 and p16. 
satellite cell strains was not significantly associated with telomere length (β = 
0.60, 95 % CI -1.3 to 2.3, p = 0.48). 
Oxidative stress
To determine whether satellite cells from RA patients were more susceptible to 
oxidative stress, we administered a single dose of 250 μM H2O2 for 60 minutes at 
37 °C to the cell cultures. Twenty-four hours after oxidative stress, the myogenic 
purity, viability and proliferation index were decreased in both the RA and OA 
group. None of the cell strains were able to reach confluence after three weeks or 
to form colonies after oxidative stress. The satellite cells from the RA group were 
as susceptible to oxidative stress as the OA group as shown in table II, also after 
adjustment for age, gender, batch and myogenic purity (data not shown). 
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Figure 4: Telomere length of human satellite cells
Telomere length was measured by flow cytometry using fluorescence in situ hybridization 
without (A) or with the fluorescein-conjugated PNA probe (B). Propidium iodide (PI) was used 
for labeling DNA content. The telomere probe signal was measured in the FL-1 channel and 
the PI signal in the FL-3 channel. G0/1 phase sample and control cells were gated according 
to their PI specific signal on a dot blot (FL1-H vs. FL3-H). Relative telomere length (RTL) was 
calculated by: RTL = (mean FL1 sample cells with probe – mean FL1 sample cells without 
probe) / (mean FL1 control cells with probe – mean FL1 control cells without probe) * 2 * 100 %. 
Representative images are shown of the one of the RA patients. For each sample analyzed 
20,000 counts were acquired. 
DIScuSSIon
The regenerative potential of human muscle stem cells is thought to be influenced 
by their microenvironment, including cytokines. To determine the potential 
deleterious effect of inflammation on the regenerative capacity of skeletal muscle, 
we compared muscle biopsies obtained from patients with chronic inflammation 
(RA) to control patients (OA). We found no differences in myogenic purity, viability, 
growth speed, differentiation and maximum proliferative capacity. These results 
were confirmed by no difference in major pathways involved in muscle regeneration, 
including the expression of proteins involved in replicative and stress induced 
premature senescence and apoptosis. Telomere length was shorter in RA patients 
compared to controls. 
Mechanisms involved in the regenerative potential of muscle include the ability 
to restore the quiescent satellite cell pool which has been shown to decrease during 
aging by a decrease in the number of satellite cells present in muscle biopsies 9, 14. 
Recently, we have shown that chronic inflammation does not influence the number 
of satellite cells in human muscle 19. In the present study, we provide new evidence 




affected by chronic inflammation. Mechanisms affecting the regenerative potential 
of muscle include the number of satellite cells which are able to proliferate, their 
growth speed and their maximum proliferative capacity which have been shown 
to be affected by age 8. In the present study we demonstrate in vitro, that chronic 
inflammation in vivo does neither affect any of the growth characteristics nor 
the differentiation potential of human satellite cells. Regenerative potential of 
human satellite cells is limited by the progressive erosion of their telomeres after 
each cell division leading to critically short telomere length and the activation of 
replicative senescence through a p53 and p21 dependent pathway 20. The erosion 
of telomeres can be prevented by the catalytic subunit of the telomerase (hTERT) 
leading to extension of replicative life 21. The mean relative telomere length in RA 
patients was significantly lower after correction for age, gender, myogenic purity, 
batch and number of population doublings, which could suggest an increased 
turnover of these cells. However, this difference was minimal and the expression 
of p53, p21 and hTERT proteins were not different between RA and OA patients. 
Therefore, we conclude that chronic inflammation does not significantly increase 
nuclear turnover which is in agreement with our findings regarding the growth 
characteristics of satellite cells cultures. Stress induced premature senescence 
has been shown to be induced by p16 in aging and myotonic dystrophy 17, 22. Here 
we demonstrate that p16 is not increased in chronic inflammation. Apoptosis and 
programmed cell death was not detected during the amplification of either chronic 
inflammation (RA) or control cells (OA) using anti-cleaved caspase 3 23.
An unexpected finding was the low mean myogenic purity after explantation in 
both groups, as myogenic purity was shown to be high in both young and old age, 
which could have been due to the different biopsy material and procedures used in 
the different studies 8. To optimize myogenic purity, we performed a CD56 magnetic 
selection procedure and only cell populations with a mean myogenic purity higher 
than 75 % were included in our study. Some cell cultures showed spontaneous 
differentiation and were, therefore, excluded. Because of low myogenic purity and 
increased spontaneous differentiation, we were able to obtain fewer biopsies in the 
RA group than in the OA group for in vitro experiments. Although the difference 
in muscle biopsy quality was not significant, this could indicate that chronic 
inflammation does influence satellite cell behavior and ultimately the regenerative 
potential of the muscle. Non-myogenic stem cells have, however, been shown to 
contribute to muscle regeneration 24. After thawing, we also observed a decrease 
in mean myogenic purity in both groups. Freezing could have led to stress by 
cold shock, ice formation, activation of apoptosis mechanisms and alteration of 
certain signalling pathways. Fetal and newborn muscle cells have been shown to 
conserve their high myogenic purity after long-term cryopreservation; however, 
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adult cells are more difficult to explant and have a lower myogenic purity 25. In the 
present study, we did not observe a correlation between myoblast telomere length 
and replicative capacity. Furthermore, we did not observe a correlation between 
telomere length and other markers of replicative capacity like the expression of 
p21, p53 or hTERT. A potential explanation involves the induction of pathways 
involved in stress induced senescence, being telomere length independent, 
which cannot be excluded during in vitro replicative senescence 26. Serial culturing 
represents a major difference from the in vivo environment, including changes in 
their physical environment, the cell to cell interaction and different nutrition supply, 
which could induce oxidative stress, DNA damage and, finally, stress induced 
premature senescence 27, 28.
As a model for chronic inflammation, the study included patients suffering 
from RA who indeed showed a higher level of inflammation compared to OA 
patients as indicated by CRP, ESR and number of leucocytes. Furthermore, the two 
groups showed the same age distribution. Although OA is associated with local 
inflammation 29, we did not use a healthy control group because such a control 
group is physically more active, which would then possibly confound the results 30. 
Furthermore, healthy patients without an underlying chronic condition are not 
available for the same muscle biopsy area, technique and biopsy size. The strength 
of this study is the rigorous standardization in terms of patient selection, muscle 
biopsy location, cell culture experiments in batches with both RA and OA patients 
and the extensive phenotyping of the satellite cell populations. The limitations of 
this study are that the influence of chronic inflammation on the in vitro regenerative 
potential of human satellite cells may not be found due to the selection of muscle 
biopsies with good quality. Secondly, the in vitro experiments might not reflect 
the in vivo situation and finally the small number of included patients made it 
impossible to differentiate within and between the groups on the presence of 
biological treatment (for example, anti TNF). In addition, it should be noted that 
there was a certain selection since the myogenic purity was lower in the RA group 
and many cells were lost to spontaneous differentiation which could be due to an 
increased expression of p16. However, including more patients was not possible 
due to the extensive phenotyping of each satellite cell strain. Furthermore, the RA 
group included more females (75 %) compared to the OA group (50 %). Myogenic 
purity and gender were adjusted for in the linear regression model and had no 
effect on satellite cell regenerative potential in vitro.
Muscle weakness is an increasing clinical problem and occurs upon injury, 
neuromuscular diseases and aging, leading to disability and increased mortality 1-3, 
31, 32. Stem cell therapy is one possible strategy to regenerate muscle. Although 




cell therapy is still limited by homing and a reduced ability to resist the environment 
of the damaged muscle 33. Conboy et al. showed that heterochronic parabiosis 
could restore the regenerative capacity of aged satellite cells 34. The circulating 
factors presented by a shared circulatory system could be the possible explanation 
for the observed rejuvenation. Therefore, the microenvironment of muscle in which 
pro-inflammatory cytokines have been shown to result in a higher catabolic rate and 
loss of muscle mass might be crucial for the regenerative potential 11, 12. One of the 
hallmarks of inflammation is the release of interleukins and tumour necrosis factor-α 
(TNFα) attracting macrophages which are critical in the repair of skeletal muscle 
by the release of cytokines and growth factors and by phagocytosis. However, in 
their attempt to enhance tissue repair they may also destroy surrounding healthy 
muscle fibers 35. Furthermore, TNF-α induces activation of transcription factor 
NF-κB, which results in activation of the ubiquitin-proteasome pathway and 
breakdown of MyoD and myogenin, which are essential regulators for satellite cell 
differentiation 36 as well as contractile proteins essential in maintaining muscle 
mass. Inflammatory factors could be the cause of lower muscle strength of patients 
with RA compared to OA 14.
In vitro, our results demonstrate no difference in potential regenerative capacity 
between satellite cells from patients with chronic inflammation and control patients. 
This could be due to the fact that the satellite cells of both patient groups were 
put in culture and, therefore, both experienced an optimized microenvironment 
for proliferation and differentiation. Consequently, our results show that there is no 
difference in satellite cell behavior in vitro, indicating that circulating inflammatory 
factors in vivo could be the cause of the decrease in muscle strength. Further 
evidence of the in vivo influence of inflammatory cytokines has been shown by anti-
inflammatory treatment, which has been shown to improve muscle regeneration 
after injection with mesoangioblasts 37. 
In conclusion, in the present study we found evidence that chronic inflammation 
in RA does not affect the in vitro regenerative potential of human satellite cells. 
This result underscores the in vivo influence of inflammatory factors on muscle 
regeneration. Identification of mechanisms influencing muscle regeneration by 
modulation of its microenvironment may improve strategies to regenerate human 
muscle, in particular in conditions such as muscle injury, neuromuscular disorders 
and aging.
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Introduction: Traumatic brachial plexus injury causes severe functional impairment 
of the arm. Elbow flexion is often affected. Nerve surgery or tendon transfers 
provide the only means to obtain improved elbow flexion. Unfortunately, the 
functionality of the arm often remains insufficient. Stem cell therapy could 
potentially improve muscle strength and avoid muscle-tendon transfer. This pilot 
study assesses the safety and regenerative potential of autologous bone marrow-
derived mononuclear cell injection in partially denervated biceps. 
Methods: Nine brachial plexus patients with insufficient elbow flexion (i.e., partial 
denervation) received intramuscular escalating doses of autologous bone marrow-
derived mononuclear cells, combined with tendon transfers. Effect parameters 
included biceps biopsies, motor unit analysis on needle electromyography and 
computerised muscle tomography, before and after cell therapy. 
Results: No adverse effects in vital signs, bone marrow aspiration sites, injection 
sites, or surgical wound were seen. After cell therapy there was a 52 % decrease in 
muscle fibrosis (p = 0.01), an 80 % increase in myofibre diameter (p = 0.007), a 50 % 
increase in satellite cells (p = 0.045) and an 83 % increase in capillary-to-myofibre 
ratio (p < 0.001) was shown. CT analysis demonstrated a 48 % decrease in mean 
muscle density (p = 0.009). Motor unit analysis showed a mean increase of 36 % in 
motor unit amplitude (p = 0.045), 22 % increase in duration (p = 0.005) and 29 % 
increase in number of phases (p = 0.002). 
Conclusions: Mononuclear cell injection in partly denervated muscle of brachial 
plexus patients is safe. The results suggest enhanced muscle reinnervation and 
regeneration. 
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IntRoDuctIon
Brachial plexus injury (BPI) is often a result of a high-energy road traffic accident in 
young adults 1, 2. The upper brachial plexus (C5-C6) is commonly affected, resulting 
in paresis of shoulder function and elbow flexion 1-4. Nerve surgery is aimed at 
restoring innervation of the biceps muscle, but often a deficit in the functionality 
of the arm remains. In that case, secondary surgery can improve arm function by 
transfer of the flexor-pronator group of the forearm (Steindler procedure) for active 
elbow flexion 5-10. However, neither nerve surgery nor tendon transfers come close 
to restoring normal elbow flexion 6.
Any procedure that improves elbow flexion without sacrificing the function of 
transferred donor muscles will have advantages for the patient. One approach 
is to improve the regenerative capacity of the partially denervated muscles. 
Denervation causes loss of contractile force and muscle atrophy. If innervation is 
restored quickly, good restorative ability exists. Conversely, prolonged interruption 
of innnervation results in irreversible muscle atrophy, interstitial fibrosis and muscle 
fattening 11-14. Since regeneration of denervated muscles not only depends on 
nerve supply, but also on its regenerative capability, the muscle can be a target 
organ for cell therapy. 
Muscle satellite cells are responsible for repair and maintenance of skeletal 
muscles; they are the main source of new myofibres. Myogenic precursor cells 
proliferate, fuse and form new myofibres in response to muscle damage 15. 
Exhaustion of the pool of available satellite cells may contribute to poor functional 
recovery of long-term denervated muscle 16, 17. A progressive and rapid decrease 
in the capillary-to-muscle fibre ratio occurs, further limiting regeneration 18. 
Transplantation of primary satellite cells has been shown to improve the properties 
of reinnervated skeletal muscles in rabbits 19. However, poor cellular survival 
and limited cell dissemination hampers successful satellite cell transplantation. 
Furthermore, only few cells fuse with host fibres. This suggests that a subpopulation 
of myogenic cells (i.e. stem cells) may be optimally suited for transplantation 20, 21. 
Bone marrow (BM)-derived cells migrate to the site of muscle injury and contribute 
to the satellite cell pool 22-24. The injection of autologous BM-derived mononuclear 
cells (MNCs) has been applied in clinical studies focusing on the muscles of the 
heart and leg 25-28.
The primary objective was to assess the safety of autologous BM-derived MNC 
injection in partially denervated muscles of BPI patients. The secondary objective 
was to obtain a first estimate on regenerative potential of injected BM-derived 






This was a prospective study on autologous BM-derived MNC therapy for partially 
denervated biceps muscles of BPI patients, with focus on safety and the effect on 
muscle. Three escalating doses were evaluated in three groups, each comprising 
three patients. The MNC dose was equivalent to 50 % (group A), 100 % (group B), 
and 200 % (group C) of the cell dose in a former study at our institution 25. The 
protocol was approved by the medical ethics committee of Leiden University 
Medical Center. The Declaration of Helsinki protocols were followed and patients 
gave written, informed consent. The clinical trial was registered under ClinicalTrials.
gov identifier: NCT00755586. 
Patients
Nine adult traumatic BPI patients with partial denervation of the biceps muscle 
(Medical Research Council (MRC) grades between 1 and 3) were included 29. All 
patients were at an end-stage of functional results (i.e. ≥ 2 years after trauma 
or nerve surgery). Patients with a complete paralysis of the biceps muscle were 
excluded as they were assumed to have no regenerative capacity (MRC grade 0). 
This was corroborated by the absence of motor unit potentials (MUPs) during needle 
electromyography (EMG). Other exclusion criteria were a history of central or other 
peripheral neurological disorders, humeral fractures, and contraindication for BM 
harvesting (such as bleeding diathesis or an international normalised ratio (INR) > 2). 
BM aspiration and MNC separation
BM was aspirated from one location at the posterior iliac crest. The procedure 
was performed under local (group A) or general anaesthesia (groups B and C). 
Due to ethical considerations associated with the use of general anaesthesia, in 
groups B and C the MNC injection was combined with a Steindler procedure, 
which was considered the standard surgical procedure in patients with an elbow 
flexion deficiency 5. BM was separated as previously described 25, 28. The isolated 
MNCs were concentrated in a volume of 10 ml. The isolation and concentration 
procedure was performed in a certified clean-room facility according to good 
manufacturing practice (GMP) 25, 28. Further details of the methods are provided 
as supplementary material. 
MNC injection
BM-derived MNCs were injected at 20 sites at the maximum palpable thickness of 
the biceps and at a standard injection depth of 0.5 cm. A total volume of 10 mL was 
injected. Further details of the methods are provided as supplementary material. 
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Safety
In order to assure safety, the absence of adverse events and muscle fibrosis was 
documented before proceeding to the next dose level. Vital signs were checked 
and the BM aspiration, MNC injection and surgical wound site were examined 
during a 24-hour hospital admission and at three and six months after cell therapy. 
The safety of MNC injection at muscle level was assessed by CT analysis and 
histology. 
Evaluation of patients
All patients were evaluated pre-operatively and at three and six months post-
operatively using clinical scores, CT analysis and EMG. Histology of the biceps 
muscle was undertaken pre-operatively and at three months post-operatively. 
Before analysis, all images were blinded for date and patients characteristics. 
Clinical functionality
Active and passive range of movement (ROM) of the injured elbow was measured 
using a handheld goniometer. Force measurement of the injured biceps muscle 
was assessed using the MRC motor scale. Pain at rest was scored using a visual 
analogue scale (VAS) (0 - no pain to 10 - extreme pain). Finally, the Disabilities of 
the Arm, Shoulder, And Hand (DASH) questionnaire and the Short-Form Health 
Survey (SF-) 36 were used to measure quality of life and functional outcome 30, 31. 
To compare the DASH score with the SF-36 we calibrated the score to a 100-point 
metric score from 0 (worst health) to 100 (best health). The SF-36 score ranges from 
0 (worst health) to 100 (best health). 
CT scan
Patients were scanned using the Aquilion 64-slice CT scanner (Toshiba Medical 
Systems, Otawara, Japan). A total of 50 consecutive 1.0-mm multiplane 
reconstruction (MPR) images were computed in the coronal plane perpendicular 
to the main axis of the humerus. The MPR images were analysed and the mean 
muscle density (MMD) was calculated 32. The MMD of the injured (injected) biceps 
muscle was compared with control muscles (the injured (non-injected) triceps 
muscle and non-injured (non-injected) contralateral biceps muscle). Further details 
of the methods are provided as supplementary material. 
Quantitative needle EMG
Quantitative needle EMG was performed using disposable EMG needle electrodes 
with a Medelec Synergy EMG system (Oxford Instruments, Oxford, United Kingdom). 
EMG of the injured biceps muscle was compared with that of control muscles (the 




biceps muscle). Since the mean number of MUPs of the triceps muscle was too low 
(≤ 2), the brachialis muscle was selected as a control. The multi-MUP analysis was 
performed using Medelec Synergy software version 11 (Oxford Instruments) 33. 
Further details of the methods are provided as supplementary material. 
Histochemistry and immunohistochemistry of muscle biopsy
A biopsy of 0.5 cm × 0.5 cm × 0.5 cm of the injured biceps muscle was taken at the 
site of the MNC injection 34. It was immediately fixed in 4 % buffered formalin and 
embedded in paraffin. Tissue sections of 5 µm thickness were cut, deparaffinised 
and rehydrated for Masson’s trichrome staining, routine haematoxylin and eosin 
(H&E) staining and immunohistochemistry to evaluate muscle, vascular and neural 
regeneration. For immunohistochemistry Pax7, CD56 and von Willebrand Factor (vWF) 
were used. Further details of the methods are provided as supplementary material. 
Muscle analysis
Muscle sections were analysed using a Zeiss image analysis system (KS400; Zeiss, 
Sliedrecht, The Netherlands) coupled to a camera (DXC-950P; Sony, Amsterdam, 
The Netherlands) and ImageJ software v1.38X (National Institutes of Health, 
Bethesda, Maryland). From each stained section, random images were selected, 
analysing at least 200 fibres. Further details of the methods are provided as 
supplementary material. 
Statistical analysis
All tests were two-tailed and p - values < 0.05 were considered significant. SPSS 
v20.0 (SPSS Inc., Chicago, Illinois) was used to perform the analyses. Baseline 
characteristics are presented as mean and range. Data from muscle biopsies, EMG, 
CT, and clinical function are presented as mean and standard deviation (sd). Elbow 
flexion strength using the MRC motor scale is displayed as median and range. A 
paired t-test or one-way analysis of variance (ANOVA) was used to analyse the 
muscle biopsy parameters. A mixed model analysis was used to analyse EMG, CT 
and clinical functionality parameters. Patients were included as random effects on 
each outcome parameter. In order to determine changes in outcome at follow-up, 
the variable ‘time’ was included as fixed effect. In order to determine any dose–
effect response between group A, B and C, the variable ‘group’ was also included 
in the mixed model as a fixed effect. 
ReSultS
Baseline patient and injected MNC characteristics are shown in table I. During 
hospital stay and follow-up, no adverse events in vital signs (blood pressure, pulse 
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rate, temperature), BM aspiration site, injection sites or surgical wound (haematoma, 
infection) were observed. Post-operatively, the mean decrease in haemoglobin (Hb) 
concentration was 0.2 mmol/l (group A), 1.0 mmol/l (group B), and 1.8 mmol/l 
(group C). Hb concentration was normalized in all patients six months after BM 
aspiration. In order to assess the safety of MNC injection at a local muscular level, 
quantitative CT analysis and histology were used. With quantitative CT analysis, 
the MMD of the injured biceps muscle was compared with injured and non-injured 
control muscles. A significant decrease in the MMD of the injured biceps muscles 
in the total patient group was observed (p = 0.03). The decrease was 32 % at three 
months (p = 0.04) and 48 % at six months follow-up (p = 0.009). No dose effect 
was observed. The non-injured contralateral biceps and the injured (non-injected) 
triceps muscle showed no significant change in MMD (figure 1).
A Masson’s Trichrome staining was performed to analyse the possible formation 
of muscle fibrosis after cell injection. As compared with the pre-injection biopsy, 
a decrease of 52 % in mean areas of fibrosis of the injured biceps muscle was 
measured at three months after cell injection in the total patient group (p = 0.01). 
No dose effect was observed (figure 2).
Table I: Baseline patient and injected mononuclear cell characteristics 
Group A (n = 3) Group B (n = 3) Group C (n = 3)
Age * (years) 33 (20 to 45) 30 (25 to 33) 23 (20 to 28)
Male † (n) 3 (100) 3 (100) 3 (100)
Brachial plexus injury type † (n)
C5 - C6 1 (33) 1 (33) 0
C5 - C7 0 2 (67) 3 (100)
C5 - Th1 2 (67) 0 0
Time after trauma * (years) 7.4 (2 to 17) 8.0 (3 to 17) 2.9 (2 to 3)
Neurosurgery † (n) 3 (100) 2 (67) 3 (100)
Time after neurosurgery * (years) 7.0 (2.0 to 16.5) 10.1 (4.0 to 16.3) 2.6 (2.2 to 2.9)
Elbow flexion strength # (MRC scale) 3 (3) 2 (2 to 3) 2 (2 to 3)
Active elbow flexion RoM * (°) 65 (25 to 100) 12 (0 to 35) 30 (0 to 90)
Injected mononuclear cells * (x 108 cells) 0.89 (0.6 to 1.3) 4 ‡ 8 ‡
CD34+ * (x 106 cells) 2.5 (0.5 to 5) 10.8 (7 to 16) 23.6 (15 to 32)
CD34-  * (x 106 cells) 86.5 (57 to 127) 389 (384 to 393) 776 (769 to 785)
*Values are given as mean with range. †Values are given as number of patients with percentage. 
#Values are given as median with range. ‡No range is given as the exact number of cells was 




Figure 1: Muscle density
Graphs showing the mean muscle density (MMD) of the injured and non-injured biceps (A) and 
triceps (B) muscle pre-transplantation and at three and six months follow-up for the total patient 
group. Error bars denote 95 % confidence interval (HU, Hounsfield unit). 
Figure 2: Masson’s Trichrome staining
Histological images showing Masson’s Trichrome staining of a representative muscle biopsy a) 
pre- and b) three months post-transplantation (magnification 5 ×). 
In order to assess any regenerative potential of the injected MNCs, quantitative 
needle EMG and histology were performed. The mean amplitude, duration, and 
number of phases of the MUPs of the injured biceps muscle were compared with 
injured and non-injured control muscles. After three months, the increase was 
36 % in mean amplitude (p = 0.045), 22 % in duration (p = 0.005) and 29 % in 
number of phases (p = 0.002). The increase in number of phases were sustained 
at six months follow-up (p = 0.001). A dose-effect relation between group A, 
B and C was observed only in the mean amplitude (p = 0.03). The non-injured 
contralateral biceps muscle, the injured (non-injected) brachialis muscle and non-
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injured brachialis muscle showed no significant changes in amplitude, duration, 
or number of MUP phases. The mean number of analyzed MUPs was 5.3 (SD 2.2). 
This low number represents the severity of the nerve lesions in which patients were 
unable to recruit more motor units (figure 3).
Figure 3: Quantitative needle electromyography
Graphs showing the mean amplitude (a and b), duration (c and d) and number of phases (e and f) 
of motor unit potentials of the injured and non-injured biceps (left column) and brachialis muscle 
(right column) pre-transplantation and at three and six months follow-up for the total patient 




The myogenic repair potential of the injected MNC cells was also evaluated using 
the histology of the injured biceps muscle. Analysis of all patients showed a mean 
increase of 80 % in myofibre diameter three months after the cell injection compared 
with the pre-injection biopsy (p = 0.007). Pax7 staining demonstrated a 50 % 
increase in the number of satellite cells (p = 0.045). Von Willebrand Factor staining 
showed an increase of 83 % in the number of capillaries per myofibre (p < 0.001). 
No significant increase was demonstrated in the number of centronucleated 
myofibres or CD56 positive myofibres after cell therapy (table II). 
Histological muscle regeneration was most apparent in group B, which 
observed a 126 % increase in myofibre diameter, a 186 % increase in percentage 
of centronucleated myofibres, a 117 % increase in number of satellite cells, a 100 % 
increase in capillaries per myofibre and a 70 % decrease in the area of fibrosis. No 
dose-effect relation was observed in any of the histological measurements. Figure 
4 shows a representative example of H&E, Pax7, and vWF and CD56 staining of 
a muscle biopsy before and after cell therapy in group B. After cell therapy, the 
muscle biopsy of one patient in group A did not contain 200 muscle fibres and was 
therefore excluded from analysis. In group A, no analysis of the CD56 staining could 
be performed because one patient’s muscle biopsy after cell therapy contained 
only 120 myofibres and was therefore excluded.
In order to observe function improvement after MNC injection, we measured 
the active flexion ROM and strength of the injured elbow before and after cell 
therapy compared with the injured and non-injured control muscles. In addition, 
quality of life questionnaires (SF-36 and DASH) and the VAS score for pain were 
used. Overall, all patients had a significant increase in active flexion ROM and 
flexion strength. The flexion ROM increase was 152 % at three months (p < 0.001) 
and 147 % at six months follow-up (p < 0.001). The flexion strength increase was 
38 % at three months (p < 0.001) and 46 % at six months follow-up (p < 0.001). 
As expected, the increase in active elbow flexion ROM and flexion strength was 
most prominently significant in patient groups where cell therapy was combined 
with a modified Steindler procedure (groups B and C). No significant changes in 
SF-36, DASH or VAS score were observed comparing pre- and post-injection at 
three months (table III). 
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Table II: Histological results 
Mean (sd) biceps histology
Group
p-value* Total (n = 9)A (n = 3) B (n = 3) C (n = 3)
Myofibre diameter (µm)
0 months 254 (68) 173 (46) 171 (12) 193 (53)
3 months 392 (165) 391 (44) 274 (71) 347 (98)
Mean difference +138 +218 +103 0.39  0.007 †
Centro-nuclear myofibres (%)
0 months 5.1 (2.5) 2.1 (1.5) 2.6 (1.7) 3.1 (2.0)
3 months 2.7 (0.8) 6.0 (3.1) 3.4 (1.9) 4.2 (2.5)
Mean difference -2.4 +3.9 +0.8 0.01 0.30 †
Fibrosis (%)
0 months 18 (2) 31 (2) 23 (4) 25 (6)
3 months 17 (15) 9 (4) 12 (2) 12 (7)
Mean difference -1 -22 -11 0.06 0.01 †
Pax7+ myofibres (%)
0 months 17 (4) 6 (3) 14 (6) 12 (6)
3 months 18 (8) 13 (3) 23 (10) 18 (8)
Mean difference +1 +7 +9 0.45 0.045 †
vWF+ per myofibre (%)
0 months 0.8 (0.04) 0.5 (0.1) 0.5 (0.1) 0.6 (0.2)
3 months 1.1 (0.2) 1.0 (0.2) 1.1 (0.4) 1.1 (0.2)
Mean difference +0.3 +0.5 +0.6 0.33 < 0.001 †
CD56+ myofibres (%)
0 months 16 (n/a)‡ 18 (6) 25 (3) 21 (5)§
3 months 16 (n/a)‡ 18 (8) 21 (12) 19 (7)§
Mean difference 0 0 -4 0.94 0.60 †
Mean myofibre diameter, centro-nuclear myofibres, fibrosis, Pax7+ myofibres, vWF per myofibre 
and CD56+ myofibres of muscle biopsies of the injured biceps muscle before MNC injection and 
at three months follow-up * comparison of mean differences between time points between the 
groups (one-way analysis of variance (ANOVA)), † difference between time points for all patients 






Histological images for specimens taken pre-transplantation (left column) and at three months 
follow-up (right column), showing staining of a representative muscle biopsy with haematoxylin 
and eosin (a and b: × 20), Pax7 (c and d: × 40), vWF (e and f: × 40) and CD56 (g and h: × 40). 
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Table III: Clinical results 
Group
Mean (sd) outcome* A (n = 3) B (n = 3) C (n = 3) P - value† Total (n = 9)
Flexion ROM (°) 0.22
    0 months 65 (38) 12 (20) 30 (52) 36 (41)
    3 months 82 (28) 115 (5) 107 (15) 101 (22)
    6 months 88 (20) 100 (20) 110 (22) 99 (20)
        p-value‡ < 0.001‡
Median flexion strength (MRC grade) 
(range)
0.02
    0 months 3 (3 to 3) 2 (2 to 3) 2 (2 to 3) 2 (2 to 3)
    3 months 3 (3 to 3) 4 (3 to 4) 4 (3 to 4) 3 (3 to 4)
    6 monthss 3 (3 to 4) 4 (4 to 4) 4 (4 to 4) 4 (3 to 4)
        p-value‡ < 0.001‡
SF-36 0.06
    0 months 86 (6) 57 (16) 69 (6) 78 (15)
    3 months 91 (5) 71 (18) 74 (9) 78 (14)
    6 months 82 (11) 72 (15) 75 (10) 76 (12)
        p-value‡ 0.06‡
DASH-DLV 0.15
    0 months 43 (19) 35 (25) 75 (16) 51 (25)
    3 months 64 (39) 68 (19) 76 (12) 69 (23)
    6 months 41 (16) 71 (17) 74 (16) 65 (20)
        p-value‡ 0.09‡
VAS for pain 0.02
    0 months 0.8 (0.8) 6.1 (2.1) 1.0 (1.1) 2.7 (2.9)
    3 months 0.8 (0.6) 2.3 (2.0) 1.3 (1.6) 1.5 (1.5)
    6 months 0.8 (0.6) 2.0 (0.5) 2.2 (3.0) 1.7 (1.7)
        p-value‡ 0.24‡
Elbow flexion range of movement (ROM) and strength of the injured elbow together with 
the Short-Form 36 and Disabilities of the Arm Shoulder and Hand (DASH; Dutch language 
version) questionnaires and visual analogue scale (VAS) for pain before mononuclear cell 
(MNC) injection and after three and six months * MRC, Medical Research Council; SF-36, Short-
Form 36 (scored from 0 to 100); DASH-DLV, Disabilities of the Arm Shoulder and Hand – Dutch 
language version (scored from 0 to 100); VAS, visual analogue scale (scored from 0 (no pain) to 
10 (extreme pain), † comparison of differences between pre-op and six months in the groups 






Autologous BM-derived MNC injection in a partially denervated biceps muscle 
is safe and shows no adverse events with respect to vital signs, BM aspiration 
sites, injection sites or surgical wounds. Only a mild anaemia was observed, which 
recovered fully. The interstitial fibrosis present at long-term denervation decreased 
by 52 % after MNC injection. These results run parallel to the results of CT scan 
analysis, which demonstrated a decrease of 48 % in MMD. 
Our secondary aim was to estimate myogenic repair and reinnervation of partial 
denervated muscles after MNC injection. Histological analysis, quantitative needle 
EMG and CT scan analysis demonstrated muscle improvement after MNC injection, 
which was not present in the control muscles of the sound arm or in the non-
injected injured muscles of the affected arm. 
Our study has some limitations. While useful to quantify fatty degeneration of 
rotator cuff muscles, CT analysis only provides an indirect measure of the amount 
of muscle lipid or fibrosis 32. We observed a significant decrease in MMD of the 
injured biceps muscles after cell injection, which could reflect decrease in muscle 
fibrosis and increase in muscle vascularisation, muscle fattening or oedema from 
the procedure 35. Histology of the muscle biopsies demonstrated a 52 % decrease 
in muscle fibrosis. In addition, an 83% increase in capillaries per myofibre was 
observed. Using routine H&E staining, no increase in muscle fattening was seen, 
thus the decrease in MMD reflects either a decrease in muscle fibrosis or an increase 
in muscle vascularisation. The presence of muscle denervation was assessed using 
quantitative needle EMG. Analysing a minimum of 20 MUPs per analysed muscle 
is generally accepted in the literature 33, 36, 37. Unfortunately, we could not obtain 
a minimum of 20 MUPs per analysed muscle (mean 5.3 MUPs, SD 2.2), due to 
the partial denervation. Nevertheless a significant difference in mean amplitude, 
duration and the number of phases was found. 
Another limitation was that in groups B and C, the BM-derived MNC injection 
was combined with a flexor-pronator transfer, which improves elbow flexion. 
Since the flexor-pronator group has to be fixated to the distal humerus with a 
bicortical screw, it is possible that BM may leak underneath the screw, stimulating 
the muscle in its vicinity (biceps triceps). However, CT changes were not seen in 
the control triceps muscle, nor were EMG improvements in the injured but non-
injected brachialis muscle. A final limitation was low number of patients and lack 
of a control patient group (i.e. modified Steindler in a partially denervated biceps 
muscle with no MNC injection). 
Quantitative needle EMG was used to determine muscle innervation. After 
injection of BM-derived MNC cells, an increase of 36 % in amplitude, 22 % in 
duration, and 29 % in number of phases of MUPs was observed, suggestive for 
140
Bone marrow cells to regenerate muscle
8
muscle reinnervation. Both human and animal studies have shown that BM stromal 
cells can differentiate into neural cells and improve nerve regeneration 38-41.
Histology was used to evaluate the myogenic repair on a microscopic level. 
Upon muscle denervation, animal studies have shown a decrease from 2104 µm to 
50 µm in myofibre diameter, a decrease from 1.6 % to 0.2 % in capillary-to-myofibre 
ratio and an increase from 11 % to 35 % in fibrosis 14, 17, 18. Our data are consistent 
with these studies, demonstrating a mean myofibre diameter of 193 µm, a mean 
capillary-to-myofibre ratio of 0.6 and a mean fibrosis of 25 % before cell injection. 
The number of cells in the satellite pool within a muscle appears to be correlated 
to postnatal growth characteristics of the muscle (Pax7). In adult muscle, up to 
10 % Pax7 positive myofibres have been reported 16, 17, 42. Before cell injection, we 
observed mean Pax7 positive myofibres of 11.9 % (SD 6.5). This higher percentage 
of Pax7 fibres is probably due to the partially denervated biceps muscle in the 
current study. 
After MNC injection, we observed an increase of 50 % in Pax7 positive 
myofibres and an increase of 83 % in vWF positive capillaries per myofibre. This 
may demonstrate that MNC injection can result in restoration of the satellite cell 
pool and vascular bed, which can play an important role in functional recovery 
following long-term denervation. Indeed, the increase of 80 % in myofibre diameter 
suggested myofibre regeneration and thus restoration of muscle atrophy. Muscle 
regeneration was most prominently observed in patient group B, with an increase 
of 117 % in Pax7 positive myofibres, 100 % in capillary-to-myofibre ratio, 126 % in 
myofibre diameter, 186 % in centronuclear myofibres and a decrease of 70 % in 
fibrosis. These results are suggestive of an optimal dose in group B, although a 
dose-effect response was not significant. 
Skeletal muscle is a regenerative tissue in which mononuclear precursor cells 
respond to injury by dividing and fusing with damaged fibres 15. As such, it is an 
attractive target for cell-based therapy. Muscle fibre regeneration levels of up 
to 12 % have been achieved by using appropriate transplant variables, including 
cell dose and mode of cell delivery 24. The present study is the first in which BM 
transplantation in a human muscle denervation model was assessed with objective 
measurements (histology, CT muscle and EMG). In humans, transplantation of the 
MNC fraction of the adult BM enhanced cardiac- and skeletal muscle function 
in post-ischaemic heart failure and peripheral artery disease 25-28. These effects 
could be attributed to the incorporation of stem cells and building muscle or 
by supplying the logistics required for efficient proliferation of innate cells via 
paracrine effects  43,  44. Heterochronic parabiosis was shown to restore the 
regenerative potential of satellite cells, which suggests that satellite cell activity can 




the in vitro regenerative potential of human satellite cells, which underscores the 
in vivo influence of the microenvironment on muscle regeneration 46. Unravelling 
the molecular mechanism behind the observed regeneration in BPI patients is 
a challenge that still has to be met. In the future, this can be studied in newly 
developed animal models representative for BPI 47, 48.
In conclusion, BM-derived MNC injection is safe in partially denervated muscle 
of traumatic BPI patients. Significant muscle improvement has been observed 
in muscle biopsies, quantitative needle EMG and CT scan analysis. Although 
promising, the preliminary results of the present study require confirmation in a 
larger controlled clinical study. 
SuPPleMentaRy MateRIal
Bone marrow aspiration and mononuclear cell (MNC) separation
Bone marrow (BM) was aspirated from one location at the posterior iliac crest 
under aseptic conditions in the operating theatre using a 14-gauge, 40 mm needle 
(Sterylab, Milan, Italy). The procedure was performed under local (group A) or under 
general anaesthesia (groups B and C). In group A, 60 ml of BM was aspirated, which 
was considered the maximum amount that can be aspirated under local anesthesia. 
Following separation, a mean mononuclear cell (MNC) dose of 0.89 × 108 MNCs 
(SD 0.38) was obtained. In groups B and C, a MNC dose of 4.0 × 108 MNCs and 8.0 
× 108 MNCs was anticipated, respectively. In order to get these cell concentrates, 
350 ml and 650 ml of BM was aspirated under general anaesthesia for groups B 
and C, respectively. Due to ethical considerations, in these two patient groups BM 
aspiration was performed in combination with a modified Steindler procedure, 
which is our standard secondary surgical procedure with a flexion deficiency of 
the elbow. BM was collected in flasks containing Hanks balanced salt solution and 
heparin and was then separated over a density gradient (Ficoll isopaque specific 
density of 1.077 g/cm3). The MNCs were harvested and washed in 0.9 % NaCl with 
0.5 % human serum albumin (RVG 16910; Sanquin, Amsterdam, The Netherlands). 
The BM-derived MNC doses were concentrated in a volume of 10 ml. The Ficoll 
isolation procedure was performed in a clean-room facility according to good 
manufacturing practice (GMP) and took approximately three hours 25, 28.
MNC injection
BM-derived MNCs were injected in the biceps brachii muscle. The 20 injections 
were centred on the largest diameter of the muscle belly at a distance of 
approximately 0.5 cm × 0.5 cm from each other. With each injection, a volume of 
0.5 ml MNCs was injected at a standard injection depth in the muscle belly (which 
was palpated manually) of 0.5 cm using a 26-gauge needle (Becton Dickinson, 
142
Bone marrow cells to regenerate muscle
8
Breda, the Netherlands). The same surgeon, who also performed the tendon 
transfer, performed these injections (RN). 
Clinical functionality
In order to maximise reliability and validity of the range of movement (ROM) 
measurements, the arm was kept in a standardised position (0 ° anteflexion, 0 ° 
abduction, 0° rotation of the shoulder). Force measurement of the injured biceps 
muscle was also performed in a standardised arm position (0 ° anteflexion, 0 ° 
abduction, 0 ° rotation of the shoulder and 90 ° elbow flexion). All measurements 
were performed by the same examiner (RN).
CT scan
The Aquilion 64-slice CT scanner was used (Toshiba Medical Systems, Otawara, 
Japan). The scanning parameters were set at 135 kVp and a detector pitch of 53 
(pitch factor 0.828). A soft-tissue filter and boost three-dimensional (3D) artifact 
suppression was used, producing a 512 × 512 matrix of 1 mm thick slices (slice 
overlap: 0.2 mm). A total of 50 consecutive multiplane reconstruction (MPR) images 
were computed by reconstructing images in the coronal and sagital plane so that 
in every patient axial, slices were used for analysis, thereby correcting for oblique 
slices. As observed, the largest transversal diameter of the biceps brachii muscle 
was shifted from the midpoint of the humerus to the distal 2/3 point of the humerus. 
Therefore, 50 consecutive images were selected from 25 mm superior and 25 mm 
inferior to this distal 2/3 point of the humerus. This was measured using the most 
superior part of the humeral head and the most superior part of the olecranon. 
Images were first recalibrated for air (-1000 HU) based on samples outside the 
patient. Subsequently, the triceps muscle and the biceps brachii muscle were 
manually outlined as separate regions of interest (ROI). All pixels containing bone 
tissue were automatically excluded from the segmentation by applying a threshold 
value of 200 HU. A histogram was constructed from all pixels within the outlined 
ROI to calculate the mean muscle density (MMD) 32.
Quantitative needle electromyography
Quantitative needle electromyography (EMG) was performed using the Medelec 
Synergy EMG system (Oxford Instruments, Oxford, United Kingdom). The EMG 
signals were recorded with filter settings of 5 Hz for high pass and 10 kHz for low 
pass. For the biceps brachii muscle, the electrode was positioned in the middle of 
the muscle belly. For the brachialis muscle, the electrode was positioned medial to 
the biceps muscle at the level where the latter muscle adheres to the tendon. When 
the EMG signal was crisp, no further adjustment of the electrode position was 




for 30 seconds. Potentials that were regarded as belonging to unique motor units 
but were judged to represent a motor unit already collected were omitted, as well 
as those with a noisy baseline or other artifacts. Among the remaining MUPs, the 
automatic duration cursor settings were manually corrected if necessary. If the 
duration cursor was changed, the amplitude and number of phases of the MUPs 
were recalculated before analysis 33. All analyses and re-analyses were performed 
by the first author (SH) and an experienced neurophysiologist (JvD) blinded to the 
patient characteristics.
Histochemistry and immunohistochemistry of muscle biopsy
A biopsy of the injured biceps muscle was performed at the site of the MNC 
injection using a forceps with two sharp-edged jaws (Blakesley Conchotoma; DK 
Instruments, West Bengal, India) 34. The muscle biopsies before and after cell 
therapy in group A were taken under local anaesthesia at the outpatient clinic. 
The muscle biopsies before cell therapy in groups B and C were performed under 
general anaesthesia in combination with the modified Steindler procedure. The 
muscle biopsies after cell therapy in groups B and C were taken under local 
anaesthesia at the outpatient clinic. 
For Masson’s trichrome staining, sections were incubated subsequently for 
60 minutes at 56 °C in Bouin’s fluid (640960; Klinipath, Duiven, the Netherlands), 
15 minutes in 1 % Biebrich Scarlet (03336; Brunschwig Chemie, Amsterdam, the 
Netherlands), 15 minutes in 5 % Tungstophosphoric acid (1005830100; Merck, 
Damstadt, Germany) and 10 minutes in 2 % light green SF yellowish (C.I. 42095, 
115941; Merck) resulting in a green staining for fibrosis and red staining for muscle 
fibres.
For immunohistochemistry, the primary antibodies monoclonal mouse anti-
human Pax7 (1:20, 352-523; Developmental Studies Hybridoma Bank, Iowa City, 
Iowa), monoclonal mouse anti-human CD56 (1:80, clone NCAM16.2, 345811; BD 
Biosciences, Erembodegem-Aalst, Belgium), and polyclonal rabbit anti-human 
von Willebrand Factor (vWF) (1:4000, A0082; Dakocytomation, Heverlee, Belgium) 
were used. Sections were pretreated by boiling for 20 minutes at pH 6.0 in 
10 mM citric acid buffer (C0759-500G; Sigma-Aldrich Chemie, Zwijndrecht, the 
Netherlands) (Pax7 and vWF)or at pH 9.0 in 1 mM ethylenediamine-tetraacetic 
acid disodium salt buffer (1073; Baker, Deventer, the Netherlands) (CD56) for 
antigen retrieval. Next, sections were incubated for 60 min in 5 % normal goat 
serum (NGS) (X0907; DakoCytomation, Heverlee, Belgium) and 1 % bovine 
serum albumin (BSA) (A9647-50G; Sigma-Aldrich Chemie) in phosphate buffered 
saline (PBS) to block nonspecific binding. For Pax7, 0.3 % Triton X 100 (T8787; 
Sigma-Aldrich Chemie) and 0.01 % hydrochloric acid (1003171000; Merck) was 
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added to the blocking solution. Sections were incubated with the primary 
antibodies overnight and subsequently for 20 minutes in 0.3 % hydrogen peroxide 
(1072090250; Merck) in PBS to block endogenous peroxidase. Next, the sections 
were incubated for 60 minutes with the biotinylated secondary antibody rabbit 
anti-mouse (1:200, E0464; Dako-Cytomation) (Pax7, CD56) or goat anti-rabbit 
(1:200, E0432; DakoCytomation) (vWF). In order to visualise immunolabelling, 
sections were incubated for 30 minutes with horseradish peroxidase labeled 
avidinbiotin complex (Vectastain Elite ABC kit, PK6100; Brunschwig, Amsterdam, 
the Netherlands) and subsequently with diaminobenidine (DAB liquid, K3468; 
DakoCytomation) as chromogenic substrate resulting in a brown precipitate. 
Finally, sections were counterstained for one minute with Harris’ haematoxilline 
solution (1092532500; Merck), dehydrated and mounted on Micromount (1731; 
Surgipath Europe, Peterborough, United Kingdom).
Muscle analysis
The area of fibrosis was analysed in the Masson-trichrome stained sections by 
dividing each pixel into three color components (hue, saturation, intensity). The 
threshold was defined and kept constant throughout the analysis. The percentage 
of green fibrotic area was measured. The haematoxylin and eosin (H&E) stained 
sections were used to measure the myofibre diameter and the percentage 
of centronucleated, regenerating myofibres. In order to measure the myofibre 
diameter and the percentage of centronucleated myofibres, only transversely 
cut myofibres were measured. In order to compensate for myofibres that were 
partially longitudinal the minimal diameter was calculated. The Pax7 and CD56 
stained sections were used to calculate the percentage of myofibres containing 
a Pax7 positive cell and percentage of CD56 positive myofibres respectively. The 
vWF sections were used to assess the number of capillaries around each fibre. All 
transversely cut capillaries were counted. If a capillary was sectioned longitudinally, 
it was counted as one each time it crossed a junction between three or more 
muscle fibres.
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SuMMaRy anD RecoMMenDatIonS foR futuRe 
ReSeaRcH
Functional level
The aim of this thesis is to evaluate determinants of outcome, which will have an 
effect on overall functionality of the patient with an OBPI. Symptoms of OBPI vary 
widely over the course of time and from individual to individual and are related 
to various degrees of denervation, muscle weakness, contractures and bone 
deformities with their subsequent functional limitations. To date, no universally 
accepted overall framework is available to assess the outcome of patients with 
OBPI. At the functional level, the developmental process of outcome measures 
using the ICF is described (chapter 2). The first step is to conduct four preparatory 
studies to identify ICF categories important for OBPI: a) a systematic literature 
review to identify outcome measures, b) a qualitative study using focus groups, c) an 
expert survey and d) a cross-sectional, multicentre study. The proposed method 
to develop ICF Core Sets for OBPI yields a practical tool for multiple purposes: 
for clinicians to systematically assess and evaluate the individual’s functioning, for 
researchers to design and compare studies, and for patients to get more insight 
into their health problems and their management. 
Clinical level
At the clinical level, impaired muscles and joint deformities and their treatment 
options are addressed. Long-term denervation results in muscle degeneration 
including muscle atrophy, fatty degeneration and interstitial fibrosis in the muscle. 
Assessment of contractile CSA might yield valuable insight in pathophysiology and 
might be used to predict the outcome of conservative and surgical procedures. 
Volumes of interest were manually drawn on MRI scans by two independent observers 
to calculate the percentage of muscle fat, the total CSA and the contractile CSA 
in both the sound and the injured upper extremity in patients with a traumatic BPI 
(chapter 3). The contractile CSA showed the highest association with active flexion 
and muscle force compared to fat percentage and total CSA. The mean contractile 
CSA was lower in the affected biceps brachii 8 cm2 (SD 5.1) compared to a mean 
of 19 cm2 (SD 4.9) in the non-affected biceps brachii (p < 0.001) with an excellent 
inter-observer reliability (ICC 0.88). The contractile CSA of the affected biceps brachii 
was associated with active elbow flexion with an estimate of 7.1 °, 95 % CI 2.8 to 
11.5, p = 0.003), i.e. an increase of 1.0 cm2 of contractile CSA results in an increase 
of 7.1 ° active elbow flexion. The contractile CSA of the affected biceps brachii was 
associated with muscle strength in MRC with an odds ratio of 2.6 (95 % CI 1.1 to 6.1, 
p = 0.029). One cm2 increase in contractile CSA of the affected biceps brachii was 




The effect of serial casting on elbow flexion contractures in OBPI was evaluated 
(chapter 4). A prospective consecutive cohort study was performed with a median 
of 5-year follow-up. Forty-one patients with elbow flexion contractures ≥ 30° were 
treated with serial casting for a maximum of 8 weeks until the flexion contracture 
was ≤ 10 °. Serial casting improved elbow flexion contractures with an increase 
of passive extension from a median -40 ° (IQR -50 to -30) before casting to -15 ° 
(IQR -10 to -20, p < 0.001) after casting. Recurrences were frequently observed. 
Overall, twenty (49 %) patients showed thirty-seven recurrences. The severity of 
elbow flexion contracture was only a small predictor for recurrent elbow flexion 
contracture with a hazard ratio of 0.93 (95 % CI 0.89 to 0.96, p < 0.001).
The effect of botulinum toxin A (BTX-A) injection in the subscapular muscle in 
patients with internal rotation contracture was evaluated using the external rotation 
and the need for tendon transfer for external rotation as outcome (chapter 5). 
A prospective comparative study was performed including 15 consecutive patients 
treated with BTX-A (2 IU/kg body weight) under general anaesthesia and a historic 
control group of 67 patients with mean age 30 months (SD 10). BTX-A injection 
in the subscapular muscle increased the passive external rotation in adduction 
from -1 ° (95 % CI -10 to 8) to 32 ° (95 % CI 17 to 46) at 3 months. BTX-A injection 
also reduced the need for tendon transfer surgery as 6 patients were indicated 
for surgery in the BTX-A group compared to 66 in the control group. At 5 years 
follow-up, 10 patients in the BTX-A group were indicated for surgery with a hazard 
ratio of 4.0 (95 % CI 1.9 to 8.4). 
Cellular level
Finally at the cellular level, muscle degeneration is characterized in both 
inflammation (rheumatoid-RA) and osteoarthritis (OA) as well as in denervated 
muscles. In the latter group, also cell therapy is explored as a treatment option. 
The effect of chronic inflammation compared to non-inflammatory muscles around 
the knee joint on the regenerative potential of satellite cells in human muscle was 
studied (chapter 6, 7). As a model for chronic inflammation, muscle biopsies form 
16 patients suffering from osteoarthritis were compared to 11 patients suffering 
from rheumatoid arthritis. Histological characteristics showed no significant 
differences in type II muscle fiber atrophy, lipofuscin accumulation, or satellite 
cell number in RA compared to OA patients. After mononuclear cell explantation, 
myogenic purity, viability, proliferation index, number of colonies, myogenic 
colonies, growth speed, maximum number of population doublings and fusion 
index were not different between RA and OA patients. Furthermore, the expression 
of proteins involved in replicative and stress-induced premature senescence and 




between OA and RA patients. Mean telomere length was shorter in the RA group 
compared to the OA group. In conclusion, chronic inflammation in RA does not 
affect the in vitro regenerative potential of human satellite cells. 
A pilot study is described to assess the safety and regenerative potential 
of autologous bone marrow-derived mononuclear cell injection in a partially 
denervated biceps muscle of BPI patients (chapter 8). Nine adult traumatic BPI 
patients with insufficient active elbow flexion received intramuscular escalating 
doses of autologous bone marrow-derived mononuclear cells, combined with 
an elbow flexorpronator group transfer (Steindler procedure). Mononuclear cell 
injection in a partially denervated biceps muscle of these brachial plexus patients 
was safe and showed no adverse effects on vital signs, bone marrow aspiration 
sites, injection sites, or surgical wound. Results suggest enhanced muscle 
regeneration with a 52 % decrease in muscle fibrosis (p = 0.01), an 80 % increase 
in myofiber diameter (p = 0.007), a 50 % increase in satellite cells (p = 0.045) and 
an 83 % increase in capillary-to-myofiber ratio (p < 0.001) was shown. CT analysis 
demonstrated a 48 % decrease in mean muscle density (p = 0.009). Motor unit 
analysis showed a mean increase of 36 % in motor unit amplitude (p = 0.045), 22 % 
increase in duration (p = 0.005) and 29 % increase in number of phases (p = 0.002). 
Recommendations for future research
At the functional level, studies on the evaluation of OBPI show high variability 
between the used outcome variables. Children with OBPI experience difficulties 
in all areas of functioning, as well as in both environmental and personal factors 1. 
These results underscore the need for the development and use of outcome 
variables representing all domains of health status in these patients. Future research 
should include the evaluation of functionality problems in OBPI patients with an 
expert survey and a cross-sectional, multicentre study. The latter was recently done 
at our institution in 1000 Patients (ZAP-Plexus www.zenuwcentrum.org). As for the 
definition of valid functionality outcome scores for OBPI, a first version of ICF Core 
Sets should be defined at a Delphi conference to integrate the evidence from the 
preparatory studies. In a second step, field-testing among patients should validate 
this first version of Core Sets for OBPI. In the future, standardised ICF Core Sets will 
not only be useful for research, but also in the important shared decision making 
process between patient and physician.  Eventually these ICF data can be used to 
quantify the severity of OBPI and compare them between patient groups and even 
medical centers, to improve decision making in the clinical settings. 
A result of muscle degeneration includes the development of contractures 
including elbow flexion contractures and internal rotation contractures around 




insight into the underlying factors of contractures including muscle imbalance, 
reduced longitudinal muscle growth, capsular fibrosis and posture which could 
reveal possible treatment strategies 2-6. To unravel the impaired movement, the 
combination of a haptic manipulator and surface EMG could be use to discriminate 
neural (active and reflexive) and non-neural contributors (passive muscle and 
connective tissue properties) 7. Muscle degeneration as reflected by both muscle 
atrophy and fatty degeneration can be quantified using three-point Dixon MRI 
with an excellent reproducibility. Contractile CSA was significantly associated with 
active muscle flexion force. Future research should determine whether quantitative 
measurement of muscle degeneration could predict the outcome of conservative 
and surgical procedures.  Case reports on posterior shoulder dislocation at young 
age have been described before, suggesting direct trauma at birth as a cause of 
the dislocation 8-11, which is contradictory to observations at successive MRI’s in our 
clinic 12. However, at outdoor clinics the awareness of the occurrence of potential 
contractures should be recognised at the shoulder (internal rotation and abduction 
contractures) and at the elbow (flexion and supination contractures). Therefore, 
specialised multidisciplinary clinics (the Dutch model), involving neurosurgeons, 
orthopaedic surgeons, rehabilitation physicians as well as physiotherapists and 
ergo therapists are necessary for optimal care of the patients and their family.
At the cellular level, muscle regeneration has potential despite the partial 
denervation 13, 14. Cell therapy can be a therapeutic option to replenish the exhausted 
satellite cell pool. Future research should focus on the identification of mechanisms 
influencing muscle regeneration by modulation of its microenvironment to improve 
strategies for muscle regeneration. Furthermore, future research should determine 
whether a combination of nerve repair en muscle regeneration could be effective. 
Animal models are available to identify mechanisms for nerve repair and muscle 
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Het plexus brachialis letsel is een tractie letsel van de plexus brachialis wat kan 
ontstaan tijdens de partus of door een trauma op latere leeftijd. Er is een ruime 
variëteit in het type symptomen waar patiënten met een plexus brachialis last 
van kunnen ondervinden zoals verschillende mate van denervatie, spierzwakte, 
contracturen, botdeformiteiten en functionele beperkingen. Ondanks natuurlijk 
herstel is er vaak neurochirurgische en orthopaedisch chirurgische behandeling 
noodzakelijk om de functie van de schouder, elleboog, pols en hand te verbeteren. 
Om te bepalen of een behandeling nodig is en om te onderzoeken wat het resultaat 
is van een behandeling, is het noodzakelijk om een wereldwijd geaccepteerde 
en betrouwbare methode te ontwikkelen om de mate van herstel na het plexus 
brachialis letsel te kunnen beschrijven (hoofdstuk 2). De eerste stap hiervoor is het 
verrichten van 4 voorbereidende onderzoeken: een systematische literatuurstudie 
naar welke meetinstrumenten gebruikt worden, een qualitatieve studie naar 
symptomen van een plexus letsel. Dit wordt gedaan met patiënt focusgroepen, een 
enquête onder deskundigen en een zogenaamde cross-sectionele studie van deze 
patiënten. Met de resultaten van deze 4 voorbereidende onderzoeken wordt een 
eerste versie van kernsymptomen geformuleerd tijdens een consensus conferentie. 
Vervolgens wordt deze eerste set van kernsymptomen getest bij patiënten met 
een plexus brachialis letsel.
Spierdegeneratie
Langdurige denervatie resulteert in spierdegeneratie waaronder atrofie, 
spiervervetting en fibrose in de spier. Het doel van de studie in hoofdstuk 3 was 
om de mate van spieratrofie en vervetting van spieren in de bovenarm te meten en 
te analyseren of spierdegeneratie geassocieerd was aan de mate van beweging van 
de elleboog en de biceps spierkracht. Het vetpercentage, de totale oppervlakte 
van de spier en de contractiele oppervlakte van de spier was te meten met een zeer 
hoge betrouwbaarheid. De contractiele oppervlakte was lager in de aangedane 
biceps (gemiddeld 8 cm2) vergeleken met de niet aangedane biceps (gemiddeld 
19 cm2). Uit de multivariate analyse bleek dat de contractiele oppervlakte van de 
bicepsspier geassocieerd was met de mate van buigen van de elleboog en aan 
de spierkracht.
Het doel van de studie in hoofdstuk 4 was om te evalueren of gipsredressie 
effectief is om elleboog flexiecontracturen te behandelen bij patiënten met een 
obstetrisch plexus brachialis letsel. Een cohort studie werd verricht met 41 patiënten 
die gedurende 5 jaar werden gevolgd. Deze patiënten hadden een elleboog 




met gipsredressie totdat de elleboog flexie contractuur 10 graden of minder was. 
Gipsredressie verbeterde de passieve elleboog extensie van een mediaan van 
-40 graden naar -15 graden. Bij 20 patiënten ontstond een recidief waarvoor zij 
opnieuw behandeld werden met gipsredressie. De ernst van de contractuur was 
een geringe voorspeller voor het krijgen van een recidief. De patiënttevredenheid 
was gemiddeld. Bij 4 patiënten ging de flexie achteruit en bij 2 patiënten moest de 
behandeling met gipsredressie voortijdig vervangen worden door een nachtspalk 
omdat zij klachten hadden van de gipsredressie. 
Het effect van botoxinjectie in de subscapularis spier om endorotatie contracturen 
te verminderen bij patiënten, werd onderzocht in hoofdstuk 5. Een vergelijkende 
studie werd verricht met 15 patiënten die behandeld werden met botox en 67 
patiënten die in het verleden geen botoxinjectie hadden ondergaan. Na 3 maanden 
was de passieve exorotatie in adductie in de botoxgroep toegenomen van -1 graden 
naar 32 graden. Patiënten zonder botoxinjectie hadden een verdere verslechtering 
van de passieve exorotatie. Botoxinjectie verminderde ook de noodzaak tot een 
spierpees transpositie. Na 5 jaar hadden 10 patiënten (67 %) in de botoxgroep een 
operatie-indicatie versus 66 patiënten (99 %) in de groep zonder botox behandeling.
Spierregeneratie
Satellietcellen zijn de stamcellen van een spier en zorgen voor spierregeneratie. Niet 
alleen de satellietcellen zelf, maar ook omgevingsfactoren kunnen van invloed zijn 
op de regeneratie capaciteit. Het doel van de studies in de hoofdstukken 6 en 7 was 
om de invloed van ontstekingsfactoren te onderzoeken op de regeneratiecapaciteit 
van satellietcellen. Tijdens het plaatsen van een totale knieprothese, werden 
spierbiopten genomen van 16 patiënten met artrose en deze biopten werden 
vergeleken met spierbiopten van 11 patiënten met reumatoïde artritis die een hoge 
mate van ontstekingsfactoren hebben. De spiercelhistologie was niet verschillend 
tussen patiënten met artrose of reuma. Bij het kweken van de satellietcellen was er 
geen verschil in de groeisnelheid, levensvatbaarheid en de differentiatiecapaciteit. 
Ook de expressie van eiwitten die betrokken zijn bij de regeneratiecapaciteit, was 
niet verschillend tussen beide groepen. De gemiddelde telomeerlengte was echter 
wel korter in reumapatiënten vergeleken met artrosepatiënten. De conclusie was 
dat satellietcellen in staat zijn om te delen en te differentiëren indien zij uit hun 
omgeving met ontstekingsfactoren gehaald worden.
In hoofdstuk 8 werd de veiligheid en het regeneratie potentieel van 
mononucleaire cellen uit autoloog beenmerg onderzocht. Bij 9 patiënten met een 
plexus brachialis letsel werden mononucleaire cellen uit het beenmerg gewonnen 
en geïnjecteerd in de partieel gedenerveerde bicepsspier. Er werden geen 




in spiervezel diameter, 50% toename in aantal satellietcellen en 83% toename in 
bloedvaten-spiervezel verhouding. De CT scan liet een afname zien van 48% in 
spierdichtheid en het  electromyogram liet een toename zien van 36% in amplitude, 
22% in duur en 29 % in het aantal fases. Deze resultaten zijn allen suggestief voor 
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